url,triplets
https://www.globenewswire.com/news-release/2025/03/12/3041298/0/en/Clene-Demonstrates-Strengthened-ALS-Survival-Benefit-with-CNM-Au8-Treatment.html,"Clene, SUBJ","demonstrates, PRED","survival, OBJ","benefit, OBJ","CNM-Au8, SUBJ","delivers, PRED","benefit, OBJ","Clene, SUBJ","announced, PRED","evidence, OBJ","HEALEY, SUBJ","shows, PRED","advantage, OBJ","Clene, SUBJ","a, O","clinical-stage, O","biopharmaceutical, O","company, O","focused, O","on, O","revolutionizing, O","the, O","treatment, O","of, O","neurodegenerative, O","diseases, O","Rob, SUBJ","Etherington, SUBJ","stated, PRED","Merit, SUBJ","Cudkowicz, SUBJ","said, PRED","Regimen, SUBJ","A, SUBJ","was, PRED","one, OBJ","Clene, SUBJ","is, PRED","a, O","late, O","clinical-stage, O","biopharmaceutical, O","company, O","focused, O","on, O","improving, O","mitochondrial, O","health, O","CNM-Au8, SUBJ","is, PRED","an, O","oral, O","suspension, O","RESTORE-ALS, SUBJ","is, PRED","a, O","Phase, O","3, O","confirmatory, O","global, O","Clene, SUBJ","contains, PRED","statements, OBJ","Ignacio, SUBJ","Guerrero-Ros, SUBJ","David, SUBJ","Schull, SUBJ","Kevin, SUBJ","Gardner, SUBJ"
https://www.globenewswire.com/news-release/2025/03/11/3041026/0/en/Oculis-Reports-Q4-and-Full-Year-2024-Financial-Results-and-Provides-Company-Update.html,"Oculis, SUBJ","Reports, PRED","Q4, OBJ","and, O","Full, O","Year, O","2024, O","Financial, O","Results, O","and, O","Accessibility, O","Skip, O","TopNav, O","Oculis, SUBJ","Reports, PRED","Q4, OBJ","and, O","Full, O","Year, O","2024, O","Financial, O","Results, O","and, O","Provides, PRED","Company, O","Update, OBJ","March, O","11, O","2025, O","1630, O","ET, O","Source, O","Oculis, SUBJ","Holding, O","AG, O","Oculis, SUBJ","Holding, O","AG, O","Successful, O","2024, O","marked, O","by, O","significant, O","clinical, O","advancements, O","across, O","Oculis, SUBJ","late-stage, O","and, O","highly, O","differentiated, O","clinical, O","pipeline, O","targeting, O","retina, O","OCS-01, OBJ","in, O","diabetic, O","macular, O","edema, O","neuro-ophthalmic, O","Privosegtor, OBJ","OCS-05, OBJ","in, O","acute, O","optic, O","neuritis, O","and, O","precision, O","medicine, O","Licaminlimab, OBJ","OCS-02, OBJ","in, O","dry, O","eye, O","disease, O","treatmentsRecent, O","positive, O","topline, O","results, O","in, O","the, O","ACUITY, O","Phase, O","2, O","trial, O","showed, O","Privosegtor, SUBJ","OCS-05s, O","neuroprotective, O","benefits, O","in, O","anatomical, O","preservation, O","of, O","the, O","retina, O","and, O","visual, O","function, O","improvements, O","in, O","acute, O","optic, O","neuritisOversubscribed, O","100, O","million, O","equity, O","financing, O","completed, O","to, O","support, O","the, O","advancement, O","of, O","Oculis, SUBJ","late-stage, O","clinical, O","portfolioUpcoming, O","RD, O","Day, O","planned, O","on, O","April, O","15, O","2025, O","to, O","showcase, O","pipeline, O","potential, O","and, O","company, O","strategyCash, O","cash, O","equivalents, O","and, O","short-term, O","investments, O","of, O","109, O","million, O","as, O","of, O","December, O","31, O","2024, O","together, O","with, O","approximately, O","93, O","million, O","net, O","proceeds, O","of, O","recent, O","financing, O","provides, O","cash, O","runway, O","into, O","early, O","2028, O","ZUG, O","Switzerland, O","March, O","11, O","2025, O","GLOBE, O","NEWSWIRE, O","Oculis, SUBJ","Holding, O","AG, O","Nasdaq, O","OCS, O","XICE, O","OCS, O","Oculis, SUBJ","or, O","the, O","Company, O","a, O","global, O","biopharmaceutical, O","company, O","focused, O","on, O","innovations, O","addressing, O","ophthalmic, O","and, O","neuro-ophthalmic, O","diseases, O","with, O","significant, O","unmet, O","medical, O","needs, O","today, O","announced, O","results, O","for, O","the, O","quarter, O","and, O","full, O","year, O","ended, O","December, O","31, O","2024, O","and, O","provided, O","an, O","overview, O","of, O","the, O","Companys, O","progressRiad, SUBJ","Sherif, SUBJ","M.D., O","Chief, O","Executive, O","Officer, O","of, O","Oculis, O","We, O","had, O","a, O","momentous, O","year, O","in, O","2024, O","and, O","a, O","strong, O","start, O","to, O","2025, O","We, O","delivered, O","two, O","positive, O","Phase, O","2, O","topline, O","readouts, O","from, O","the, O","ACUITY, O","Privosegtor, OBJ","OCS-05, OBJ","trial, O","in, O","acute, O","optic, O","neuritis, O","showing, O","neuroprotective, O","effects, O","and, O","the, O","RELIEF, O","trial, O","of, O","Licaminlimab, OBJ","OCS-02, OBJ","in, O","dry, O","eye, O","disease, O","DED, O","with, O","a, O","precision, O","medicine, O","approach, O","In, O","addition, O","we, O","are, O","on, O","track, O","to, O","complete, O","enrollment, O","in, O","the, O","coming, O","months, O","for, O","both, O","Phase, O","3, O","DIAMOND, O","trials, O","of, O","OCS-01, OBJ","in, O","diabetic, O","macular, O","edema, O","DME, O","The, O","recent, O","100, O","million, O","equity, O","financing, O","is, O","another, O","significant, O","milestone, O","for, O","Oculis, SUBJ","to, O","propel, O","its, O","pipeline, O","As, O","we, O","continue, O","to, O","execute, O","on, O","our, O","vision, O","to, O","be, O","a, O","leader, O","in, O","ophthalmic, O","and, O","neuro-ophthalmic, O","fields, O","and, O","to, O","bring, O","innovative, O","sight-saving, O","treatments, O","to, O","market, O","2025, O","will, O","be, O","a, O","year, O","in, O","which, O","we, O","remain, O","focused, O","on, O","execution, O","to, O","advance, O","our, O","late-stage, O","clinical, O","portfolio, O","We, O","look, O","forward, O","to, O","sharing, O","updates, O","on, O","our, O","portfolio, O","strategy, O","at, O","our, O","upcoming, O","RD, O","Day, O","Q4, O","2024, O","and, O","Recent, O","Highlights, O","Clinical, O","Highlights, O","and, O","Upcoming, O","Milestones, O","OCS-01, SUBJ","On-track, PRED","to, O","complete, O","enrollment, O","in, O","Phase, O","3, O","DIAMOND, O","program, O","in, O","DME, O","with, O","top-line, O","data, O","readout, O","expected, O","in, O","first, O","half, O","of, O","2026, O","NDA, SUBJ","submission, PRED","readiness, O","for, O","post-ocular, O","surgery, O","also, O","on, O","track, O","in, O","Q1, O","2025, O","Privosegtor, SUBJ","OCS-05, SUBJ","Positive, PRED","topline, O","results, O","from, O","the, O","Phase, O","2, O","ACUITY, O","trial, O","in, O","patients, O","with, O","acute, O","optic, O","neuritis, O","where, O","Privosegtor, SUBJ","OCS-05, SUBJ","achieved, PRED","primary, O","endpoint, O","of, O","safety, O","and, O","three, O","secondary, O","efficacy, O","endpoints, O","demonstrating, O","improvement, O","for, O","Privosegtor, SUBJ","OCS-05, SUBJ","compared, PRED","to, O","placebo, O","in, O","objective, O","structural, O","measures, O","of, O","retinal, O","thickness, O","and, O","functional, O","vision, O","improvement, O","FDA, SUBJ","interactions, PRED","are, O","planned, O","for, O","the, O","second, O","half, O","of, O","2025, O","to, O","discuss, O","the, O","ACUITY, O","trial, O","results, O","and, O","align, O","on, O","the, O","next, O","steps, O","including, O","a, O","registrational, O","development, O","program, O","for, O","acute, O","optic, O","neuritis, O","Licaminlimab, SUBJ","OCS-02, SUBJ","Positive, PRED","readout, O","from, O","the, O","Phase, O","2b, O","RELIEF, O","trial, O","in, O","signs, O","of, O","DED, O","and, O","FDA, SUBJ","interaction, PRED","conducted, O","in, O","Q1, O","2025, O","confirmed, O","development, O","path, O","forward, O","with, O","a, O","precision, O","medicine, O","approach, O","Further, O","business, O","and, O","pipeline, O","development, O","updates, O","to, O","be, O","provided, O","during, O","the, O","RD, O","Day, O","on, O","April, O","15, O","2025, O","in, O","New, O","York, OBJ","City, OBJ","Q4, O","and, O","Full, O","Year, O","2024, O","Financial, O","Highlights, O","Cash, O","position, O","As, O","of, O","December, O","31, O","2024, O","the, O","Company, O","had, O","total, O","cash, O","cash, O","equivalents, O","and, O","short-term, O","investments, O","of, O","CHF, O","98.7, O","million, O","or, O","109.0, O"
https://www.globenewswire.com/news-release/2025/03/11/3040993/0/en/Verrica-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html,"Verrica, SUBJ","Pharmaceuticals, SUBJ","reported, PRED","Fourth, OBJ","Quarter, OBJ","financial, OBJ","results, OBJ","Verrica, SUBJ","generated, PRED","growth, OBJ","Verrica, SUBJ","reports, PRED","revenue, OBJ","Verrica, SUBJ","advance, PRED","pipeline, OBJ","Verrica, SUBJ","strengthened, PRED","sheet, OBJ","Verrica, SUBJ","scheduled, PRED","call, OBJ","Dr., SUBJ","said, PRED","Rieger, SUBJ","continued, PRED","Verrica, SUBJ","raised, PRED","capital, OBJ","Verrica, SUBJ","is, PRED","track, OBJ","Verrica, SUBJ","will, PRED","remain, OBJ","Verrica, SUBJ","will, PRED","focus, OBJ","Verrica, SUBJ","reported, PRED","data, OBJ","Verrica, SUBJ","anticipate, PRED","Verrica, SUBJ","will, PRED","advancing, OBJ","Verrica, SUBJ","has, PRED","place, OBJ","Verrica, SUBJ","will, PRED","host, OBJ","The, SUBJ","will, PRED","be, OBJ","The, SUBJ","will, PRED","also, OBJ","The, SUBJ","will, PRED","be, OBJ","The, SUBJ","will, PRED","also, OBJ","The, SUBJ","will, PRED","be, OBJ","Verrica, SUBJ","had, PRED","Verrica, SUBJ","had, PRED","cash, OBJ","Verrica, SUBJ","could, PRED","have, OBJ","Verrica, SUBJ","excludes, PRED","expense, OBJ","Verrica, SUBJ","excludes, PRED","expense, OBJ","Verrica, SUBJ","believes, PRED","Verrica, SUBJ","excludes, PRED","expense, OBJ","Verrica, SUBJ","should, PRED","be, OBJ","Verrica, SUBJ","should, PRED","not, OBJ","Verrica, SUBJ","should, PRED","not, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ","YCANTH, SUBJ","is, PRED","product, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041437/0/en/Shuttle-Pharma-Announces-Pricing-of-5-75-Million-Underwritten-Offering.html,"Shuttle, SUBJ","Pharmaceuticals, SUBJ","Holdings, SUBJ","Inc., SUBJ","announced, PRED","Offering, OBJ","Shuttle, SUBJ","Pharma, SUBJ","intends, PRED","proceeds, OBJ","WestPark, SUBJ","Capital, SUBJ","Inc., SUBJ","acted, PRED","Book-Runner, OBJ","Offering, SUBJ","is, PRED","made, PRED","Shuttle, SUBJ","Pharmaceuticals, SUBJ","Founded, PRED","Georgetown, OBJ","University, OBJ","Medical, OBJ","Center, OBJ","Shuttle, SUBJ","Pharma, SUBJ","is, PRED","company, OBJ","Shuttle, SUBJ","Pharma, SUBJ","will, PRED","Present, PRED","Showcase, OBJ","Shuttle, SUBJ","Pharma, SUBJ","Developing, PRED","Tests, OBJ","Shuttle, SUBJ","Pharma, SUBJ","Filing, PRED","application, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041248/0/en/Prime-Biome-Reviews-And-Complaints-A-Detailed-Study-Released-That-s-Needs-to-Be-Adopted-for-Which-Type-of-Peoples.html,"Prime, OBJ","Biome, OBJ","released, PRED","a, O","Detailed, O","Study, OBJ","needs, PRED","to, O","be, O","adopted, PRED","for, O","which, O","Type, O","of, O","Peoples?, O","March, O","12,, O","2025, O","0711, O","ET, O","Source, O","PrimeBiome, ORG","PrimeBiome, ORG","ST., O","PETERSBURG,, O","Fla., O","March, O","12,, O","2025, O","GLOBE, O","NEWSWIRE, O","--, O","This, O","is, O","a, O","comprehensive, O","examination, O","of, O","the, O","groundbreaking, O","research, O","behind, O","Prime, OBJ","Biome, OBJ","It, O","is, O","a, O","cutting-edge, O","probiotic, O","supplement, O","made, PRED","to, O","promote, PRED","gut, O","and, O","skin, O","health,, O","thereby, O","enhancing, O","general, O","well-being, O","from, O","the, O","inside, O","out., O","Dr., O","Jessica, SUBJ","Burgy,, SUBJ","developed, PRED","FDA, ORG","inspected, PRED","Jessica, SUBJ","Burgy, SUBJ","has, PRED","FDA, ORG","evaluated, PRED","Jessica, SUBJ","Burgy, SUBJ","Co-Founder, O","contact, O","primebiome.com, O","FDA, ORG","intended, PRED","Jessica, SUBJ","Burgy, SUBJ","is, PRED","pregnant,, O"
https://www.globenewswire.com/news-release/2025/03/12/3041328/0/en/FOXO-TECHNOLOGIES-INC-PROVIDES-UPDATE-ON-ITS-BEHAVIORAL-HEALTH-SUBSIDIARY-MYRTLE-RECOVERY-CENTERS-INC.html,"FOXO, SUBJ","provides, PRED","update, OBJ","Myrtle, SUBJ","announce, PRED","occupancy, OBJ","Myrtle, SUBJ","finalized, PRED","contracts, OBJ","Myrtle, SUBJ","announce, PRED","participation, OBJ","ETAADAC, SUBJ","serves, PRED","platform, OBJ","Robert, SUBJ","said, PRED","progress, OBJ","ETAADAC, SUBJ","provides, PRED","opportunity, OBJ","FOXO, SUBJ","owns, PRED","subsidiaries, OBJ","Rennova, SUBJ","operates, PRED","hospital, OBJ","Myrtle, SUBJ","operates, PRED","facility, OBJ","FOXO, SUBJ","is, PRED","company, OBJ","Sebastien, SUBJ","Contact, PRED","Sainsbury, OBJ","FOXO, SUBJ","announced, PRED","split, OBJ","FOXO, SUBJ","filed, PRED","Report, OBJ"
https://www.globenewswire.com/news-release/2025/03/11/3040686/0/en/Better-Choice-Company-Signs-Binding-Letter-of-Intent-to-Acquire-Choice-Specialty-Pharmacy-Expanding-U-S-Presence.html,"Better, SUBJ","Choice, SUBJ","Company, SUBJ","signed, PRED","a, O","binding, O","Letter, O","of, O","Intent, O","to, O","acquire, PRED","Choice, OBJ","Specialty, OBJ","Pharmacy, OBJ","Better, SUBJ","Choice, SUBJ","Company, SUBJ","expects, PRED","to, O","strengthen, PRED","U.S., OBJ","presence, O","Michael, SUBJ","Young, SUBJ","said, PRED","Choice, SUBJ","Specialty, SUBJ","Pharmacy, SUBJ","Group, SUBJ","is, PRED","a, O","provider, O","The, O","acquisition, O","strengthens, PRED","Better, OBJ","Choices, OBJ","commitment, O","Better, SUBJ","Choice, SUBJ","Company, SUBJ","Inc., SUBJ","is, PRED","a, O","company, O","Kent, SUBJ","Cunningham, SUBJ","is, PRED","CEO, OBJ","Valter, SUBJ","Pinto, SUBJ","is, PRED","Managing, OBJ","Director, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041230/18362/en/Amarin-Reports-Fourth-Quarter-Financial-Results-Business-Update-and-Announces-Important-Corporate-Action.html,"Amarin, SUBJ","reported, PRED","Fourth Quarter Financial Results, OBJ","Amarin, SUBJ","announces, PRED","Important Corporate Action, OBJ","Amarin, SUBJ","reports, PRED","2024 Total Revenues, OBJ","Amarin, SUBJ","reports, PRED","Operating Expenses, OBJ","Amarin, SUBJ","reports, PRED","Year End 2024 Cash Position, OBJ","Aaron Berg, SUBJ","said, PRED","opportunities, OBJ","Amarin, SUBJ","generated, PRED","revenue, OBJ","Amarin, SUBJ","ended, PRED","year, OBJ","Amarin, SUBJ","captured, PRED","revenue, OBJ","Amarin, SUBJ","unlocked, PRED","access, OBJ","Amarin, SUBJ","progressed, PRED","countries, OBJ","Aaron Berg, SUBJ","commented, PRED","steps, OBJ","Amarin, SUBJ","announced, PRED","intent, OBJ","Amarin, SUBJ","announced, PRED","Ratio Change, OBJ","Amarin, SUBJ","announced, PRED","Ratio Change, OBJ","Amarin, SUBJ","host, PRED","Conference Call, OBJ","Amarin, SUBJ","continued, PRED","commercialization, OBJ","Amarin, SUBJ","continued, PRED","efforts, OBJ","Amarin, SUBJ","secured, PRED","reimbursement, OBJ","Amarin, SUBJ","secured, PRED","reimbursement, OBJ","Amarin, SUBJ","continues, PRED","progress, OBJ","Amarin, SUBJ","continues, PRED","processes, OBJ","Amarin, SUBJ","continued, PRED","launch, OBJ","Amarin, SUBJ","will support, PRED","presentation, OBJ","Amarin, SUBJ","reported, PRED","revenue, OBJ","Amarin, SUBJ","reported, PRED","revenue, OBJ","Amarin, SUBJ","reported, PRED","revenue, OBJ","Amarin, SUBJ","reported, PRED","revenue, OBJ","Amarin, SUBJ","reported, PRED","revenue, OBJ","Amarin, SUBJ","reported, PRED","revenue, OBJ","Amarin, SUBJ","is committed, PRED","opportunity, OBJ","Amarin, SUBJ","continues, PRED","explore, OBJ","Amarin, SUBJ","reaffirms, PRED","belief, OBJ","Amarin, SUBJ","continues, PRED","explore, OBJ","Amarin, SUBJ","will host, PRED","conference call, OBJ","Amarin, SUBJ","is, PRED","company, OBJ","VASCEPA, SUBJ","was launched, PRED","United States, OBJ","VASCEPA, SUBJ","was approved, PRED","FDA, OBJ","VASCEPA, SUBJ","was launched, PRED","United States, OBJ","VASCEPA, SUBJ","is approved, PRED","sold, OBJ","VASCEPA, SUBJ","is approved, PRED","sold, OBJ","VASCEPA, SUBJ","is approved, PRED","sold, OBJ","VASCEPA, SUBJ","is approved, PRED","sold, OBJ","VASCEPA, SUBJ","is approved, PRED","sold, OBJ","VASCEPA, SUBJ","is approved, PRED","sold, OBJ","VASCEPA, SUBJ","is approved, PRED","sold, OBJ","VASCEPA, SUBJ","is approved, PRED","sold, OBJ","VASCEPA, SUBJ","is approved, PRED","sold, OBJ","VASCEPA, SUBJ","is approved, PRED","sold, OBJ","VASCEPA, SUBJ","is indicated, PRED","adjunct, OBJ","VASCEPA, SUBJ","is indicated, PRED","adjunct, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","is contraindicated, PRED","patients, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","is contraindicated, PRED","patients, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED","risk, OBJ","VASCEPA, SUBJ","was associated, PRED"
https://www.globenewswire.com/news-release/2025/03/12/3041293/0/en/Acumen-Pharmaceuticals-to-Present-During-International-Conference-on-Alzheimer-s-and-Parkinson-s-Diseases-2025-and-American-Academy-of-Neurology-Annual-Meeting.html,"Acumen, SUBJ","Pharmaceuticals, SUBJ","to, O","Present, PRED","During, O","International, OBJ","Conference, OBJ","on, O","Alzheimers, OBJ","and, O","Parkinsons, OBJ","Diseases, OBJ","Acumen, SUBJ","Pharmaceuticals, SUBJ","to, O","Present, PRED","During, O","American, OBJ","Academy, OBJ","of, OBJ","Neurology, OBJ","Annual, OBJ","Meeting, OBJ","Oral, O","presentations, O","will, O","highlight, O","the, O","implementation, O","of, O","a, O","validated, O","research-use, O","plasma, O","pTau217, O","assay, O","in, O","the, O","participant, O","screening, O","process, O","for, O","the, O","Phase, O","2, O","ALTITUDE-AD, O","study, O","of, O","sabirnetug, O","Acumen, SUBJ","Pharmaceuticals, SUBJ","Inc., SUBJ","to, O","Present, PRED","During, O","International, OBJ","Conference, OBJ","on, O","Alzheimers, OBJ","and, O","Parkinsons, OBJ","Diseases, OBJ","Acumen, SUBJ","Pharmaceuticals, SUBJ","Inc., SUBJ","to, O","Present, PRED","During, O","American, OBJ","Academy, OBJ","of, OBJ","Neurology, OBJ","Annual, OBJ","Meeting, OBJ","Acumen, SUBJ","Pharmaceuticals, SUBJ","Inc., SUBJ","NASDAQ, OBJ","ABOS, OBJ","is, O","a, O","clinical-stage, O","biopharmaceutical, O","company, O","developing, O","a, O","novel, O","therapeutic, O","that, O","targets, O","soluble, O","amyloid, O","beta, O","oligomers, O","AβOs, O","for, O","the, O","treatment, O","of, O","Alzheimers, OBJ","disease, OBJ","Acumen, SUBJ","Pharmaceuticals, SUBJ","Inc., SUBJ","today, O","announced, PRED","upcoming, O","scientific, O","presentations, O","at, O","the, O","International, OBJ","Conference, OBJ","on, O","Alzheimers, OBJ","and, O","Parkinsons, OBJ","Diseases, OBJ","and, O","Related, OBJ","Neurological, OBJ","Disorders, OBJ","ADPD, OBJ","in, O","Vienna, OBJ","Austria, OBJ","Acumen, SUBJ","Pharmaceuticals, SUBJ","Inc., SUBJ","today, O","announced, PRED","upcoming, O","scientific, O","presentations, O","at, O","the, O","American, OBJ","Academy, OBJ","of, OBJ","Neurology, OBJ","AAN, OBJ","Annual, OBJ","Meeting, OBJ","in, O","San, OBJ","Diego, OBJ","Oral, O","presentations, O","will, O","focus, O","on, O","implementation, O","of, O","a, O","validated, O","research-use, O","plasma, O","pTau217, O","assay, O","in, O","the, O","clinical, O","trial, O","participant, O","screening, O","process, O","Poster, O","presentations, O","will, O","focus, O","on, O","methods, O","of, O","interrogating, O","the, O","binding, O","of, O","AβOs, O","to, O","a, O","model, O","of, O","human, O","neurons, O","methods, O","to, O","more, O","accurately, O","assess, O","the, O","AβO, O","selectivity, O","of, O","nonclinical, O","assays, O","and, O","sabirnetug, O","and, O","early, O","effects, O","of, O","sabirnetug, O","on, O","synaptic, O","biomarkers, O","in, O","AD, OBJ","Acumen, SUBJ","is, O","advancing, PRED","sabirnetug, OBJ","Acumen, SUBJ","is, O","advancing, PRED","a, O","potential, O","next-generation, O","antibody, O","treatment, O","for, O","early, O","symptomatic, O","AD, OBJ","ADPD, O","presentation, O","details, O","are, O","as, O","follows, O","Oral, O","Presentation, O","ALTITUDE-AD, O","Use, O","of, O","Plasma, O","pTau217, O","Screening, O","in, O","An, O","Ongoing, O","Phase, O","2, O","Study, O","of, O","Sabirnetug, O","for, O","Early, O","Symptomatic, O","Alzheimers, OBJ","Disease, OBJ","Eric, SUBJ","Siemers, SUBJ","is, O","Presenting, PRED","Author, OBJ","Protocol, O","for, O","the, O","Preparation, O","of, O","Stable, O","Monomeric, O","Amyloid, O","Beta, O","1522, O","Erika, SUBJ","Cline, SUBJ","is, O","Presenting, PRED","Author, OBJ","Utility, O","of, O","Human, O","iPSC-Derived, O","Neuronal, O","Model, O","for, O","Evaluating, O","Synaptic, O","Binding, O","of, O","Amyloid, O","Βeta, O","Oligomers, O","Elizabeth, SUBJ","Johnson, SUBJ","is, O","Presenting, PRED","Author, OBJ","AAN, O","presentation, O","details, O","are, O","as, O","follows, O","Oral, O","Presentation, O","ALTITUDE-AD, O","Use, O","of, O","Plasma, O","pTau217, O","Assay, O","to, O","Screen, O","Potential, O","Participants, O","in, O","an, O","Ongoing, O","Randomized, O","Double-Blind, O","Placebo-Controlled, O","Phase, O","2, O","Study, O","of, O","Sabirnetug, O","for, O","Early, O","Alzheimers, OBJ","Disease, OBJ","Todd, SUBJ","Feaster, SUBJ","is, O","Presenting, PRED","Author, OBJ","Poster, O","Presentation, O","INTERCEPT-AD, O","Biomarker, O","Results, O","Early, O","effect, O","of, O","sabirnetug, O","treatment, O","on, O","synaptic, O","biomarkers, O","in, O","Alzheimers, OBJ","disease, OBJ","Elizabeth, SUBJ","Johnson, SUBJ","is, O","Presenting, PRED","Author, OBJ","Sabirnetug, SUBJ","ACU193, SUBJ","is, O","a, O","humanized, O","monoclonal, O","antibody, O","mAb, O","discovered, PRED","and, O","developed, PRED","based, O","on, O","its, O","selectivity, O","for, O","soluble, O","amyloid, O","beta, O","oligomers, O","AβOs, O","Sabirnetug, SUBJ","ACU193, SUBJ","aims, PRED","to, O","address, O","the, O","hypothesis, O","that, O","soluble, O","AβOs, O","are, O","an, O","early, O","and, O","persistent, O","underlying, O","cause, O","of, O","the, O","neurodegenerative, O","process, O","in, O","Alzheimers, OBJ","disease, OBJ","Sabirnetug, SUBJ","has, PRED","been, O","granted, O","Fast, O","Track, O","designation, O","for, O","the, O","treatment, O","of, O","early, O","AD, OBJ","by, O","the, O","U.S., OBJ","Food, OBJ","and, O","Drug, OBJ","Administration, OBJ","Sabirnetug, SUBJ","is, O","currently, O","being, O","evaluated, PRED","in, O","a, O","Phase, O","2, O","study, O","in, O","patients, O","with, O","early, O","AD, OBJ","ALTITUDE-AD, SUBJ","Phase, SUBJ","2, SUBJ","Initiated, PRED","in, O","2024, O","ALTITUDE-AD, SUBJ","is, O","a, O","Phase, OBJ","2, OBJ","multi-center, O","randomized, O","double-blind, O","placebo-controlled, O","clinical, O","trial, O","designed, PRED","to, O","evaluate, O","the, O","efficacy, O","and, O","safety, O","of, O","sabirnetug, OBJ","ACU193, OBJ","infusions, O","administered, O","once, O","every, O","four, O","weeks, O","in, O","slowing, O","cognitive, O","and, O","functional, O","decline, O","as, O","compared, O","to, O","placebo, O","in, O","participants, O","with, O","early, O","Alzheimers, OBJ","disease, OBJ","The, O","study, O","will, O","enroll, PRED","approximately, O","540, O","individuals, O","with, O","early, O","Alzheimers, OBJ","disease, OBJ","The, O","global, O","study, O","is, O","currently, O","ongoing, O","at, O","multiple, O","investigative, O","sites, O","located, O","in, O","the, O","United, OBJ","States, OBJ","Canada, OBJ","UK, OBJ","and, O","the, O","European, OBJ","Union, OBJ","Acumen, SUBJ","Pharmaceuticals, SUBJ","is, O","a, O","clinical-stage, O","biopharmaceutical, O","company, O","developing, PRED","a, O","novel, O","therapeutic, O","that, O","targets, O","toxic, O","soluble, O","amyloid, O","beta, O","oligomers, O","AβOs, O","for, O","the, O","treatment, O","of, O","Alzheimers, OBJ","disease, OBJ","Acumen, SUBJ","Pharmaceuticals, SUBJ","scientific, O","founders, O","pioneered, PRED","research, O","on, O","AβOs, O","Acumen, SUBJ","is, O","currently, O","focused, PRED","on, O","advancing, O"
https://www.globenewswire.com/news-release/2025/03/11/3040985/0/en/Lyell-Immunopharma-Reports-Business-Highlights-and-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2024.html,"Lyell, SUBJ","Immunopharma, SUBJ","Inc, SUBJ","Acquired, PRED","ImmPACT, OBJ","Bio, OBJ","Lyell, SUBJ","strengthened, PRED","pipeline, OBJ","Lyell, SUBJ","Presented, PRED","data, OBJ","Lyell, SUBJ","Acceleration, PRED","development, OBJ","Lyell, SUBJ","initiate, PRED","trial, OBJ","Lyell, SUBJ","expect, PRED","trial, OBJ","Lyell, SUBJ","Advancing, PRED","candidates, OBJ","Lyell, SUBJ","expected, PRED","IND, OBJ","Cash, SUBJ","support, PRED","pipeline, OBJ","SOUTH, SUBJ","SAN, SUBJ","FRANCISCO, SUBJ","Calif, SUBJ","Reported, PRED","results, OBJ","Lyell, SUBJ","reported, PRED","results, OBJ","Lyell, SUBJ","reported, PRED","highlights, OBJ","Lynn, SUBJ","said, PRED","data, OBJ","Lyell, SUBJ","believe, PRED","IMPT-314, OBJ","Lyell, SUBJ","expect, PRED","data, OBJ","Lyell, SUBJ","plan, PRED","programs, OBJ","Lyell, SUBJ","plan, PRED","programs, OBJ","Lyell, SUBJ","expect, PRED","IND, OBJ","Lyell, SUBJ","Advancing, PRED","candidates, OBJ","Lyell, SUBJ","is, PRED","company, OBJ","Lyell, SUBJ","is, PRED","pipeline, OBJ","IMPT-314, SUBJ","is, PRED","candidate, OBJ","IMPT-314, SUBJ","is, PRED","product, OBJ","IMPT-314, SUBJ","is, PRED","candidate, OBJ","IMPT-314, SUBJ","has, PRED","Designation, OBJ","Phase, SUBJ","is, PRED","trial, OBJ","Phase, SUBJ","is, PRED","trial, OBJ","Initial, SUBJ","Presented, PRED","Meeting, OBJ","Data, SUBJ","reported, PRED","patients, OBJ","Lyell, SUBJ","expect, PRED","data, OBJ","Lyell, SUBJ","expect, PRED","trial, OBJ","Lyell, SUBJ","expect, PRED","trial, OBJ","Lyell, SUBJ","expect, PRED","IND, OBJ","Lyell, SUBJ","Advancing, PRED","candidates, OBJ","Lyell, SUBJ","Presented, PRED","data, OBJ","Lyell, SUBJ","streamlined, PRED","expenses, OBJ","Lyell, SUBJ","Reported, PRED","loss, OBJ","Lyell, SUBJ","Reported, PRED","loss, OBJ","Net, SUBJ","included, PRED","expense, OBJ","Net, SUBJ","included, PRED","expense, OBJ","NonGAAP, SUBJ","was, PRED","loss, OBJ","NonGAAP, SUBJ","was, PRED","loss, OBJ","GAAP, SUBJ","were, PRED","expenses, OBJ","GAAP, SUBJ","were, PRED","expenses, OBJ","NonGAAP, SUBJ","were, PRED","expenses, OBJ","NonGAAP, SUBJ","were, PRED","expenses, OBJ","GAAP, SUBJ","were, PRED","expenses, OBJ","GAAP, SUBJ","were, PRED","expenses, OBJ","NonGAAP, SUBJ","were, PRED","expenses, OBJ","NonGAAP, SUBJ","were, PRED","expenses, OBJ","Operating, SUBJ","include, PRED","expenses, OBJ","Operating, SUBJ","include, PRED","charge, OBJ","Cash, SUBJ","were, PRED","securities, OBJ","Cash, SUBJ","believes, PRED","balances, OBJ","Lyell, SUBJ","is, PRED","company, OBJ","Lyell, SUBJ","utilizes, PRED","technologies, OBJ","Lyell, SUBJ","is, PRED","Francisco, OBJ","Lyell, SUBJ","is, PRED","Washington, OBJ","Forward-Looking, SUBJ","contains, PRED","statements, OBJ","Lyell, SUBJ","may, PRED","statements, OBJ","Lyell, SUBJ","cautions, PRED","risks, OBJ","Lyell, SUBJ","Received, PRED","Designation, OBJ","RMAT, SUBJ","was, PRED","Designation, OBJ","RMAT, SUBJ","recognizes, PRED","data, OBJ","Lyell, SUBJ","Announces, PRED","Participation, OBJ","SOUTH, SUBJ","SAN, SUBJ","FRANCISCO, SUBJ","Calif, SUBJ","Announces, PRED","Participation, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041288/0/en/Annual-General-Meeting-2025-GN-Store-Nord-A-S.html,"GN, SUBJ","Store, SUBJ","Nord, SUBJ","AS, SUBJ","held, PRED","its, O","Annual, O","General, O","Meeting, O","The, O","Annual, O","General, O","Meeting, SUBJ","was, PRED","held, PRED","in, O","accordance, O","with, O","the, O","agenda, O","announced, PRED","on, O","February, O","17, O","2025, O","The, O","report, OBJ","by, O","the, O","Board, SUBJ","of, SUBJ","Directors, SUBJ","was, PRED","noted, PRED","by, O","the, O","general, O","meeting, O","The, O","Annual, O","Report, OBJ","2024, OBJ","and, O","the, O","proposal, OBJ","on, O","distribution, O","of, O","annual, O","profits, O","including, O","no, O","distribution, O","of, O","dividends, O","were, PRED","approved, PRED","Jukka, SUBJ","Pekka, SUBJ","Pertola, SUBJ","Klaus, SUBJ","Holse, SUBJ","Hélène, SUBJ","Barnekow, SUBJ","Jørgen, SUBJ","Bundgaard, SUBJ","Hansen, SUBJ","and, O","Kim, SUBJ","Vejlby, SUBJ","Hansen, SUBJ","were, PRED","re-elected, PRED","to, O","the, O","Board, OBJ","of, OBJ","Directors, OBJ","Charlotte, SUBJ","Johs, SUBJ","and, O","Lise, SUBJ","Skaarup, SUBJ","Mortensen, SUBJ","were, PRED","elected, PRED","as, O","new, O","members, O","of, O","the, O","Board, OBJ","of, OBJ","Directors, OBJ","PricewaterhouseCoopers, SUBJ","Statsautoriseret, SUBJ","Revisionspartnerselskab, SUBJ","was, PRED","re-elected, PRED","as, O","auditor, OBJ","Jukka, SUBJ","Pekka, SUBJ","Pertola, SUBJ","was, PRED","elected, PRED","Chair, OBJ","of, OBJ","the, O","Board, OBJ","of, OBJ","Directors, OBJ","Klaus, SUBJ","Holse, SUBJ","was, PRED","elected, PRED","Deputy, OBJ","Chair, OBJ","of, OBJ","the, O","Board, OBJ","of, OBJ","Directors, OBJ","Jukka, SUBJ","Pekka, SUBJ","Pertola, SUBJ","was, PRED","also, O","elected, PRED","as, O","Chair, OBJ","of, OBJ","the, O","Technology, OBJ","Innovation, OBJ","Committee, OBJ","Hélène, SUBJ","Barnekow, SUBJ","was, PRED","elected, PRED","as, O","Chair, OBJ","of, OBJ","the, O","Remuneration, OBJ","Nomination, OBJ","Committee, OBJ","Lise, SUBJ","Skaarup, SUBJ","Mortensen, SUBJ","was, PRED","elected, PRED","as, O","Chair, OBJ","of, OBJ","the, O","Audit, OBJ","Committee, OBJ","Rune, SUBJ","Sandager, SUBJ","Investor, O","Relations, O","Steen, SUBJ","Frentz, SUBJ","Laursen, SUBJ","Media, O","Relations, O","GN, SUBJ","facilitates, PRED","communication, OBJ","GN, SUBJ","was, PRED","founded, PRED","GN, SUBJ","employs, PRED","7,000, OBJ","people, OBJ","GN, SUBJ","is, PRED","listed, PRED","on, O","Nasdaq, OBJ","Copenhagen, OBJ"
https://www.globenewswire.com/news-release/2025/03/11/3040906/0/en/OSE-Immunotherapeutics-and-GERCOR-Announce-Positive-Topline-Phase-2-Result-for-Clinical-Trial-TEDOPaM-Evaluating-OSE2101-Tedopi-in-Advanced-Pancreatic-Cancer.html,"OSE, SUBJ","Immunotherapeutics, SUBJ","and, O","GERCOR, SUBJ","Announce, PRED","Positive, OBJ","Topline, OBJ","Phase, OBJ","2, OBJ","Result, OBJ","for, O","Clinical, O","Trial, O","TEDOPaM, OBJ","Evaluating, PRED","OSE2101, OBJ","Tedopi, OBJ","in, O","Advanced, O","Pancreatic, O","Cancer, O","OSE, SUBJ","Immunotherapeutics, SUBJ","and, O","GERCOR, SUBJ","Announce, PRED","Positive, OBJ","Topline, OBJ","Phase, OBJ","2, OBJ","Result, OBJ","for, O","Clinical, O","Trial, O","TEDOPaM, OBJ","Evaluating, PRED","OSE2101, OBJ","Tedopi, OBJ","in, O","Advanced, O","Pancreatic, O","Cancer, O","Primary, OBJ","endpoint, OBJ","met, PRED","in, O","randomized, O","Phase, OBJ","2, OBJ","trial, OBJ","evaluating, PRED","OSE2101, OBJ","Tedopi, OBJ","with, O","FOLFIRI, OBJ","in, O","Advanced, O","Pancreatic, O","Cancer, O","Detailed, O","results, OBJ","to, O","be, O","presented, PRED","at, O","upcoming, O","medical, O","congresses, O","NANTES, SUBJ","France, SUBJ","March, O","11, O","600pm, O","CET, O","-, O","OSE, SUBJ","Immunotherapeutics, SUBJ","SA, SUBJ","ISIN, O","FR0012127173, OBJ","Mnemo, O","OSE, SUBJ","and, O","the, O","GERCOR, SUBJ","Group, SUBJ","today, O","announced, PRED","that, O","the, O","primary, OBJ","endpoint, OBJ","has, O","been, O","reached, PRED","in, O","TEDOPaM, OBJ","GERCOR, SUBJ","D17-01, OBJ","PRODIGE, OBJ","63, OBJ","trial, OBJ","a, O","Phase, OBJ","2, OBJ","clinical, O","trial, OBJ","sponsored, PRED","and, O","conducted, PRED","by, O","the, O","French, SUBJ","GERCOR, SUBJ","Oncology, SUBJ","Clinician, SUBJ","Group, SUBJ","evaluating, PRED","OSE2101, OBJ","Tedopi, OBJ","the, O","off-the-shelf, O","neoepitope-based, O","therapeutic, O","cancer, O","vaccine, O","in, O","advanced, O","or, O","metastatic, O","Pancreatic, O","Ductal, O","Adenocarcinoma, O","PDAC, OBJ","TEDOPaM, SUBJ","is, O","a, O","randomized, O","non-comparative, O","Phase, OBJ","2, OBJ","trial, OBJ","evaluating, PRED","FOLFIRI1, OBJ","Arm, OBJ","A, OBJ","and, O","cancer, O","vaccine, OBJ","OSE2101, OBJ","Tedopi, OBJ","plus, O","FOLFIRI, OBJ","chemotherapy, OBJ","Arm, OBJ","B, OBJ","as, O","maintenance, O","treatment, O","in, O","HLA-A2, OBJ","positive, O","patients, O","with, O","PDAC, OBJ","with, O","no, O","progression, O","after, O","eight, O","cycles, O","of, O","FOLFIRINOX, OBJ","induction, O","chemotherapy, O","The, O","primary, OBJ","endpoint, OBJ","of, O","the, O","trial, OBJ","was, O","the, O","one-year, O","overall, O","survival, O","OS, OBJ","rate, OBJ","in, O","the, O","experimental, O","Arm, OBJ","B, OBJ","Fleming, OBJ","2-stage, OBJ","design, OBJ","H0, OBJ","25, OBJ","H1, OBJ","50, OBJ","1-sided, OBJ","alpha, OBJ","2.5, OBJ","power, OBJ","90, OBJ","107, OBJ","patients, OBJ","were, O","enrolled, PRED","with, O","a, O","11, OBJ","ratio, OBJ","The, O","TEDOPaM, SUBJ","trial, SUBJ","met, PRED","its, O","primary, OBJ","objective, OBJ","showing, PRED","positive, OBJ","outcomes, OBJ","according, O","to, O","the, O","predefined, O","statistical, O","hypothesis, O","with, O","minimal, O","toxicity, O","for, O","OSE2101, OBJ","Tedopi, OBJ","combined, PRED","with, O","FOLFIRI, OBJ","as, O","maintenance, O","treatment, O","Prof., O","Cindy, SUBJ","Neuzillet, SUBJ","MD, O","PhD, O","Curie, SUBJ","cancer, O","research, O","Institute, SUBJ","Saint-Cloud, SUBJ","Principal, O","Investigator, O","of, O","the, O","TEDOPaM, OBJ","study, OBJ","Nicolas, SUBJ","Poirier, SUBJ","CEO, SUBJ","of, O","OSE, SUBJ","Immunotherapeutics, SUBJ","GERCOR, SUBJ","is, O","a, O","multidisciplinary, O","association, O","dedicated, PRED","to, O","clinical, O","research, O","in, O","oncology, O","whose, O","purpose, O","is, O","to, O","improve, PRED","the, O","care, O","of, O","patients, O","affected, PRED","by, O","cancer, O","by, O","developing, PRED","clinical, O","research, O","in, O","the, O","scope, O","of, O","an, O","independent, O","multidisciplinary, O","and, O","multi-focused, O","cooperative, O","group, O","OSE, SUBJ","Immunotherapeutics, SUBJ","is, O","a, O","biotech, O","company, O","dedicated, PRED","to, O","developing, PRED","first-in-class, O","assets, O","in, O","immuno-oncology, O","IO, O","and, O","immuno-inflammation, O","II, O","that, O","address, PRED","the, O","unmet, O","patient, O","needs, O","of, O","today, O","and, O","tomorrow, O","OSE, SUBJ","Immunotherapeutics, SUBJ","is, O","based, PRED","between, O","Nantes, SUBJ","and, O","Paris, SUBJ","and, O","is, O","quoted, PRED","on, O","Euronext, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041523/0/en/Passing-of-Genmab-A-S-Annual-General-Meeting.html,"Genmab, SUBJ","approved, PRED","Annual Report for 2024, OBJ","Board of Directors, SUBJ","given, PRED","discharge, OBJ","years profit, SUBJ","carried, PRED","forward, OBJ","2024 Compensation Report, SUBJ","approved, PRED","O, OBJ","Six members, SUBJ","re-elected, PRED","Board of Directors, OBJ","Deloitte, SUBJ","re-elected, PRED","auditor, OBJ","Board of Directors, SUBJ","adopted, PRED","amendments, OBJ","Board of Directors, SUBJ","adopted, PRED","remuneration, OBJ","Company, SUBJ","reduce, PRED","share capital, OBJ","Company, SUBJ","cancel, PRED","shares, OBJ","Company, SUBJ","acquire, PRED","treasury shares, OBJ","Company, SUBJ","issue, PRED","warrants, OBJ","Deirdre P. Connelly, SUBJ","gave, PRED","report, OBJ","Dr. Jan van de Winkel, SUBJ","presented, PRED","plans, OBJ","Mr. Anthony Pagano, SUBJ","presented, PRED","Annual Report, OBJ","report, SUBJ","approved, PRED","O, OBJ","discharge, SUBJ","given, PRED","Board of Directors, OBJ","years profit, SUBJ","carried, PRED","forward, OBJ","2024 Compensation Report, SUBJ","approved, PRED","O, OBJ","Ms. Deirdre P. Connelly, SUBJ","re-elected, PRED","Board of Directors, OBJ","Ms. Pernille Erenbjerg, SUBJ","re-elected, PRED","Board of Directors, OBJ","Mr. Rolf Hoffmann, SUBJ","re-elected, PRED","Board of Directors, OBJ","Ms. Elizabeth OFarrell, SUBJ","re-elected, PRED","Board of Directors, OBJ","Dr. Paolo Paoletti, SUBJ","re-elected, PRED","Board of Directors, OBJ","Dr. Anders Gersel Pedersen, SUBJ","re-elected, PRED","Board of Directors, OBJ","Deloitte, SUBJ","re-elected, PRED","auditor, OBJ","Board of Directors, SUBJ","adopted, PRED","proposals, OBJ","Genmab, SUBJ","is, PRED","company, OBJ","Genmab, SUBJ","headquartered, PRED","Copenhagen, OBJ","Genmab, SUBJ","established, PRED","1999, OBJ","Marisol Peron, SUBJ","is, PRED","Senior Vice President, OBJ","Andrew Carlsen, SUBJ","is, PRED","Vice President, OBJ","Genmab, SUBJ","does, PRED","undertake, OBJ","Genmab, SUBJ","own, PRED","trademarks, OBJ","Genmab, SUBJ","initiated, PRED","program, OBJ","Genmab, SUBJ","announced, PRED","Net sales, OBJ","Genmab, SUBJ","receives, PRED","royalties, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041279/0/en/OBI-Pharma-Receives-Most-Promising-ADC-Clinical-Candidate-in-Taiwan-Award.html,"OBI, SUBJ","Pharma, SUBJ","Receives, PRED","Most, O","Promising, O","ADC, O","Clinical, O","Candidate, O","in, O","Taiwan, OBJ","Award, O","Dr., O","Heidi, SUBJ","Wang, SUBJ","Accepts, PRED","Award, OBJ","on, O","Behalf, O","of, O","OBI, OBJ","Pharma, OBJ","at, O","ADC, O","Asia, O","Congress, O","2025, O","and, O","Gives, PRED","a, O","Presentation, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041117/0/en/Ipsen-appoints-Olivia-Brown-as-Executive-Vice-President-Global-Head-of-Neurotoxins.html,"Ipsen, SUBJ","appoints, PRED","Olivia, SUBJ","Brown, SUBJ","as, O","Executive, O","Vice-President,, O","Olivia, SUBJ","Brown, SUBJ","as, O","EVP,, O","Ipsen, SUBJ","Pharma, SUBJ","announced, PRED","today, O","the, O","appointment, O","of, O","Olivia, SUBJ","Brown, SUBJ","as,, O","Olivia, SUBJ","Brown, SUBJ","will, PRED","serve, PRED","on, O","Ipsens, SUBJ","Executive, OBJ","Leadership, OBJ","Team, OBJ","Olivia, SUBJ","Brown, SUBJ","will, PRED","report, PRED","directly, O","to, O","Chief, O","Executive, O","Officer, O","David, SUBJ","Loew, SUBJ","Ipsen, SUBJ","has, PRED","established, PRED","itself, O","as, O","one, O","of, O","the, O","leading, O","players, O","in, O","neurosciences,, O","David, SUBJ","Loew,, SUBJ","CEO,, SUBJ","said, PRED","Olivia, SUBJ","brings, PRED","over, O","20, O","years, O","of, O","global, O","leadership, O","experience, O","in, O","pharmaceuticals, O","and, O","medical, O","aesthetics,, O","Olivia, SUBJ","Brown, SUBJ","said, PRED","Ipsen, SUBJ","is, PRED","a, O","global, O","biopharmaceutical, O","company, O","Alina, SUBJ","LEVCHUK,, SUBJ","Nicolas, SUBJ","BOGLER,, SUBJ","Sally, SUBJ","BAIN,, SUBJ","Anne, SUBJ","LIONTAS,, SUBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041264/0/en/Sagimet-Biosciences-Reports-Full-Year-2024-Financial-Results-and-Provides-Corporate-Updates.html,"Sagimet, SUBJ","Biosciences, SUBJ","Inc., SUBJ","reports, PRED","Full, O","Year, O","2024, O","Financial, O","Results, O","provides, PRED","corporate, O","updates, O","March, O","12, O","2025, O","0730, O","ET, O","Source, O","Sagimet, SUBJ","Biosciences, SUBJ","Inc., SUBJ","Denifanstat, SUBJ","Phase, O","3, O","MASH, OBJ","program, O","initiated, PRED","in, O","Q4, O","2024, O","patient, O","screening, O","expected, PRED","to, O","start, O","in, O","1H, O","2025, O","Denifanstat, SUBJ","received, PRED","Breakthrough, O","Therapy, O","designation, O","from, O","FDA, OBJ","for, O","MASH, OBJ","Clearance, O","of, O","Investigational, O","New, O","Drug, O","IND, O","application, O","for, O","FASN, O","Inhibitor, O","TVB-3567, SUBJ","to, O","be, O","developed, PRED","for, O","the, O","treatment, O","of, O","acne, O","SAN, O","MATEO, O","Calif., O","March, O","12, O","2025, O","GLOBE, O","NEWSWIRE, O","Sagimet, SUBJ","Biosciences, SUBJ","Inc., SUBJ","Nasdaq, O","SGMT, SUBJ","clinical-stage, O","biopharmaceutical, O","company, O","developing, PRED","novel, O","therapeutics, O","targeting, O","dysfunctional, O","metabolic, O","and, O","fibrotic, O","pathways, O","today, O","reported, PRED","financial, O","results, O","for, O","the, O","full, O","year, O","ended, O","December, O","31, O","2024, O","2024, O","was, O","a, O","highly, O","productive, O","year, O","for, O","Sagimet, SUBJ","were, O","carrying, PRED","that, O","momentum, O","into, O","a, O","strong, O","start, O","for, O","2025, O","said, PRED","David, SUBJ","Happel, SUBJ","Chief, O","Executive, O","Officer, O","of, O","Sagimet, OBJ","We, O","are, O","pleased, O","to, O","have, O","initiated, PRED","our, O","Phase, O","3, O","denifanstat, SUBJ","program, O","in, O","MASH, OBJ","with, O","site, O","activation, O","and, O","patient, O","pre-screening, O","underway, O","and, O","patient, O","screening, O","expected, PRED","to, O","begin, O","soon, O","With, O","the, O","successful, O","Phase, O","2b, O","FASCINATE-2, O","results, O","we, O","reported, PRED","in, O","2024, O","and, O","Breakthrough, O","Therapy, O","designation, O","granted, PRED","by, O","the, O","FDA, OBJ","we, O","are, O","confident, O","in, O","denifanstats, O","potential, O","to, O","address, O","the, O","significant, O","unmet, O","need, O","for, O","patients, O","living, O","with, O","MASH, OBJ","At, O","the, O","same, O","time, O","we, O","are, O","excited, O","to, O","advance, PRED","a, O","second, O","Fatty, O","Acid, O","Synthase, O","inhibitor, O","TVB-3567, SUBJ","into, O","the, O","clinic, O","for, O","the, O","potential, O","treatment, O","of, O","moderate, O","to, O","severe, O","acne, O","following, O","IND, O","clearance, O","Given, O","the, O","potential, O","of, O","FASN, O","inhibition, O","across, O","multiple, O","disease, O","states, O","we, O","look, O","forward, O","to, O","progressing, PRED","both, O","denifanstat, SUBJ","and, O","TVB-3567, SUBJ","in, O","the, O","coming, O","year, O","Sagimet, SUBJ","announced, PRED","the, O","clearance, O","of, O","its, O","IND, O","application, O","for, O","a, O","first-in-human, O","Phase, O","1, O","clinical, O","trial, O","of, O","a, O","second, O","FASN, O","inhibitor, O","TVB-3567, SUBJ","The, O","Phase, O","1, O","trial, O","initiation, O","is, O","planned, PRED","in, O","2025, O","Sagimet, SUBJ","announced, PRED","the, O","successful, O","completion, O","of, O","end-of-Phase, O","2, O","interactions, O","with, O","the, O","FDA, OBJ","supporting, PRED","the, O","advancement, O","of, O","denifanstat, SUBJ","into, O","Phase, O","3, O","development, O","in, O","metabolic-dysfunction, O","associated, O","steatohepatitis, O","MASH, OBJ","Sagimet, SUBJ","announced, PRED","that, O","the, O","FDA, OBJ","granted, PRED","Breakthrough, O","Therapy, O","designation, O","to, O","denifanstat, SUBJ","for, O","the, O","treatment, O","of, O","non-cirrhotic, O","MASH, OBJ","with, O","moderate, O","to, O","advanced, O","liver, O","fibrosis, O","consistent, O","with, O","stages, O","F2, O","to, O","F3, O","fibrosis, O","Sagimet, SUBJ","announced, PRED","positive, O","topline, O","results, O","from, O","the, O","Phase, O","2b, O","FASCINATE-2, O","clinical, O","trial, O","evaluating, PRED","denifanstat, SUBJ","in, O","biopsy-confirmed, O","MASH, OBJ","patients, O","with, O","stage, O","F2, O","or, O","F3, O","fibrosis, O","compared, PRED","to, O","placebo, O","at, O","week, O","52, O","Sagimet, SUBJ","delivered, PRED","an, O","oral, O","presentation, O","at, O","the, O","MASH, OBJ","Pathogenesis, O","and, O","Therapeutic, O","Approaches, O","Keystone, O","Symposium, O","Sagimet, SUBJ","delivered, PRED","an, O","oral, O","presentation, O","at, O","the, O","9th, O","Annual, O","MASH-TAG, O","Conference, O","highlighting, PRED","the, O","differentiated, O","mechanism, O","of, O","action, O","of, O","the, O","FASN, O","inhibitor, O","denifanstat, SUBJ","and, O","the, O","observed, O","anti-fibrotic, O","effect, O","in, O","the, O","Phase, O","2b, O","FASCINATE-2, O","study, O","in, O","F2F3, O","MASH, OBJ","Sagimet, SUBJ","presented, PRED","clinical, O","denifanstat, SUBJ","and, O","preclinical, O","FASN, O","inhibitor, O","data, O","at, O","the, O","American, O","Association, O","for, O","the, O","Study, O","of, O","Liver, O","Disease, O","AASLD, OBJ","The, O","Liver, O","Meeting, O","2024, O","Sagimet, SUBJ","announced, PRED","the, O","publication, O","of, O","results, O","from, O","the, O","Phase, O","2b, O","FASCINATE-2, O","clinical, O","trial, O","of, O","denifanstat, SUBJ","in, O","The, O","Lancet, O","Gastroenterology, O","Hepatology, OBJ","Sagimet, SUBJ","delivered, PRED","an, O","oral, O","presentation, O","at, O","the, O","8th, O","Annual, O","MASH, OBJ","Drug, O","Development, O","Summit, O","highlighting, PRED","denifanstats, SUBJ","direct, O","anti-fibrotic, O","activity, O","in, O","MASH, OBJ","Sagimet, SUBJ","announced, PRED","several, O","appointments, O","to, O","its, O","board, O","of, O","directors, O","including, O","industry, O","leaders, O","Tim, SUBJ","Walbert, SUBJ","Paul, SUBJ","Hoelscher, SUBJ","Dr., O","Anne, SUBJ","Phillips, SUBJ","and, O","Jennifer, SUBJ","Jarrett, SUBJ","Sagimet, SUBJ","appointed, PRED","Thierry, SUBJ","Chauche, SUBJ","as, O","Chief, O","Financial, O","Officer, O","Sagimet, SUBJ","completed, PRED","a, O","follow-on, O","offering, O","of, O","9,000,000, O","shares, O","of, O","its, O","Series, O","A, O","common, O","stock, O","resulting, PRED","in, O","104.7, O","million, O","in, O","net, O","proceeds, O","Sagimet, SUBJ","expects, PRED","to, O","initiate, O","screening, O","of, O","patients, O","in, O","the, O","first, O","half, O","of, O","2025, O","Sagimet, SUBJ","plans, PRED","to, O","seek, O","accelerated, O","approval, O","in, O","the, O","US, O","and, O","Europe, OBJ","based, O","on, O","this, O","52-week, O","data, O","Sagimet, SUBJ","expects, PRED","to, O","announce, O","topline, O","results, O","in, O","the, O","second, O","quarter, O","of, O"
https://www.globenewswire.com/news-release/2025/03/11/3040930/0/en/Nymox-Announces-Dismissal-of-Delaware-Action-Against-Ascella.html,"Nymox, SUBJ","Announces, PRED","Dismissal, OBJ","of, O","Delaware, SUBJ","Action, PRED","Against, O","Ascella, OBJ","Paul, SUBJ","said, PRED","Nymox, SUBJ","has submitted, PRED","applications, OBJ","Nymox, SUBJ","continues, PRED","Nymox, SUBJ","has reported, PRED","data, OBJ","Nymox, SUBJ","has tested, PRED","Fexapotide, SUBJ","has led, PRED","Such, O","risks, O","and, O","uncertainties, O","include, O","Nymox, SUBJ","undertakes, PRED","Nymoxs, SUBJ","filed, PRED"
https://www.globenewswire.com/news-release/2025/03/11/3040988/0/en/Sanara-MedTech-to-Report-Fourth-Quarter-and-Full-Year-2024-Financial-Results-on-March-25-2025.html,"Sanara, SUBJ","MedTech, SUBJ","to, O","Report, PRED","Fourth, O","Quarter, O","and, O","Full, O","Year, O","2024, O","Financial, O","Results, OBJ","on, O","March, O","25, O","2025, O","The, O","Company, SUBJ","will, O","host, PRED","a, O","conference, O","call, OBJ","and, O","webcast, OBJ","on, O","March, O","25, O","2025, O","at, O","800, O","a.m., O","Eastern, O","Time, O","Sanara, SUBJ","markets, PRED","and, O","distributes, PRED","surgical, O","wound, O","and, O","skincare, O","products, OBJ","Sanara, SUBJ","markets, PRED","and, O","distributes, PRED","CellerateRX, OBJ","Surgical, O","Activated, O","Collagen, OBJ","Sanara, SUBJ","markets, PRED","and, O","distributes, PRED","FORTIFY, OBJ","TRG, OBJ","Tissue, O","Repair, O","Graft, OBJ","Sanara, SUBJ","markets, PRED","and, O","distributes, PRED","FORTIFY, OBJ","FLOWABLE, OBJ","Extracellular, O","Matrix, OBJ","Sanara, SUBJ","markets, PRED","and, O","distributes, PRED","a, O","portfolio, O","of, O","advanced, O","biologic, O","products, OBJ","Sanara, SUBJ","sells, PRED","BIAKŌS, OBJ","Antimicrobial, O","Skin, O","and, O","Wound, O","Cleanser, OBJ","Sanara, SUBJ","sells, PRED","BIAKŌS, OBJ","Antimicrobial, O","Wound, O","Gel, OBJ","Sanara, SUBJ","sells, PRED","BIAKŌS, OBJ","Antimicrobial, O","Skin, O","and, O","Wound, O","Irrigation, O","Solution, OBJ","The, O","Company, SUBJ","believes, PRED","it, O","has, O","the, O","ability, O","to, O","drive, O","its, O","pipeline, OBJ","Sanara, SUBJ","is, O","seeking, PRED","long-term, O","strategic, O","partnerships, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041141/0/en/Angelini-Ventures-leads-10-million-Series-A-financing-in-Vantis-a-Digital-Care-Innovation-company.html,"Angelini, SUBJ","Ventures, SUBJ","leads, PRED","Series, OBJ","A, O","financing, OBJ","in, O","Vantis, OBJ","Vantis, SUBJ","is, PRED","company, O","Angelini, SUBJ","Ventures, SUBJ","announces, PRED","it, O","has, O","led, O","a, O","Series, OBJ","A, O","financing, OBJ","round, OBJ","in, O","Vantis, OBJ","Health, OBJ","Vantis, SUBJ","is, PRED","company, O","Vantis, SUBJ","is, PRED","based, PRED","in, O","Munich, OBJ","Vantis, SUBJ","is, PRED","addressing, PRED","Germanys, O","most, O","pressing, O","healthcare, O","challenges, O","Vantis, SUBJ","aims, PRED","The, O","financing, OBJ","round, OBJ","was, O","led, O","by, O","Angelini, SUBJ","Ventures, SUBJ","Angelini, SUBJ","Ventures, SUBJ","investment, OBJ","in, O","Vantis, OBJ","Angelini, SUBJ","Ventures, SUBJ","is, PRED","advancing, PRED","Vantis, SUBJ","model, OBJ","aligns, PRED","Nils, SUBJ","Bottler, SUBJ","said, PRED","Vantis, SUBJ","is, PRED","redefining, PRED","Till, SUBJ","Jansen, SUBJ","emphasizes, PRED","Angelini, SUBJ","Ventures, SUBJ","is, PRED","Angelini, SUBJ","Ventures, SUBJ","will, O","invest, PRED","Angelini, SUBJ","Industries, SUBJ","is, PRED","Angelini, SUBJ","Industries, SUBJ","represents, PRED","Vantis, SUBJ","is, PRED","Vantis, SUBJ","leverages, PRED","Vantis, SUBJ","invests, PRED","Paolo, SUBJ","Di, SUBJ","Giorgio, SUBJ","Martina, SUBJ","Palmese, SUBJ","Daniele, SUBJ","Pinosa, SUBJ","Fausta, SUBJ","Tagliarini, SUBJ","Daniele, SUBJ","Murgia, SUBJ","Sylvie, SUBJ","Berrebi, SUBJ","Sandi, SUBJ","Greenwood, SUBJ","Mark, SUBJ","Swallow, SUBJ","Angelini, SUBJ","Ventures, SUBJ","Appoints, PRED","Dr., O","Regina, SUBJ","Hodits, SUBJ","Angelini, SUBJ","Ventures, SUBJ","co-leads, PRED","financing, OBJ","in, O","Nobi, OBJ","Angelini, SUBJ","Ventures, SUBJ","investment, OBJ","in, O","Nobi, OBJ","demonstrates, PRED"
https://www.globenewswire.com/news-release/2025/03/12/3041239/0/en/Tilray-Grows-Its-Non-Alcoholic-Craft-Beer-Line-Runner-s-High-Brewing-Across-the-East-Coast-and-Mid-West-Regions.html,"Tilray, SUBJ","Grows, PRED","Its, O","Non-Alcoholic, O","Craft, O","Beer, O","Line, O","Runners, SUBJ","High, SUBJ","Brewing, SUBJ","Connects, PRED","with, O","Social, O","Running, O","Communities, O","Runners, SUBJ","High, SUBJ","Catters, PRED","to, O","Lifestyle, O","Preferences, O","Tilray, SUBJ","Brands, SUBJ","Inc, SUBJ","announced, PRED","Tilray, SUBJ","Beverages, SUBJ","the, O","beverage, O","division, O","of, O","Tilray, SUBJ","Brands, SUBJ","Inc, SUBJ","distributes, PRED","Prinz, SUBJ","Pinakatt, SUBJ","stated, PRED","Runners, SUBJ","High, SUBJ","is, PRED","collaborating, O","with, O","Union, OBJ","Fit, OBJ","Hub, OBJ","Runners, SUBJ","High, SUBJ","maintains, PRED","the, O","Peachtree, OBJ","Road, OBJ","Race, OBJ","The, O","Peachtree, SUBJ","Road, SUBJ","Race, SUBJ","is, PRED","scheduled, O","Atlanta, OBJ","Georgia, OBJ","Tilray, SUBJ","Brands, SUBJ","Inc, SUBJ","is, PRED","Tilray, SUBJ","Brands, SUBJ","Inc, SUBJ","supports, PRED","Tilray, SUBJ","Brands, SUBJ","Inc, SUBJ","leads, PRED","Terrapin, SUBJ","Beer, SUBJ","Co, SUBJ","Celebrates, PRED","Terrapin, SUBJ","Beer, SUBJ","Co, SUBJ","partners, PRED","Breckenridge, SUBJ","Distillery, SUBJ","Announces, PRED","Breckenridge, SUBJ","Distillery, SUBJ","Releases, PRED"
https://www.globenewswire.com/news-release/2025/03/11/3041067/0/en/Teknova-and-Pluristyx-Announce-Collaboration-to-Streamline-the-Manufacture-of-Next-Generation-Cell-Therapies.html,"Teknova, SUBJ","Announce, PRED","Collaboration, OBJ","Pluristyx, SUBJ","Announce, PRED","Collaboration, OBJ","Teknova, SUBJ","Become, PRED","Manufacturer, OBJ","Teknova, SUBJ","Become, PRED","Distributor, OBJ","Pluristyx, SUBJ","launched, PRED","PluriFreeze, OBJ","Pluristyx, SUBJ","identified, PRED","formulation, O","Pluristyx, SUBJ","designed, PRED","PluriFreeze, OBJ","Teknova, SUBJ","enable, PRED","access, O","Teknova, SUBJ","make, PRED","distributor, O","Gunstream, SUBJ","said, PRED","O, O","Teknova, SUBJ","marry, PRED","scale, O","Teknova, SUBJ","help, PRED","developers, O","Fryer, SUBJ","added, PRED","O, O","Teknova, SUBJ","help, PRED","access, O","Teknova, SUBJ","make, PRED","solutions, O","Teknova, SUBJ","innovating, PRED","manufacture, O","Teknova, SUBJ","offer, PRED","solutions, O","Teknova, SUBJ","headquartered, PRED","Hollister, OBJ","Pluristyx, SUBJ","is, PRED","company, O","Pluristyx, SUBJ","offering, PRED","products, O","Pluristyx, SUBJ","delivering, PRED","therapies, O","Lowell, SUBJ","is, PRED","Contact, O","Henry, SUBJ","is, PRED","Contact, O","Geelhood, SUBJ","is, PRED","Contact, O"
https://www.globenewswire.com/news-release/2025/03/12/3041368/0/en/Journey-Medical-Corporation-to-Participate-in-the-37th-Annual-ROTH-Conference.html,"Journey, SUBJ","Medical, SUBJ","Corporation, SUBJ","to, O","Participate, PRED","in, O","the, O","37th, O","Annual, O","ROTH, OBJ","Conference, OBJ","Claude, SUBJ","Maraoui, SUBJ","will, O","participate, PRED","in, O","a, O","fireside, O","chat, O","Jaclyn, SUBJ","Jaffe, SUBJ","Contact, PRED","Tony, SUBJ","Plohoros, SUBJ","Contact, PRED","Journey, SUBJ","Medical, SUBJ","Corporation, SUBJ","Appoints, PRED","Ramsey, OBJ","Alloush, OBJ","Journey, SUBJ","Medical, SUBJ","Corporation, SUBJ","Reports, PRED","FDA, SUBJ","Approval, PRED","Emrosi, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041106/0/en/Tecan-reports-2024-financial-results-enhancing-operational-resilience-amid-challenging-conditions.html,"Tecan, SUBJ","reports, PRED","2024, OBJ","financial, O","results, O","Tecan, SUBJ","enhancing, PRED","operational, O","resilience, OBJ","Dr., O","Achim, SUBJ","von, O","Leoprechting, SUBJ","commented, PRED","conditions, O","Tecan, SUBJ","is, PRED","navigating, O","Tecan, SUBJ","has, PRED","implemented, O","Tecan, SUBJ","optimized, PRED","operations, O","Tecan, SUBJ","is, PRED","driving, O","Tecan, SUBJ","positioning, PRED","us, O","Tecan, SUBJ","established, PRED","office, O","Tecan, SUBJ","acquiring, PRED","distributor, O","Tecan, SUBJ","previewed, PRED","Veya, OBJ","Tecan, SUBJ","launched, PRED","Veya, OBJ","Tecan, SUBJ","expanded, PRED","ecosystem, O","Tecan, SUBJ","highlighted, PRED","relationships, O","Tecan, SUBJ","assisted, PRED","THINK, OBJ","Tecan, SUBJ","is, PRED","manufacturing, O","Tecan, SUBJ","aims, PRED","to, O","double, O","Tecan, SUBJ","has, PRED","integrated, O","Tecan, SUBJ","will, PRED","propose, O","Tecan, SUBJ","anticipates, PRED","year, O","Tecan, SUBJ","demonstrated, PRED","commitment, O","Tecan, SUBJ","forecasts, PRED","margin, O","Tecan, SUBJ","reiterated, PRED","outlook, O","Tecan, SUBJ","will, PRED","hold, O","The, O","Annual, O","General, O","Meeting, O","of, O","Tecans, O","shareholders, O","will, O","take, O","place, O","A, O","Q1, O","2025, O","Qualitative, O","Update, O","will, O","be, O","published, O","The, O","2025, O","Interim, O","Report, O","will, O","be, O","published, O","A, O","Q3, O","2025, O","Qualitative, O","Update, O","will, O","be, O","published, O","Tecan, SUBJ","generated, PRED","sales, O","Tecan, SUBJ","maintains, PRED","network, O","Tecan, SUBJ","was, PRED","founded, O","Martin, SUBJ","BrändleSenior, OBJ","Vice, O","President, O","Monica, SUBJ","Manotas, OBJ","Karen, SUBJ","Huebscher, OBJ","Myra, SUBJ","Eskes, OBJ"
https://www.globenewswire.com/news-release/2025/03/11/3040664/0/en/AMPS-Launches-ClaimInsight-A-Next-Generation-Payment-Integrity-Suite-Built-for-Accuracy-Speed-and-Value.html,"Advanced, SUBJ","Medical, SUBJ","Pricing, SUBJ","Solutions, SUBJ","launches, PRED","ClaimInsight, OBJ","Jonathan, SUBJ","Jeffress, SUBJ","said, PRED","AMPS, SUBJ","is, PRED","introducing, PRED","Payers, SUBJ","choose, PRED","ClaimInsight, OBJ","John, SUBJ","Flack, SUBJ","Appointed, PRED","CFO, OBJ","AMPS, SUBJ","Raises, PRED"
https://www.globenewswire.com/news-release/2025/03/11/3040743/0/en/Baylor-Genetics-to-Showcase-Genetic-Testing-Innovations-for-Rare-Disease-at-ACMG-2025-Annual-Clinical-Genetics-Meeting.html,"Baylor, SUBJ","Genetics, SUBJ","to, O","Showcase, PRED","Genetic, OBJ","Testing, OBJ","Innovations, OBJ","for, O","Accessibility, O","Skip, O","TopNav, O","Baylor, SUBJ","Genetics, SUBJ","to, O","Showcase, PRED","Genetic, OBJ","Testing, OBJ","Innovations, OBJ","for, O","Rare, OBJ","Disease, OBJ","at, O","ACMG, OBJ","2025, O","Annual, O","Clinical, O","Genetics, O","Meeting, O","March, O","11,, O","2025, O","1000, O","ET, O","Source, O","Baylor, SUBJ","Genetics, SUBJ","HOUSTON,, O","March, O","11,, O","2025, O","GLOBE, O","NEWSWIRE, O","--, O","As, O","Baylor, SUBJ","Genetics, SUBJ","celebrates, PRED","a, O","decade, O","of, O","leadership, O","at, O","the, O","forefront, O","of, O","genetic, OBJ","testing,, O","it, O","is, O","set, O","to, O","exhibit, O","its, O","latest, O","scientific, OBJ","studies, OBJ","in, O","genetic, OBJ","testing, OBJ","at, O","the, O","2025, O","ACMG, OBJ","Annual, O","Clinical, O","Genetics, O","Meeting,, O","taking, O","place, O","March, O","18-22,, O","2025,, O","in, O","Los, PLACE","Angeles,, PLACE","CA., O","The, O","Company, SUBJ","will, O","be, O","located, O","at, O","Booth, O","217, O","at, O","the, O","Los, PLACE","Angeles, PLACE","Convention, O","Center., O","We, O","are, O","excited, O","to, O","share, O","several, O","recent, O","studies, O","with, O","our, O","colleagues, O","at, O","ACMG,, OBJ","particularly, O","as, O","we, O","continue, O","to, O","make, O","significant, O","strides, O","in, O","variant, OBJ","detection,, OBJ","functional,, OBJ","and, O","clinical, OBJ","significance,, OBJ","said, O","Christine, PERSON","Eng,, PERSON","M.D.,, O","Chief, O","Medical, O","Officer, O","and, O","Chief, O","Quality, O","Officer, O","at, O","Baylor, ORG","Genetics,, ORG","This, O","data, O","underscores, O","Baylor, SUBJ","Genetics, SUBJ","mission, O","to, O","get, O","answers, O","for, O","those, O","living, O","with, O","an, O","undiagnosed, O","rare, OBJ","disease, OBJ","and, O","end, O","the, O","diagnostic, O","odyssey, O","for, O","patients, PERSON","and, O","families., PERSON","At, O","the, O","event,, O","Baylor, SUBJ","Genetics, SUBJ","will, O","highlight, O","its, O","innovative, OBJ","testing, OBJ","solutions, OBJ","in, O","the, O","rare, OBJ","disease, OBJ","space, O","with, O","one, O","presentation, O","and, O","three, O","poster, O","sessions, O","Presentation, O","Detecting, PRED","Mitochondrial, OBJ","Electron, OBJ","Transport, OBJ","Chain, OBJ","Enzyme, OBJ","Defects, OBJ","in, O","Low-Heteroplasmy, OBJ","Single, OBJ","Large-Scale, OBJ","mtDNA, OBJ","Deletion, OBJ","Syndromes, OBJ","SLSMDs, OBJ","Presenter, O","Xueyang, PERSON","Pan,, PERSON","PhD, O","Session, O","Platform, O","Session, O","5, O","Neurodevelopmental, O","Biochemical, OBJ","Genes, OBJ","Date, O","Time, O","March, O","21,, O","130, O","p.m., O","145, O","p.m., O","PT, O","Location, O","Petree, PLACE","Hall, PLACE","C, O","Posters, O","located, O","in, O","Exhibit, PLACE","Hall, PLACE","Reflex, OBJ","RNA, OBJ","Sequencing, OBJ","for, O","Enhanced, OBJ","Variant, OBJ","Classification, OBJ","on, O","ESGS, OBJ","Improves, PRED","Patient, OBJ","Outcomes, OBJ","Presenter, O","Mei, PERSON","Ling, PERSON","Chong,, PERSON","PhD, O","Poster, O","ID, O","P645, O","Date, O","Time, O","March, O","20,, O","1030, O","a.m., O","1130, O","a.m., O","PT, O","Clinical, OBJ","Significance, OBJ","of, O","mRNA, OBJ","Nonstop, OBJ","Decay, OBJ","in, O","Rare, OBJ","Disease, OBJ","Diagnosis, OBJ","Presenter, O","Yue, PERSON","Zhou,, PERSON","PhD, O","Poster, O","ID, O","P731, O","Date, O","Time, O","March, O","20,, O","1030, O","a.m., O","1130, O","a.m., O","PT, O","Identification, PRED","of, O","a, O","Novel, OBJ","Variant, OBJ","in, O","the, O","MAD1L1, OBJ","Gene, OBJ","in, O","an, O","Individual, OBJ","with, O","Mosaic, OBJ","Variegated, OBJ","Aneuploidy, OBJ","Syndrome, OBJ","Presenter, O","Veronica, PERSON","Ortiz,, PERSON","PhD, O","Poster, O","ID, O","P783, O","Date, O","Time, O","March, O","20,, O","1030, O","a.m., O","1130, O","a.m., O","PT, O","Attendees, O","can, O","also, O","connect, O","with, O","Baylor, ORG","Genetics, ORG","team, PERSON","of, O","experts, PERSON","at, O","Booth, O","217, O","to, O","explore, O","the, O","latest, O","trends, O","in, O","genetic, OBJ","testing, OBJ","and, O","precision, OBJ","diagnostics., OBJ","Discover, O","Baylor, SUBJ","Genetics, SUBJ","comprehensive, OBJ","testing, OBJ","portfolio,, OBJ","featuring, O","rapid, OBJ","Whole, OBJ","Genome, OBJ","Sequencing, OBJ","WGS, OBJ","and, O","Whole, OBJ","Exome, OBJ","Sequencing, OBJ","WES, OBJ","tests, OBJ","among, O","the, O","fastest, O","and, O","most, O","accurate, O","precision, OBJ","diagnostic, OBJ","tools, OBJ","available., O","Learn, O","about, O","RNA, OBJ","sequencing,, OBJ","designed, O","to, O","enhance, O","the, O","detection, O","of, O","specific, OBJ","qualified, OBJ","variants, OBJ","using, O","curated, OBJ","genetic, OBJ","data,, OBJ","expert, OBJ","interpretation,, OBJ","and, O","AI-driven, OBJ","predictive, OBJ","algorithms., OBJ","With, O","RNAseq,, OBJ","qualified, OBJ","variants, OBJ","can, O","be, O","reclassified,, O","enabling, O","faster, O","and, O","more, O","actionable, O","diagnoses, OBJ","and, O","treatments., OBJ","Members, PERSON","of, O","the, O","media, PERSON","are, O","invited, O","to, O","interview, O","Baylor, ORG","Genetics, ORG","executives, PERSON","and, O","subject, PERSON","matter, PERSON","experts., PERSON","To, O","schedule, O","a, O","meeting, O","in, O","advance,, O","please, O","contact, O","baylorgeneticssvmpr.com, O","About, O","Baylor, SUBJ","Genetics, SUBJ","As, O","a, O","pioneer, O","of, O","precision, OBJ","medicine, OBJ","for, O","over, O","45, O","years,, O","Baylor, SUBJ","Genetics, SUBJ","is, O","a, O","leading, O","diagnostic, OBJ","genomics, OBJ","partner, OBJ","offering, O","a, O","full, O","spectrum, O","of, O","clinically, O","relevant, O","genetic, OBJ","testing,, OBJ","including, O","Whole, OBJ","Genome, OBJ","Sequencing,, OBJ","Whole, OBJ","Exome, OBJ","Sequencing,, OBJ","and, O","focused, OBJ","panels., OBJ","Through, O","a, O","joint, O","venture, O","of, O","H.U., ORG","Group, ORG","Holdings,, ORG","Inc., ORG","and, O","Baylor, ORG","College, ORG","of, ORG","Medicine,, ORG","Baylor, SUBJ","Genetics, SUBJ","combines, PRED","rapid, OBJ","and, O","comprehensive, OBJ","precision, OBJ","diagnostics, OBJ","options, OBJ","with, O","the, O","support, O","of, O","genetic, OBJ","counselors, OBJ","to, O","help, O","clinicians, PERSON","avoid, O","a, O","lengthy, OBJ","diagnostic, OBJ","odyssey, OBJ","for, O","their, O","patients,, PERSON","guide, O","medical, OBJ","management,, OBJ","and, O","ensure, O","no, O","patient, PERSON","with, O","a, O","genetic, OBJ","disorder, OBJ","gets, O"
https://www.globenewswire.com/news-release/2025/03/12/3041384/0/en/Ascentage-Pharma-to-Report-Full-Year-2024-Financial-Results-and-Provide-Corporate-Update-on-March-27-2025.html,"Ascentage, SUBJ","Pharma, SUBJ","to, O","Report, PRED","Full, O","Year, O","2024, O","Financial, O","Results, OBJ","Ascentage, SUBJ","Pharma, SUBJ","to, O","Provide, PRED","Corporate, O","Update, OBJ","Ascentage, SUBJ","Pharma, SUBJ","announced, PRED","that, O","it, O","will, O","release, PRED","full, O","year, O","2024, O","financial, O","results, OBJ","Ascentage, SUBJ","Pharma, SUBJ","will, O","provide, PRED","an, O","update, OBJ","Ascentage, SUBJ","Pharma, SUBJ","will, O","host, PRED","a, O","Chinese, O","Mandarin, O","investor, O","event, OBJ","Ascentage, SUBJ","Pharma, SUBJ","is, O","a, O","global, O","biopharmaceutical, O","company, O","engaged, PRED","in, O","discovering, OBJ","Ascentage, SUBJ","Pharma, SUBJ","is, O","a, O","global, O","biopharmaceutical, O","company, O","engaged, PRED","in, O","developing, OBJ","Ascentage, SUBJ","Pharma, SUBJ","is, O","a, O","global, O","biopharmaceutical, O","company, O","engaged, PRED","in, O","commercializing, OBJ","Ascentage, SUBJ","Pharma, SUBJ","has, PRED","been, O","listed, PRED","on, O","the, O","Main, O","Board, O","of, O","the, O","Stock, O","Exchange, O","of, O","Hong, O","Kong, O","Limited, O","Ascentage, SUBJ","Pharma, SUBJ","has, PRED","been, O","listed, PRED","on, O","the, O","Nasdaq, O","Global, O","Market, OBJ","Hogan, SUBJ","Wan, SUBJ","is, O","Head, O","of, O","IR, O","and, O","Strategy, O","at, O","Ascentage, OBJ","Pharma, OBJ","Stephanie, SUBJ","Carrington, SUBJ","is, O","at, O","ICR, OBJ","Healthcare, OBJ","Sean, SUBJ","Leous, SUBJ","is, O","at, O","ICR, OBJ","Healthcare, OBJ","Ascentage, SUBJ","Pharma, SUBJ","To, O","Present, PRED","Data, OBJ","Ascentage, SUBJ","Pharma, SUBJ","Announces, PRED","Inclusion, OBJ","Ascentage, SUBJ","Pharma, SUBJ","is, O","a, O","global, O","biopharmaceutical, O","company, O","engaged, PRED","in, O","discovering, OBJ","Ascentage, SUBJ","Pharma, SUBJ","is, O","a, O","global, O","biopharmaceutical, O","company, O","engaged, PRED","in, O","developing, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041260/0/en/Mesoblast-CEO-to-Deliver-Featured-Presentation-at-ISCT-North-America-Virtual-Town-Hall.html,"Mesoblast, SUBJ","CEO, PRED","to, O","Deliver, PRED","Featured, OBJ","Presentation, OBJ","at, O","ISCT, OBJ","Silviu, SUBJ","Itescu, SUBJ","will, O","deliver, PRED","the, O","Featured, OBJ","Presentation, OBJ","at, O","the, O","International, OBJ","Cell, OBJ","Gene, OBJ","Therapy, OBJ","ISCT, OBJ","North, OBJ","America, OBJ","Regional, OBJ","Virtual, OBJ","Town, OBJ","Hall, OBJ","Mesoblast, SUBJ","is, O","a, O","world, O","leader, O","in, O","developing, O","allogeneic, O","off-the-shelf, O","cellular, O","medicines, O","RYONCIL, SUBJ","is, O","being, O","developed, PRED","for, O","additional, O","inflammatory, O","diseases, O","Rexlemestrocel-L, SUBJ","is, O","being, O","developed, PRED","for, O","heart, O","failure, O","and, O","chronic, O","low, O","back, O","pain, O","Mesoblast, SUBJ","has, O","established, PRED","commercial, O","partnerships, OBJ","in, O","Japan, OBJ","Europe, OBJ","and, O","China, OBJ","Mesoblast, SUBJ","has, O","locations, O","in, O","Australia, OBJ","the, O","United, OBJ","States, OBJ","and, O","Singapore, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041407/0/en/Cylinder-joins-Teladoc-Health-s-Connected-Care-Program-to-expand-access-to-virtual-digestive-care.html,"Cylinder, SUBJ","joins, PRED","Teladoc, OBJ","Healths, OBJ","Connected, O","Care, O","Program, O","to, O","accessibility, O","Skip, O","TopNav, O","Cylinder, SUBJ","joins, PRED","Teladoc, OBJ","Healths, OBJ","Connected, O","Care, O","Program, O","to, O","expand, PRED","access, O","to, O","virtual, O","digestive, O","care, O","The, O","integration, O","enables, O","seamless, O","referrals, O","for, O","GI, O","Care, O","through, O","Teladoc, OBJ","Healths, OBJ","platform, O","Teladoc, SUBJ","Health, OBJ","NYSE, O","TDOC,, O","the, O","global, O","leader, O","in, O","virtual, O","care,, O","to, O","expand, PRED","access, O","to, O","high-quality,, O","personalized, O","gastrointestinal, O","care,, O","Bill, SUBJ","Snyder, SUBJ","said, PRED","Cylinder, SUBJ","partnering, PRED","Teladoc, OBJ","Health,, OBJ","Teladoc, SUBJ","Healths, SUBJ","commitment, O","to, O","expanding, PRED","its, O","connected, O","care, O","partnerships,, O","Cylinder, SUBJ","delivers, PRED","Cylinder, SUBJ","has, PRED","helped, PRED","Cylinder, SUBJ","showcases, PRED","Teladoc, SUBJ","Health, SUBJ","empowers, PRED","Merrita, SUBJ","Villa, SUBJ","Cylinder, SUBJ","hits, PRED","Cylinder, SUBJ","acquires, PRED","Dieta, OBJ","Health,, OBJ"
https://www.globenewswire.com/news-release/2025/03/11/3040630/0/en/Capricor-Therapeutics-to-Present-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Corporate-Update-on-March-19.html,"Capricor, SUBJ","Therapeutics, SUBJ","to, O","Present, PRED","Fourth, OBJ","Quarter, OBJ","and, O","Full, OBJ","Year, OBJ","2024, OBJ","Financial, OBJ","Results, OBJ","and, O","Recent, OBJ","Corporate, OBJ","Update, OBJ","on, O","March, OBJ","19, OBJ","Company, SUBJ","to, O","Host, PRED","Conference, OBJ","Call, OBJ","March, OBJ","19, OBJ","2025, OBJ","at, O","430, OBJ","p.m., OBJ","ET, OBJ","March, SUBJ","11, SUBJ","2025, SUBJ","0900, OBJ","ET, OBJ","Source, O","Capricor, SUBJ","Therapeutics, SUBJ","Capricor, SUBJ","Therapeutics, SUBJ","SAN, OBJ","DIEGO, OBJ","March, OBJ","11, OBJ","2025, OBJ","GLOBE, O","NEWSWIRE, O","--, O","Capricor, SUBJ","Therapeutics, SUBJ","NASDAQ, OBJ","CAPR, OBJ","a, O","biotechnology, O","company, O","developing, O","transformative, O","cell, O","and, O","exosome-based, O","therapeutics, O","for, O","the, O","treatment, O","of, O","rare, O","diseases, O","will, O","release, O","its, O","financial, O","results, O","for, O","the, O","fourth, O","quarter, O","and, O","full, O","year, O","ended, O","December, O","31, O","2024, O","after, O","the, O","market, O","close, O","on, O","Wednesday, O","March, O","19, O","2025, O","Management, SUBJ","will, O","then, O","host, PRED","a, O","webcast, O","and, O","conference, O","call, O","at, O","430, O","p.m., O","ET, O","on, O","March, O","19, O","TitleCapricor, O","Therapeutics, O","Fourth, O","Quarter, O","and, O","Full, O","Year, O","2024, O","Financial, O","Results, O","and, O","Recent, O","Corporate, O","Update, O","Conference, O","Call, O","and, O","WebcastDateWednesday, O","March, O","19, O","2025, O","Time430, O","p.m., O","ETConference, O","Call, O","DetailsToll-Free, O","1-800-717-1738International, O","1-646-307-1865Conference, O","ID, O","98172Participants, O","can, O","use, O","guest, O","dial-in, O","numbers, O","above, O","and, O","be, O","answered, O","by, O","an, O","operator, O","or, O","click, O","the, O","Call, O","me, O","link, O","for, O","instant, O","telephone, O","access, O","to, O","the, O","event, O","WebcastWebcast, O","Link, O","-, O","Click, O","Here, O","A, O","replay, O","of, O","the, O","webcast, O","will, O","be, O","available, O","following, O","the, O","conclusion, O","of, O","the, O","live, O","broadcast, O","and, O","will, O","be, O","accessible, O","on, O","the, O","Companys, O","website, O","About, O","Capricor, SUBJ","Therapeutics, SUBJ","Capricor, SUBJ","Therapeutics, SUBJ","Inc., SUBJ","NASDAQ, OBJ","CAPR, OBJ","is, O","a, O","biotechnology, O","company, O","dedicated, O","to, O","advancing, O","transformative, O","cell, O","and, O","exosome-based, O","therapeutics, O","to, O","redefine, O","the, O","treatment, O","landscape, O","for, O","rare, O","diseases, O","At, O","the, O","forefront, O","of, O","our, O","innovation, O","is, O","our, O","lead, O","product, O","candidate, O","deramiocel, OBJ","an, O","allogeneic, O","cardiac-derived, O","cell, O","therapy, O","Extensive, O","preclinical, O","and, O","clinical, O","studies, O","have, O","shown, O","deramiocel, SUBJ","to, O","demonstrate, PRED","immunomodulatory, OBJ","antifibrotic, OBJ","and, O","regenerative, OBJ","actions, OBJ","specifically, O","tailored, O","for, O","dystrophinopathies, O","and, O","heart, O","disease, O","Deramiocel, SUBJ","is, O","currently, O","in, O","late-stage, O","development, O","for, O","the, O","treatment, O","of, O","Duchenne, OBJ","muscular, OBJ","dystrophy, OBJ","Capricor, SUBJ","is, O","also, O","harnessing, O","the, O","power, O","of, O","its, O","exosome, O","technology, O","using, O","its, O","proprietary, O","StealthX, OBJ","platform, OBJ","in, O","preclinical, O","development, O","focused, O","on, O","the, O","areas, O","of, O","vaccinology, O","targeted, O","delivery, O","of, O","oligonucleotides, O","proteins, O","and, O","small, O","molecule, O","therapeutics, O","to, O","potentially, O","treat, O","and, O","prevent, O","a, O","diverse, O","array, O","of, O","diseases, O","At, O","Capricor, SUBJ","we, O","stand, O","committed, O","to, O","pushing, O","the, O","boundaries, O","of, O","possibility, O","and, O","forging, O","a, O","path, O","toward, O","transformative, O","treatments, O","for, O","those, O","in, O","need, O","For, O","more, O","information, O","visit, O","capricor.com, OBJ","and, O","follow, O","Capricor, SUBJ","on, O","Facebook, OBJ","Instagram, OBJ","and, O","Twitter, OBJ","Cautionary, O","Note, O","Regarding, O","Forward-Looking, O","Statements, O","Statements, O","in, O","this, O","press, O","release, O","regarding, O","the, O","efficacy, O","safety, O","and, O","intended, O","utilization, O","of, O","Capricors, SUBJ","product, O","candidates, O","the, O","initiation, O","conduct, O","size, O","timing, O","and, O","results, O","of, O","discovery, O","efforts, O","and, O","clinical, O","trials, O","the, O","pace, O","of, O","enrollment, O","of, O","clinical, O","trials, O","plans, O","regarding, O","regulatory, O","filings, O","future, O","research, O","and, O","clinical, O","trials, O","regulatory, O","developments, O","involving, O","products, O","including, O","the, O","ability, O","to, O","obtain, O","regulatory, O","approvals, O","or, O","otherwise, O","bring, O","products, O","to, O","market, O","manufacturing, O","capabilities, O","dates, O","for, O","regulatory, O","meetings, O","statements, O","about, O","our, O","financial, O","outlook, O","the, O","ability, O","to, O","achieve, O","product, O","milestones, O","and, O","to, O","receive, O","milestone, O","payments, O","from, O","commercial, O","partners, O","plans, O","regarding, O","current, O","and, O","future, O","collaborative, O","activities, O","and, O","the, O","ownership, O","of, O","commercial, O","rights, O","potential, O","future, O","agreements, O","scope, O","duration, O","validity, O","and, O","enforceability, O","of, O","intellectual, O","property, O","rights, O","future, O","revenue, O","streams, O","and, O","projections, O","expectations, O","with, O","respect, O","to, O","the, O","expected, O","use, O","of, O","proceeds, O","from, O","the, O","recently, O","completed, O","offerings, O","and, O","the, O","anticipated, O","effects, O","of, O","the, O","offerings, O","and, O","any, O","other, O","statements, O","about, O","Capricors, SUBJ","management, SUBJ","teams, SUBJ","future, O","expectations, O","beliefs, O","goals, O","plans, O","or, O","prospects, O","constitute, O","forward-looking, O","statements, O","within, O","the, O","meaning, O","of, O","the, O","Private, O","Securities, O","Litigation, O","Reform, O","Act, O","of, O","1995, O","Any, O","statements, O","that, O","are, O","not, O","statements, O","of, O","historical, O","fact, O","including, O","statements, O","containing, O","the, O","words, O","believes, O","plans, O","could, O","anticipates, O","expects, O","estimates, O","should, O","target, O","will, O","would, O","and, O","similar, O","expressions, O","should, O","also, O","be, O","considered, O","to, O","be, O","forward-looking, O","statements, O","There, O","are, O","a, O","number, O","of, O","important, O","factors, O","that, O","could, O","cause, O","actual, O","results, O","or, O","events, O","to, O","differ, O","materially, O","from, O","those, O","indicated, O","by, O","such, O","forward-looking, O","statements, O","More, O"
https://www.globenewswire.com/news-release/2025/03/12/3041256/0/en/Theratechnologies-Presents-Encouraging-Virologic-Suppression-Data-from-the-PROMISE-US-Trial-of-Ibalizumab-at-CROI.html,"Theratechnologies, SUBJ","Presents, PRED","data, O","from, O","the, O","PROMISE-US, OBJ","Trial, OBJ","of, O","Ibalizumab, O","at, O","CROI, O","Results, SUBJ","show, PRED","levels, O","of, O","virus, O","undetectability, O","in, O","patients, O","on, O","ibalizumab-containing, O","regimens, O","as, O","in, O","controls, O","Ibalizumab, SUBJ","continues, PRED","to, O","demonstrate, O","efficacy, O","and, O","safety, O","as, O","part, O","of, O","combination, O","antiretroviral, O","therapy, O","in, O","people, O","with, O","HIV, O","MONTREAL, O","Theratechnologies, SUBJ","presented, PRED","data, O","from, O","a, O","study, O","demonstrating, O","the, O","efficacy, O","and, O","safety, O","of, O","ibalizumab, O","in, O","reducing, O","HIV, O","RNA, O","to, O","undetectable, O","levels, O","in, O","patients, O","with, O","HIV, O","In, O","a, O","poster, O","session, O","at, O","the, O","2025, O","Conference, O","on, O","Retroviruses, O","and, O","Opportunistic, O","Infections, O","CROI, O","in, O","San, O","Francisco, O","investigators, SUBJ","reported, PRED","that, O","patients, O","treated, O","with, O","regimens, O","containing, O","ibalizumab, O","achieved, O","undetectable, O","HIV, O","viral, O","load, O","levels, O","at, O","similar, O","rates, O","as, O","those, O","receiving, O","non-ibalizumab-containing, O","regimens, O","Smitha, SUBJ","Gudipati, SUBJ","stated, PRED","that, O","Theratechnologies, SUBJ","announced, PRED","the, O","study, O","design, O","and, O","baseline, O","characteristics, O","of, O","participants, O","in, O","PROMISE-US, OBJ","Christian, SUBJ","Marsolais, SUBJ","commented, PRED","that, O","Theratechnologies, SUBJ","is, PRED","a, O","biopharmaceutical, O","company, O","focused, O","on, O","the, O","commercialization, O","of, O","innovative, O","therapies, O","The, O","Company, O","undertakes, O","no, O","obligation, O","to, O","update, O","or, O","revise, O","the, O","information, O","contained, O","in, O","this, O","press, O","release, O","Julie, SUBJ","Schneiderman, SUBJ","Senior, O","Director, O","Joanne, SUBJ","Choi, SUBJ","Senior, O","Director, O"
https://www.globenewswire.com/news-release/2025/03/11/3040758/0/ar/VIVUS-%D8%AA%D8%B7%D9%84%D9%82-%D8%B9%D9%82%D8%A7%D8%B1-QSYMIA-%D9%81%D9%8A-%D8%A7%D9%84%D8%A5%D9%85%D8%A7%D8%B1%D8%A7%D8%AA-%D8%A7%D9%84%D8%B9%D8%B1%D8%A8%D9%8A%D8%A9-%D8%A7%D9%84%D9%85%D8%AA%D8%AD%D8%AF%D8%A9.html,"VIVUS, SUBJ","تطلق, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تطلق, PRED","QSYMIA, OBJ","VIVUS, SUBJ","أعلنت, PRED","QSYMIA, OBJ","VIVUS, SUBJ","حصول, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","PharmaAccess, OBJ","Alphamed, SUBJ","هو, PRED","QSYMIA, OBJ","John, SUBJ","Amos, SUBJ","قال, PRED","VIVUS, OBJ","Santosh, SUBJ","T., SUBJ","Varghese, SUBJ","قال, PRED","QSYMIA, OBJ","World, SUBJ","Obesity, SUBJ","Federation, SUBJ","شير, PRED","الإمارات, OBJ","QSYMIA, SUBJ","يوصى, PRED","السمنة, OBJ","QSYMIA, SUBJ","يوصى, PRED","الوزن, OBJ","QSIVA, SUBJ","حصل, PRED","QSYMIA, OBJ","QSIVA, SUBJ","يوصى, PRED","السمنة, OBJ","QSIVA, SUBJ","يوصى, PRED","الوزن, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعمل, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ","تعتزم, PRED","QSYMIA, OBJ","VIVUS, SUBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041234/0/en/InspireMD-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html,"InspireMD, SUBJ","engaged, PRED","FDA, OBJ","InspireMD, SUBJ","announced, PRED","approval, OBJ","InspireMD, SUBJ","enrolled, PRED","patients, OBJ","InspireMD, SUBJ","established, PRED","headquarters, OBJ","InspireMD, SUBJ","established, PRED","Miami, OBJ","InspireMD, SUBJ","achieved, PRED","revenue, OBJ","Marvin, SUBJ","commented, PRED",O,"InspireMD, SUBJ","advanced, PRED","CGuard, OBJ","InspireMD, SUBJ","advanced, PRED","Prime, OBJ","InspireMD, SUBJ","submitting, PRED","application, OBJ","InspireMD, SUBJ","submitting, PRED","PMA, OBJ","InspireMD, SUBJ","initiated, PRED","study, OBJ","InspireMD, SUBJ","initiated, PRED","CGUARDIANS, OBJ","InspireMD, SUBJ","continues, PRED",O,"InspireMD, SUBJ","working, PRED","FDA, OBJ","InspireMD, SUBJ","bringing, PRED","technology, OBJ","Mr., SUBJ","concluded, PRED",O,"InspireMD, SUBJ","increased, PRED","revenue, OBJ","InspireMD, SUBJ","decreased, PRED","profit, OBJ","InspireMD, SUBJ","increased, PRED","expenses, OBJ","InspireMD, SUBJ","decreased, PRED","income, OBJ","InspireMD, SUBJ","totaled, PRED","loss, OBJ","InspireMD, SUBJ","increased, PRED","revenue, OBJ","InspireMD, SUBJ","decreased, PRED","profit, OBJ","InspireMD, SUBJ","increased, PRED","expenses, OBJ","InspireMD, SUBJ","increased, PRED","income, OBJ","InspireMD, SUBJ","totaled, PRED","loss, OBJ","management, SUBJ","host, PRED","call, OBJ","management, SUBJ","host, PRED","conference, OBJ","management, SUBJ","provide, PRED","update, OBJ","Craig, SUBJ","is, PRED",O,"Craig, SUBJ","is, PRED",O,"Webb, SUBJ","is, PRED",O
https://www.globenewswire.com/news-release/2025/03/12/3041439/0/en/Bioxytran-Develops-a-Groundbreaking-Treatment-to-Combat-Bird-Flu-in-Egg-Laying-Chickens-Potentially-Saving-Billions.html,"Bioxytran, SUBJ","Develops, PRED","treatment, OBJ","treatment, SUBJ","Combat, PRED","Bird Flu, OBJ","Bird Flu, SUBJ","in, PRED","Chickens, OBJ","Bioxytran, SUBJ","unveiled, PRED","treatment, OBJ","treatment, SUBJ","leverages, PRED","antagonists, OBJ","antagonists, SUBJ","block, PRED","entry, OBJ","antagonists, SUBJ","shown, PRED","ability, OBJ","Company, SUBJ","is working, PRED","method, OBJ","Company, SUBJ","is seeking, PRED","partnerships, OBJ","Bioxytran, SUBJ","said, PRED","step, OBJ","David Platt, SUBJ","said, PRED","step, OBJ","CEO, SUBJ","said, PRED","step, OBJ","antagonists, SUBJ","block, PRED","proteins, OBJ","antagonists, SUBJ","attach, PRED","proteins, OBJ","Outbreaks, SUBJ","have, PRED","consequences, OBJ","outbreaks, SUBJ","require, PRED","culling, OBJ","outbreaks, SUBJ","lead, PRED","losses, OBJ","outbreaks, SUBJ","lead, PRED","disruptions, OBJ","treatment, SUBJ","could eliminate, PRED","need, OBJ","Bioxytran, SUBJ","is seeking, PRED","partnerships, OBJ","H5N1, SUBJ","said, PRED","chickens, OBJ","USDA, SUBJ","said, PRED","chickens, OBJ","administration, SUBJ","is rolling, PRED","strategy, OBJ","administration, SUBJ","has led, PRED","increase, OBJ","spread, SUBJ","could, PRED","issues, OBJ","Bioxytran, SUBJ","is, PRED","company, OBJ","Bioxytran, SUBJ","has, PRED","technologies, OBJ","Bioxytran, SUBJ","has, PRED","candidate, OBJ","ProLectin-M, SUBJ","is, PRED","drug, OBJ","ProLectin-M, SUBJ","is designed, PRED","galectins, OBJ","programs, SUBJ","are, PRED","treatment, OBJ","information, SUBJ","can, PRED","found, OBJ","Bioxytran, SUBJ","undertakes, PRED","obligation, OBJ","Bioxytran, SUBJ","Marks, PRED","Research, OBJ","BXT-25, SUBJ","can, PRED","monitored, OBJ","BXT-25, SUBJ","can, PRED","broadening, OBJ","capabilities, SUBJ","can, PRED","treat, OBJ","ProLectin-M, SUBJ","targets, PRED","galectins, OBJ","Bioxytran, SUBJ","Signs, PRED","NDA, OBJ","Bioxytran, SUBJ","Signs, PRED","University, OBJ","studies, SUBJ","have shown, PRED","promise, OBJ","studies, SUBJ","have shown, PRED","promise, OBJ","studies, SUBJ","have shown, PRED","viruses, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041299/0/en/Corvus-Pharmaceuticals-Announces-Initiation-of-Phase-2-Clinical-Trial-of-Soquelitinib-for-Patients-with-Autoimmune-Lymphoproliferative-Syndrome-ALPS.html,"Corvus, SUBJ","Pharmaceuticals, SUBJ","Announces, PRED","Initiation, OBJ","NIHNIAID, SUBJ","has, PRED","initiated, PRED","a, O","Phase, O","2, O","clinical, O","trial, O","of, O","soquelitinib, O","V., SUBJ","Koneti, SUBJ","Rao, SUBJ","is, PRED","Other, O","trial, O","sites, O","include, O","Childrens, O","Hospital, O","of, O","Philadelphia, O","Developing, O","safe, O","and, O","effective, O","targeted, O","treatments, O","to, O","address, O","ALPS, O","and, O","related, O","disorders, O","is, O","a, O","priority, O","at, O","the, O","NIAID, O","Dr., SUBJ","Rao, SUBJ","said, PRED","We, O","look, O","forward, O","to, O","investigating, O","the, O","potential, O","of, O","ITK, O","inhibition, O","with, O","soquelitinib, O","to, O","improve, O","immune, O","system, O","balance, O","and, O","reduce, O","the, O","buildup, O","of, O","dysfunctional, O","T, O","cells, O","in, O","lymph, O","nodes, O","and, O","spleens, O","and, O","autoantibodies, O","that, O","drive, O","the, O","disease, O","Richard, SUBJ","A., SUBJ","Miller, SUBJ","said, PRED","The, O","Phase, O","2, O","clinical, O","trial, O","is, O","designed, O","to, O","enroll, O","up, O","to, O","30, O","patients, O","aged, O","16, O","or, O","older, O","with, O","confirmed, O","ALPS-FAS, O","based, O","on, O","genetic, O","testing, O","Corvus, SUBJ","also, O","plans, PRED","to, O","initiate, O","a, O","Phase, O","1, O","clinical, O","trial, O","of, O","soquelitinib, O","in, O","patients, O","with, O","solid, O","tumors, O","Corvus, SUBJ","is, PRED","a, O","clinical-stage, O","biopharmaceutical, O","company, O","Richard, SUBJ","van, SUBJ","den, SUBJ","Broek, SUBJ","to, O","Board, O","of, O","Directors, O"
https://www.globenewswire.com/news-release/2025/03/11/3040978/0/en/Dianthus-Therapeutics-Highlights-Recent-Business-Achievements-and-Reports-Q4-and-FY-2024-Financial-Results.html,"Dianthus, SUBJ","Therapeutics, SUBJ","Highlights, PRED","Recent, OBJ","Business, OBJ","Achievements, OBJ","Dianthus, SUBJ","Therapeutics, SUBJ","reported, PRED","financial, OBJ","results, OBJ","Dianthus, SUBJ","Therapeutics, SUBJ","provided, PRED","update, OBJ","Marino, SUBJ","Garcia, SUBJ","said, PRED","Dianthus, SUBJ","Therapeutics, SUBJ","initiated, PRED","trial, OBJ","Dianthus, SUBJ","Therapeutics, SUBJ","announced, PRED","John, OBJ","C., OBJ","King, OBJ","Dianthus, SUBJ","Therapeutics, SUBJ","joined, PRED","Sujay, OBJ","Kango, OBJ","Dianthus, SUBJ","Therapeutics, SUBJ","appointment, PRED","John, OBJ","C., OBJ","King, OBJ","Dianthus, SUBJ","Therapeutics, SUBJ","welcomes, PRED","Sujay, OBJ","Kango, OBJ","Dianthus, SUBJ","Therapeutics, SUBJ","participate, PRED","Dianthus, SUBJ","Therapeutics, SUBJ","dedicated, PRED"
https://www.globenewswire.com/news-release/2025/03/11/3040981/16626/en/Zevra-Reports-Full-Year-2024-and-Fourth-Quarter-Financial-Results.html,"Zevra, SUBJ","Therapeutics, SUBJ","reported, PRED","financial, OBJ","results, OBJ","Neil, SUBJ","McFarlane, SUBJ","said, PRED","Zevra, SUBJ","entered, PRED","agreement, OBJ","Zevra, SUBJ","host, PRED","conference, OBJ","Zevra, SUBJ","host, PRED","webcast, OBJ","Zevra, SUBJ","initiated, PRED","launch, OBJ","Zevra, SUBJ","received, PRED","forms, OBJ","Zevra, SUBJ","had, PRED","enrollments, OBJ","Zevra, SUBJ","is, PRED","EU, OBJ","Zevra, SUBJ","presented, PRED","data, OBJ","Zevra, SUBJ","enrolled, PRED","patients, OBJ","Zevra, SUBJ","is, PRED","Europe, OBJ","Zevra, SUBJ","entered, PRED","agreement, OBJ","Zevra, SUBJ","consolidated, PRED","functions, OBJ","Zevra, SUBJ","entered, PRED","agreement, OBJ","Zevra, SUBJ","will, PRED","participate, OBJ","Zevra, SUBJ","will, PRED","host, OBJ","Zevra, SUBJ","will, PRED","host, OBJ","Zevra, SUBJ","is, PRED","therapy, OBJ","Zevra, SUBJ","is, PRED","therapy, OBJ","Zevra, SUBJ","is, PRED","treatment, OBJ","Zevra, SUBJ","is, PRED","candidate, OBJ","Zevra, SUBJ","is, PRED","product, OBJ","Zevra, SUBJ","is, PRED","company, OBJ","Zevra, SUBJ","Files, PRED","Statement, OBJ","Zevra, SUBJ","Announces, PRED","Publication, OBJ"
https://www.globenewswire.com/news-release/2025/03/11/3040639/0/en/Woodstock-Sterile-Solutions-Invests-8-million-in-New-Automated-High-Speed-State-of-the-Art-Bottle-Packaging-Line.html,"Woodstock, SUBJ","Sterile, SUBJ","Solutions, SUBJ","Invests, PRED","8, O","million, O","in, O","New, OBJ","Automated, OBJ","High-Speed, OBJ","State-of-the-Art, OBJ","Bottle, OBJ","Packaging, OBJ","Line, OBJ","Woodstock, SUBJ","Sterile, SUBJ","Solutions, SUBJ","is, PRED","expanding, PRED","its, O","BFS, O","capabilities, O","Nick, SUBJ","Buschur, SUBJ","says, PRED","Woodstock, SUBJ","Sterile, SUBJ","Solutions, SUBJ","has, PRED","delivered, PRED","BFS, O","solutions, O","Woodstock, SUBJ","Sterile, SUBJ","Solutions, SUBJ","expects, PRED","Buschur, SUBJ","says, PRED","Woodstock, SUBJ","Sterile, SUBJ","Solutions, SUBJ","has, PRED","been, PRED","recognized, PRED","Woodstock, SUBJ","Sterile, SUBJ","Solutions, SUBJ","is, PRED","expanding, PRED"
https://www.globenewswire.com/news-release/2025/03/12/3041359/0/en/Dogwood-Therapeutics-Inc-Announces-Conversion-of-Existing-19-5M-in-Debt-to-Equity-Strengthening-Balance-Sheet-Moving-Forward.html,"Dogwood, SUBJ","Therapeutics,, SUBJ","Inc., SUBJ","Announces, PRED","Conversion, PRED","of, O","Existing, O","Accessibility, O","Skip, O","TopNav, O","Dogwood, SUBJ","Therapeutics,, SUBJ","Inc., SUBJ","Announces, PRED","Conversion, PRED","of, O","Existing, O","19.5M, O","in, O","Debt, OBJ","to, O","Equity,, OBJ","Strengthening, PRED","Balance, OBJ","Sheet, OBJ","Moving, PRED","Forward, O","Largest, O","shareholder,, O","CK, SUBJ","Life, SUBJ","Sciences, SUBJ","Intl.,, SUBJ","Holdings, SUBJ","Inc., SUBJ","agrees, PRED","to, O","conversion, PRED","of, O","debt, OBJ","into, O","equity,, OBJ","removing, PRED","all, O","existing, O","debt, OBJ","from, O","Dogwoods, O","balance, OBJ","sheet, OBJ","March, O","12,, O","2025, O","0830, O","ET, O","Source, O","Dogwood, SUBJ","Therapeutics,, SUBJ","Inc., SUBJ","Dogwood, SUBJ","Therapeutics,, SUBJ","Inc., SUBJ","ATLANTA,, O","March, O","12,, O","2025, O","GLOBE, O","NEWSWIRE, O","Dogwood, SUBJ","Therapeutics,, SUBJ","Inc., SUBJ","Nasdaq, OBJ","DWTX, OBJ","Dogwood, SUBJ","or, O","the, O","Company,, O","a, O","development-stage, O","biopharmaceutical, O","company, O","focused, O","on, O","advancing, O","first-in-class,, O","non-opioid,, O","treatments, O","for, O","chronic, O","and, O","acute, O","pain,, O","announces, PRED","that, O","its, O","largest, O","shareholder,, O","CK, SUBJ","Life, SUBJ","Sciences, SUBJ","Intl.,, SUBJ","Holdings,, SUBJ","Inc., SUBJ","CKLS, SUBJ","has, PRED","agreed,, PRED","through, O","its, O","wholly-owned, O","subsidiary,, O","Conjoint, SUBJ","Inc., SUBJ","Conjoint,, SUBJ","to, O","assign, PRED","to, O","the, O","Company, OBJ","all, O","outstanding, O","in, O","debt, OBJ","under, O","the, O","previously, O","existing, O","19.5, O","million, O","Loan, OBJ","Agreement, OBJ","plus, O","accrued, O","interest, OBJ","in, O","exchange, O","for, O","284.2638, O","shares, OBJ","of, O","preferred, O","equity, OBJ","of, O","the, O","Company,, OBJ","effective, O","today., O","CKLS, SUBJ","anchored, PRED","conviction, OBJ","in, O","Halneuron,, OBJ","NaV, OBJ","1.7, OBJ","as, O","a, O","priority, O","target, O","for, O","reducing, O","pain., O","conversion, SUBJ","underscores, PRED","confidence, OBJ","in, O","the, O","Dogwood, SUBJ","management, SUBJ","teams, SUBJ","ability, OBJ","to, O","execute, PRED","the, O","Halneuron, OBJ","Phase, OBJ","2b, OBJ","chemotherapy-induced, O","neuropathic, O","pain, OBJ","CINP, OBJ","program, OBJ","Greg, SUBJ","Duncan,, SUBJ","Dogwoods, SUBJ","Chairman, SUBJ","and, O","Chief, O","Executive, O","Officer, O","said, PRED","agreement, SUBJ","enables, PRED","us, SUBJ","to, O","remove, PRED","all, O","existing, O","debt, OBJ","from, O","our, O","balance, OBJ","sheet,, OBJ","strategic, O","financing,, O","provided, PRED","by, O","CKLS, SUBJ","in, O","October, O","2024,, O","ensures, PRED","the, O","Company, SUBJ","has, PRED","sufficient, O","capital, OBJ","to, O","recruit, PRED","patients, OBJ","through, O","a, O","planned, O","interim, O","assessment, O","of, O","its, O","ongoing, O","Phase, OBJ","2b, OBJ","CINP, OBJ","trial, OBJ","in, O","Q4, O","of, O","this, O","year, O","without, O","the, O","burden, O","of, O","making, O","debt, OBJ","payments, OBJ","as, O","originally, O","structured., O","Dosing, SUBJ","of, O","the, O","first, O","patient, OBJ","in, O","its, O","Phase, OBJ","2b, OBJ","clinical, O","trial,, O","referred, PRED","to, O","as, O","the, O","HALT-CINP, OBJ","Halneuron, OBJ","Treatment, OBJ","of, O","Chemotherapy-Induced, O","Neuropathic, O","Pain, OBJ","trial,, OBJ","is, PRED","anticipated, PRED","in, O","the, O","near, O","term., O","Conjoint, SUBJ","entered, PRED","into, O","Debt, OBJ","Exchange, OBJ","and, O","Cancellation, OBJ","Agreement, OBJ","principal, SUBJ","amount, SUBJ","of, O","all, O","loans, OBJ","made, PRED","to, O","the, O","Company, OBJ","under, O","the, O","Loan, OBJ","Agreement,, OBJ","will, PRED","be, PRED","deemed, PRED","repaid, PRED","by, O","the, O","Company, SUBJ","and, O","all, O","of, O","the, O","Companys, SUBJ","obligations, OBJ","with, O","respect, O","to, O","the, O","principal, OBJ","amount, OBJ","and, O","accrued, O","interest, OBJ","will, PRED","be, PRED","satisfied, PRED","in, O","full, O","and, O","cancelled., O","Company, SUBJ","has, PRED","agreed, PRED","to, O","issue, PRED","to, O","Conjoint, OBJ","284.2638, O","shares, OBJ","of, O","Series, OBJ","A-1, OBJ","Non-Voting, OBJ","Convertible, OBJ","Preferred, OBJ","Stock,, OBJ","Each, O","share, SUBJ","of, O","A-1, OBJ","Preferred, OBJ","Stock, OBJ","will, PRED","be, PRED","convertible, PRED","into, O","10,000, O","shares, OBJ","of, O","the, O","Companys, SUBJ","common, OBJ","stock,, OBJ","terms, SUBJ","of, O","the, O","A-1, OBJ","Preferred, OBJ","Stock, OBJ","are, PRED","substantially, O","the, O","same, O","as, O","the, O","Companys, SUBJ","Series, OBJ","A, OBJ","Non-Voting, OBJ","Convertible, OBJ","Preferred, OBJ","Stock,, OBJ","Halneuron, SUBJ","is, PRED","a, O","first-in-class,, O","NaV, OBJ","1.7, OBJ","specific, O","voltage, O","gated, O","sodium, O","channel, OBJ","inhibitor, OBJ","being, O","developed, PRED","as, O","an, O","alternative, O","to, O","chronic, O","pain, OBJ","treatment, OBJ","with, O","opioids., O","Patients, SUBJ","treated, PRED","with, O","Halneuron, OBJ","demonstrated, PRED","a, O","statistically, O","significant, O","reduction, OBJ","in, O","cancer-related, O","pain, OBJ","in, O","a, O","previous, O","Phase, OBJ","2, OBJ","clinical, O","trial, OBJ","with, O","an, O","acceptable, O","safety, OBJ","profile., O","Halneuron, SUBJ","has, PRED","been, PRED","evaluated, PRED","in, O","over, O","700, O","patients, OBJ","in, O","a, O","series, O","of, O","Phase, OBJ","1, OBJ","and, O","Phase, OBJ","2, OBJ","studies, OBJ","and, O","shows, PRED","no, O","signs, OBJ","of, O","addiction, OBJ","potential., O","Dogwood, SUBJ","Therapeutics, SUBJ","is, PRED","a, O","development-stage, O","biopharmaceutical, O","company, O","focused, PRED","on, O","developing, PRED","new, O","medicines, OBJ","to, O","treat, PRED","pain, OBJ","and, O","fatigue-related, O","disorders., O","Dogwood, SUBJ","research, SUBJ","pipeline, SUBJ","includes, PRED","two, O","separate, O","mechanistic, O","platforms, OBJ","with, O","a, O","non-opioid, O","analgesic, O","program, OBJ","and, O","an, O","antiviral, OBJ","program., O","proprietary,, O","non-opioid,, O","NaV, OBJ","1.7, OBJ","analgesic, OBJ","program, SUBJ","is, PRED","centered, PRED","on, O","our, O","lead, O","development, O","candidate,, O","Halneuron,, OBJ","Halneuron, SUBJ","is, PRED","a, O","highly, O","specific, O","voltage-gated, O","sodium, O","channel, OBJ","modulator,, OBJ","a, O","mechanism, OBJ","known, PRED","to, O","be, PRED","effective, PRED","for, O","reducing, PRED","pain, OBJ","transmission., O","Halneuron, SUBJ","treatment, SUBJ","has, PRED","demonstrated, PRED","pain, OBJ","reduction, OBJ","in, O","pain, OBJ","related, PRED","to, O","general, O","cancer, OBJ","and, O","in, O","pain, OBJ","related, PRED","to, O","chronic, O","chemotherapy-induced, O","neuropathic, O","pain, OBJ","CINP., OBJ","Interim, O","data, SUBJ","from, O","the, O","Halneuron, OBJ","Phase, OBJ","2, OBJ","CINP, OBJ","study, OBJ","are, PRED","expected, PRED","in, O","Q4, O"
https://www.globenewswire.com/news-release/2025/03/12/3041115/0/en/Roche-enters-into-an-exclusive-collaboration-licensing-agreement-with-Zealand-Pharma-to-co-develop-and-co-commercialise-petrelintide-as-a-potential-foundational-therapy-for-people-.html,"Roche, SUBJ","enters, PRED","into, O","an, O","exclusive, O","collaboration, O","licensing, O","agreement, O","with, O","Zealand, SUBJ","Pharma, SUBJ","to, O","co-develop, O","and, O","co-commercialise, O","petrelintide, OBJ","Zealand, SUBJ","Pharma, SUBJ","will, O","receive, PRED","upfront, O","cash, O","payments, O","of, O","USD, O","1.65, O","billion, O","Roche, SUBJ","will, O","be, O","responsible, O","for, O","commercial, O","manufacturing, O","and, O","supply, O","Teresa, SUBJ","Graham, SUBJ","CEO, SUBJ","Roche, SUBJ","Pharmaceuticals, SUBJ","said, O","Adam, SUBJ","Steensberg, SUBJ","President, SUBJ","and, O","Chief, O","Executive, O","Officer, O","of, O","Zealand, SUBJ","Pharma, SUBJ","said, O","Under, O","the, O","terms, O","of, O","this, O","agreement, O","Zealand, SUBJ","Pharma, SUBJ","and, O","Roche, SUBJ","will, O","co-commercialise, PRED","petrelintide, OBJ","Roche, SUBJ","will, O","obtain, PRED","exclusive, O","rights, O","to, O","commercialisation, O","in, O","the, O","rest, O","of, O","the, O","world, O","Zealand, SUBJ","Pharma, SUBJ","is, O","also, O","eligible, O","for, O","development, O","milestones, O","of, O","USD, O","1.2, O","billion, O","Zealand, SUBJ","Pharma, SUBJ","will, O","pay, PRED","Roche, OBJ","USD, O","350, O","million, O"
https://www.globenewswire.com/news-release/2025/03/12/3041422/37245/en/Alpha-Pro-Tech-Ltd-Announces-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html,"Alpha, SUBJ","Pro, SUBJ","Tech, SUBJ","announces, PRED","results, OBJ","Lloyd, SUBJ","Hoffman, SUBJ","commented, PRED","housing, SUBJ","market, SUBJ","shows, PRED","weakness, OBJ","housing, SUBJ","starts, OBJ","down, PRED","sales, SUBJ","housewrap, OBJ","synthetic, OBJ","roof, OBJ","underlayment, OBJ","down, PRED","we, SUBJ","are, PRED","optimistic, OBJ","housewrap, SUBJ","sales, OBJ","were, PRED","encouraging, OBJ","housewrap, SUBJ","sales, OBJ","were, PRED","primarily, O","due, O","we, SUBJ","have, PRED","not, O","lost, O","share, OBJ","multi-family, SUBJ","housing, SUBJ","starts, OBJ","down, PRED","sales, SUBJ","synthetic, OBJ","roof, OBJ","underlayment, OBJ","ended, PRED","we, SUBJ","saw, PRED","surge, OBJ","sales, SUBJ","product, OBJ","line, OBJ","continue, PRED","we, SUBJ","expect, PRED","growth, OBJ","our, O","efforts, SUBJ","are, PRED","focused, OBJ","our, O","top, SUBJ","accounts, OBJ","have, PRED","increased, OBJ","we, SUBJ","added, PRED","Territory, OBJ","Mangers, OBJ","we, SUBJ","have, PRED","created, OBJ","position, OBJ","management, SUBJ","expects, PRED","growth, OBJ","Mr., O","Hoffman, SUBJ","continued, PRED","sales, SUBJ","garments, OBJ","in, O","2024, O","were, PRED","up, OBJ","we, SUBJ","have, PRED","signed, OBJ","agreements, OBJ","we, SUBJ","believe, PRED","achievement, OBJ","will, O","provide, O","management, SUBJ","expects, PRED","growth, OBJ","Colleen, SUBJ","McDonald, SUBJ","commented, PRED","we, SUBJ","had, PRED","available, OBJ","we, SUBJ","repurchased, PRED","shares, OBJ","we, SUBJ","had, PRED","repurchased, OBJ","we, SUBJ","retire, PRED","stock, OBJ","Alpha, SUBJ","Pro, SUBJ","Tech, SUBJ","is, PRED","parent, OBJ","company, OBJ","Alpha, SUBJ","Pro, SUBJ","Tech, SUBJ","develops, PRED","manufactures, PRED","markets, PRED","products, OBJ","Alpha, SUBJ","ProTech, SUBJ","Engineered, SUBJ","Products, SUBJ","manufactures, PRED","markets, PRED","line, OBJ","company, SUBJ","has, PRED","facilities, OBJ","Certain, O","statements, SUBJ","constitute, PRED","forward-looking, OBJ","statements, OBJ","we, SUBJ","caution, PRED","investors, OBJ","we, SUBJ","cannot, PRED","give, OBJ","assurances, OBJ","we, SUBJ","undertake, PRED","obligation, OBJ","we, SUBJ","also, O","caution, PRED","investors, OBJ","Company, SUBJ","Contact, SUBJ","Investor, SUBJ","Relations, SUBJ","Contact, SUBJ","Consolidated, O","Balance, SUBJ","Sheets, SUBJ","Assets, SUBJ","Current, O","assets, SUBJ","Cash, SUBJ","equivalents, SUBJ","Accounts, SUBJ","receivable, SUBJ","net, O","Inventories, SUBJ","net, O","Prepaid, SUBJ","expenses, SUBJ","Total, O","current, O","assets, SUBJ","Property, SUBJ","equipment, SUBJ","net, O","Goodwill, SUBJ","Right-of-use, SUBJ","assets, SUBJ","Equity, SUBJ","investment, SUBJ","Total, O","assets, SUBJ","Liabilities, SUBJ","Shareholders, SUBJ","Equity, SUBJ","Current, O","liabilities, SUBJ","Total, O","current, O","liabilities, SUBJ","Lease, SUBJ","liabilities, SUBJ","net, O","Deferred, SUBJ","income, SUBJ","tax, SUBJ","liabilities, SUBJ","net, O","Total, O","liabilities, SUBJ","Commitments, SUBJ","contingencies, SUBJ","Shareholders, SUBJ","equity, SUBJ","Common, SUBJ","stock, SUBJ","Additional, O","paid-in, SUBJ","capital, SUBJ","Retained, SUBJ","earnings, SUBJ","Accumulated, SUBJ","comprehensive, SUBJ","loss, SUBJ","Total, O","shareholders, SUBJ","equity, SUBJ","Total, O","liabilities, SUBJ","shareholders, SUBJ","equity, SUBJ","Consolidated, O","Statements, SUBJ","Income, SUBJ","Three, O","Months, SUBJ","Ended, SUBJ","Year, SUBJ","Ended, SUBJ","Net, O","sales, SUBJ","Cost, SUBJ","goods, SUBJ","sold, SUBJ","Gross, O","profit, SUBJ","Operating, O","expenses, SUBJ","Selling, SUBJ","Depreciation, SUBJ","amortization, SUBJ","Total, O","operating, O","expenses, SUBJ","Income, SUBJ","operations, SUBJ","Other, O","income, SUBJ","Equity, SUBJ","affiliate, SUBJ","Gain, SUBJ","sale, SUBJ","property, SUBJ","equipment, SUBJ","Interest, SUBJ","income, SUBJ","Total, O","other, O","income, SUBJ","Income, SUBJ","provision, SUBJ","taxes, SUBJ","Net, O","income, SUBJ","Basic, O","earnings, SUBJ","share, SUBJ","Diluted, SUBJ","earnings, SUBJ","share, SUBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041327/33240/en/Emergent-BioSolutions-and-Rocketvax-Announce-Investment-Agreement-and-Pursuit-of-a-Strategic-Relationship-for-Next-Generation-Product-Candidates.html,"Emergent, SUBJ","BioSolutions, SUBJ","and, O","Rocketvax, OBJ","Announce, PRED","Investment, OBJ","Accessibility, O","Skip, O","TopNav, O","Emergent, SUBJ","BioSolutions, SUBJ","and, O","Rocketvax, OBJ","Announce, PRED","Agreement, OBJ","and, O","Pursuit, O","of, O","a, O","Strategic, O","Relationship, O","for, O","Next-Generation, O","Product, O","Candidates, O","March, O","12, O","2025, O","0800, O","ET, O","Source, O","Emergent, SUBJ","BioSolutions, SUBJ","Emergent, SUBJ","BioSolutions, SUBJ","GAITHERSBURG, OBJ","Md., OBJ","and, O","BASEL, OBJ","Switzerland, OBJ","March, O","12, O","2025, O","GLOBE, O","NEWSWIRE, O","--, O","Emergent, SUBJ","BioSolutions, SUBJ","Inc., SUBJ","NYSE, O","EBS, SUBJ","a, O","leading, O","public, O","health, O","company, O","that, O","delivers, O","protective, O","and, O","life-saving, O","solutions, O","to, O","communities, O","across, O","the, O","world, O","and, O","Rocketvax, SUBJ","Ltd, SUBJ","one, O","of, O","Switzerlands, O","next-generation, O","vaccine, O","companies, O","and, O","a, O","member, O","of, O","the, O","Swiss, OBJ","Rockets, OBJ","Ltd, OBJ","family, O","of, O","companies, O","today, O","announced, PRED","entry, O","into, O","an, O","agreement, O","for, O","Emergents, SUBJ","strategic, O","financial, O","investment, O","into, O","Swiss, OBJ","Rockets, OBJ","Ltd, OBJ","the, O","parent, O","company, O","of, O","Rocketvax, OBJ","Ltd, OBJ","to, O","support, O","research, O","infrastructure, O","development, O","and, O","the, O","expansion, O","of, O","Swiss, OBJ","Rockets, OBJ","innovative, O","biotechnology, O","portfolio, O","Emergent, SUBJ","BioSolutions, SUBJ","GAITHERSBURG, OBJ","Md., OBJ","and, O","BASEL, OBJ","Switzerland, OBJ","March, O","12, O","2025, O","GLOBE, O","NEWSWIRE, O","--, O","Emergent, SUBJ","BioSolutions, SUBJ","Inc., SUBJ","NYSE, O","EBS, SUBJ","a, O","leading, O","public, O","health, O","company, O","that, O","delivers, O","protective, O","and, O","life-saving, O","solutions, O","to, O","communities, O","across, O","the, O","world, O","and, O","Rocketvax, SUBJ","Ltd, SUBJ","one, O","of, O","Switzerlands, O","next-generation, O","vaccine, O","companies, O","and, O","a, O","member, O","of, O","the, O","Swiss, OBJ","Rockets, OBJ","Ltd, OBJ","family, O","of, O","companies, O","today, O","announced, PRED","entry, O","into, O","an, O","agreement, O","for, O","Emergents, SUBJ","strategic, O","financial, O","investment, O","into, O","Swiss, OBJ","Rockets, OBJ","Ltd, OBJ","the, O","parent, O","company, O","of, O","Rocketvax, OBJ","Ltd, OBJ","to, O","support, O","research, O","infrastructure, O","development, O","and, O","the, O","expansion, O","of, O","Swiss, OBJ","Rockets, OBJ","innovative, O","biotechnology, O","portfolio, O","Joe, SUBJ","Papa, SUBJ","President, O","and, O","CEO, O","of, O","Emergent, OBJ","commented, PRED","Dr., O","Vladimir, SUBJ","Cmiljanovic, SUBJ","CEO, O","of, O","Rocketvax, OBJ","Ltd, OBJ","added, PRED","Emergent, SUBJ","BioSolutions, SUBJ","NYSE, O","EBS, SUBJ","will, O","host, O","a, O","conference, O","call, O","on, O","Wednesday, O","May, O","7, O","2025, O","at, O","500, O","pm, O","eastern, O","time, O","to, O","discuss, O","the, O","financial, O","Emergent, SUBJ","BioSolutions, SUBJ","GAITHERSBURG, OBJ","Md., OBJ","March, O","31, O","2025, O","GLOBE, O","NEWSWIRE, O","--, O","Emergent, SUBJ","BioSolutions, SUBJ","Inc., SUBJ","NYSE, O","EBS, SUBJ","today, O","announced, PRED","that, O","its, O","Board, O","of, O","Directors, O","has, O","authorized, O","the, O","repurchase, O","of, O","up, O","to, O","50, O","million, O","of, O","the, O"
https://www.globenewswire.com/news-release/2025/03/12/3041356/0/en/Iolyx-Therapeutics-to-Present-at-Multiple-Upcoming-Ophthalmology-Conferences.html,"Iolyx, SUBJ","Therapeutics, SUBJ","to, O","Present, PRED","at, O","Multiple, O","Upcoming, O","Ophthalmology, O","Conferences, O","Iolyx, SUBJ","Therapeutics, SUBJ","Inc., SUBJ","to, O","Present, PRED","at, O","Multiple, O","Upcoming, O","industry, O","events, O","Erin, SUBJ","Newman, SUBJ","to, O","Present, PRED","at, O","Sonoma, OBJ","Eye, OBJ","Meeting, O","Iolyx, SUBJ","Location, PRED","San, OBJ","Diego, OBJ","Dr., SUBJ","Mark, SUBJ","Hinds, SUBJ","to, O","Present, PRED","at, O","Association, OBJ","for, OBJ","Research, OBJ","in, OBJ","Vision, OBJ","and, OBJ","Ophthalmology, OBJ","ARVO, OBJ","Annual, OBJ","Meeting, O","Iolyx, SUBJ","Location, PRED","Salt, OBJ","Lake, OBJ","City, OBJ","Dr., SUBJ","James, SUBJ","Armitage, SUBJ","to, O","Present, PRED","at, O","British, OBJ","Contact, OBJ","Lens, OBJ","Association, OBJ","BCLA, OBJ","Clinical, OBJ","Conference, O","Iolyx, SUBJ","Location, PRED","Birmingham, OBJ","Elizabeth, SUBJ","Jeffords, SUBJ","to, O","Present, PRED","at, O","Annual, OBJ","International, OBJ","Ocular, OBJ","and, OBJ","Inflammation, OBJ","Society, OBJ","IOIS, OBJ","Meeting, O","Iolyx, SUBJ","Location, PRED","Rio, OBJ","de, OBJ","Janeiro, OBJ","Heather, SUBJ","Berger, SUBJ","Corporate, PRED","Contact, OBJ","at, O","Iolyx, OBJ","Madelin, SUBJ","Hawtin, SUBJ","Media, PRED","Contact, OBJ","at, O","LifeSci, OBJ","Communications, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041187/0/en/Inaugural-Global-Longevity-Summit-Architects-New-Horizons-In-Human-Health-Potential.html,"Informa, SUBJ","Connect, SUBJ","Medical, SUBJ","Division, SUBJ","announces, PRED","landmark, O","Geneva-based, O","conference, O","Global, SUBJ","Longevity, SUBJ","Summit, SUBJ","pushes, PRED","boundaries, O","Summit, SUBJ","aims, PRED","advancements, O","James, SUBJ","Ho, SUBJ","committed, PRED","advancing, O","Gordan, SUBJ","Lauc, SUBJ","committed, PRED","advancing, O","Andrea, SUBJ","B., SUBJ","Maier, SUBJ","committed, PRED","advancing, O","Erik, SUBJ","Nelson, SUBJ","committed, PRED","advancing, O","Jennifer, SUBJ","Pearlman, SUBJ","committed, PRED","advancing, O","Switzerlands, SUBJ","leadership, O","precision, O","medicine, O","Genolier, SUBJ","situates, PRED","participants, O","Global, SUBJ","Longevity, SUBJ","Summit, SUBJ","unites, PRED","researchers, OBJ","Global, SUBJ","Longevity, SUBJ","Summit, SUBJ","unites, PRED","investors, OBJ","Global, SUBJ","Longevity, SUBJ","Summit, SUBJ","unites, PRED","entrepreneurs, OBJ","Global, SUBJ","Longevity, SUBJ","Summit, SUBJ","unites, PRED","stakeholders, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041393/0/en/NeurAxis-to-Host-Fourth-Quarter-and-Full-Year-2024-Results-and-Business-Update-Call-on-Thursday-March-20-2025.html,"NeurAxis, SUBJ","will, PRED","report, PRED","results, OBJ","The, O","Company, SUBJ","has, PRED","scheduled, PRED","a, O","conference, O","call, OBJ","NeurAxis, SUBJ","is, PRED","a, O","medical, O","technology, O","company, O","commercializing, PRED","therapies, OBJ","NeurAxis, SUBJ","is, PRED","dedicated, PRED","to, O","advancing, O","science, O","NeurAxis, SUBJ","is, PRED","focused, PRED","on, O","therapies, OBJ","IB-Stim, SUBJ","is, PRED","cleared, PRED","by, O","the, O","FDA, OBJ","NeurAxis, SUBJ","to, O","Present, PRED","NeurAxis, SUBJ","Reports, PRED","Results, OBJ","NeurAxis, SUBJ","Driven, PRED","by, O","a, O","43, O","Increase, OBJ","in, O","Revenues, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041309/0/en/Solid-Biosciences-to-Present-at-the-2025-Muscular-Dystrophy-Association-MDA-Clinical-Scientific-Conference.html,"Solid, SUBJ","Biosciences, SUBJ","to, O","Present, PRED","at, O","the, O","2025, O","Muscular, OBJ","Dystrophy, OBJ","Association, OBJ","MDA, OBJ","Clinical, OBJ","Scientific, OBJ","Conference, OBJ","Solid, SUBJ","Biosciences, SUBJ","Inc., SUBJ","will, O","present, PRED","data, O","from, O","the, O","Phase, O","12, O","INSPIRE, O","DUCHENNE, O","trial, O","evaluating, O","SGT-003, O","Kevin, SUBJ","Flanigan, SUBJ","will, O","present, PRED","at, O","the, O","2025, O","Muscular, OBJ","Dystrophy, OBJ","Association, OBJ","MDA, OBJ","Clinical, OBJ","Scientific, OBJ","Conference, OBJ","Kevin, SUBJ","Flanigan, SUBJ","is, O","Advisor, O","Consultant, O","Researcher, O","at, O","Nationwide, OBJ","Childrens, OBJ","Hospital, OBJ","Duchenne, SUBJ","is, PRED","a, O","genetic, O","muscle-wasting, O","disease, O","SGT-003, SUBJ","is, PRED","an, O","investigational, O","gene, O","therapy, O","INSPIRE, SUBJ","DUCHENNE, SUBJ","is, PRED","a, O","Phase, O","12, O","clinical, O","trial, O","Solid, SUBJ","Biosciences, SUBJ","is, PRED","a, O","precision, O","genetic, O","medicine, O","company, O","Nicole, SUBJ","Anderson, SUBJ","is, PRED","Director, O","Glenn, SUBJ","Silver, SUBJ","is, PRED","Media, O","Contact, O","at, O","FINN, OBJ","Partners, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041362/0/en/Palisade-Bio-Announces-Two-Abstracts-Selected-to-be-Showcased-as-Poster-of-Distinction-and-Poster-Presentation-at-Leading-GI-Forum-Digestive-Disease-Week-DDW-2025.html,"Palisade, SUBJ","Bio, SUBJ","Announces, PRED","Two, O","Abstracts, OBJ","Selected, PRED","to, O","be, O","Accessibility, O","Skip, O","TopNav, O","Palisade, SUBJ","Bio, SUBJ","Announces, PRED","Two, O","Abstracts, OBJ","Selected, PRED","to, O","be, O","Showcased, PRED","as, O","Poster, O","of, O","Distinction, O","and, O","Poster, O","Presentation, O","at, O","Leading, O","GI, O","Forum, O","Digestive, O","Disease, O","Week, O","DDW, OBJ","2025, O","Palisade, SUBJ","Bio, SUBJ","Inc, SUBJ","PALI-2108, OBJ","a, O","Colon-Specific, O","PDE4, O","Inhibitor, O","Prodrug, O","Abstract, OBJ","was, PRED","Rated, PRED","in, O","the, O","Top, O","10, O","of, O","all, O","AGA, SUBJ","Abstracts, OBJ","Selected, PRED","for, O","Poster, O","Presentation, O","at, O","DDW, OBJ","Carlsbad, SUBJ","CA, SUBJ","Palisade, SUBJ","Bio, SUBJ","Inc, SUBJ","Nasdaq, OBJ","PALI, OBJ","Palisade, SUBJ","Palisade, SUBJ","Bio, SUBJ","or, O","the, O","Company, SUBJ","a, O","clinical-stage, O","biopharmaceutical, O","company, O","focused, PRED","on, O","developing, PRED","and, O","advancing, PRED","novel, O","therapeutics, O","for, O","patients, O","living, O","with, O","autoimmune, O","inflammatory, O","and, O","fibrotic, O","diseases, O","today, O","announced, PRED","that, O","it, O","has, O","been, O","selected, PRED","to, O","present, PRED","data, O","from, O","its, O","lead, O","program, O","PALI-2108, OBJ","for, O","the, O","treatment, O","of, O","ulcerative, O","colitis, O","at, O","Digestive, O","Disease, O","Week, O","DDW, OBJ","2025, O","being, O","held, PRED","May, O","36, O","in, O","San, O","Diego, OBJ","California, OBJ","Participation, O","details, O","are, O","as, O","follows, O","Poster, O","PresentationSession, O","Title, O","Transcriptional, O","Epigenetic, O","and, O","Genetic, O","Regulation, O","of, O","GI, O","Function, O","and, O","Disease, O","Session, O","Date, O","Time, O","May, O","4, O","2025, O","from, O","1230, O","PM, O","to, O","130, O","PM, O","PDTTitle, O","A, O","BIOINFORMATIC, O","APPROACH, O","TO, O","PALI-2108, OBJ","TREATMENT, O","IN, O","ULCERATIVE, O","COLITIS, O","REVEALS, PRED","THE, O","POTENTIAL, O","FOR, O","ANTI-FIBROTIC, O","EFFICACY, O","WITH, O","LOCAL, O","PDE4, O","INHIBITION, O","IN, O","INTESTINAL, O","FIBROSIS, O","DDW, OBJ","Poster, O","PresentationSession, O","Title, O","In, O","Vivo, O","Models, O","of, O","Gastrointestinal, O","Disorders, O","Session, O","Date, O","Time, O","May, O","5, O","2025, O","from, O","1230, O","PM, O","to, O","130, O","PM, O","PDTTitle, O","PALI-2108, OBJ","A, O","COLON-SPECIFIC, O","PDE4, O","INHIBITOR, O","PRODRUG, O","is, PRED","bioactivated, PRED","in, O","the, O","colon, OBJ","and, O","reduces, PRED","colon, OBJ","tissue, O","PDE4B, OBJ","in, O","a, O","dose-dependent, O","manner, O","increasing, PRED","C-AMP, OBJ","and, O","suppressing, PRED","TNF-Α, OBJ","in, O","a, O","mouse, OBJ","model, O","of, O","colitis, O","Digestive, O","Disease, O","Week, O","is, O","a, O","leading, O","forum, O","for, O","experts, O","in, O","the, O","field, O","of, O","gastroenterology, O","bringing, O","together, O","clinicians, O","researchers, SUBJ","and, O","pharmaceutical, O","leaders, O","to, O","discuss, O","the, O","latest, O","advancements, O","in, O","treating, O","digestive, O","diseases, O","For, O","more, O","information, O","about, O","Digestive, O","Disease, O","Week, O","please, O","visit, O","the, O","conference, O","website, O","About, O","Palisade, SUBJ","Bio, SUBJ","Palisade, SUBJ","Bio, SUBJ","is, O","a, O","clinical-stage, O","biopharmaceutical, O","company, O","focused, PRED","on, O","developing, PRED","and, O","advancing, PRED","novel, O","therapeutics, O","for, O","patients, O","living, O","with, O","autoimmune, O","inflammatory, O","and, O","fibrotic, O","diseases, O","The, O","Company, SUBJ","believes, PRED","that, O","by, O","using, O","a, O","targeted, O","approach, O","with, O","its, O","novel, O","therapeutics, O","it, O","will, O","transform, PRED","the, O","treatment, O","landscape, O","For, O","more, O","information, O","please, O","go, O","to, O","www, O","palisadebio, O","com, O","Forward, O","Looking, O","Statements, O","Any, O","statements, O","contained, O","in, O","this, O","communication, O","that, O","are, O","not, O","statements, O","of, O","historical, O","fact, O","may, O","be, O","deemed, O","to, O","be, O","forward-looking, O","statements, O","for, O","purposes, O","of, O","the, O","safe, O","harbor, O","provisions, O","of, O","the, O","Private, O","Securities, O","Litigation, O","Reform, O","Act, O","of, O","1995, O","Forward-looking, O","statements, O","include, O","but, O","are, O","not, O","limited, O","to, O","statements, O","regarding, O","the, O","safety, O","and, O","tolerability, O","PK, O","and, O","drug, O","release, O","characteristics, O","of, O","PALI-2108, OBJ","based, O","on, O","the, O","Companys, O","preclinical, O","studies, O","and, O","preliminary, O","data, O","from, O","the, O","Companys, O","Phase, O","1b2a, O","clinical, O","study, O","indications, O","and, O","anticipated, O","benefits, O","of, O","PALI-2108, OBJ","and, O","the, O","expected, O","timing, O","of, O","the, O","release, O","of, O","topline, O","data, O","from, O","the, O","Phase, O","1b2a, O","clinical, O","study, O","These, O","forward-looking, O","statements, O","are, O","based, O","on, O","the, O","Companys, O","current, O","expectations, O","Forward-looking, O","statements, O","involve, O","risks, O","and, O","uncertainties, O","The, O","Companys, O","actual, O","results, O","and, O","the, O","timing, O","of, O","events, O","could, O","differ, O","materially, O","from, O","those, O","anticipated, O","in, O","such, O","forward-looking, O","statements, O","as, O","a, O","result, O","of, O","these, O","risks, O","and, O","uncertainties, O","which, O","include, O","without, O","limitation, O","the, O","Company, SUBJ","is, O","heavily, O","dependent, PRED","on, O","the, O","success, O","of, O","PALI-2108, OBJ","which, O","is, O","in, O","the, O","early, O","stages, O","of, O","clinical, O","development, O","and, O","may, O","not, O","successfully, O","progress, PRED","through, O","clinical, O","development, O","or, O","receive, PRED","regulatory, O","approval, O","preliminary, O","clinical, O","study, O","results, O","or, O","the, O","results, O","from, O","earlier, O","preclinical, O","studies, O","may, O","not, O","be, O","predictive, O","of, O","final, O","or, O","future, O","results, O","and, O","unexpected, O","adverse, O","side, O","effects, O","or, O","inadequate, O","efficacy, O","of, O","PALI-2108, OBJ","may, O","limit, PRED","its, O","development, O","regulatory, O","approval, O","andor, O","commercialization, O","the, O","Company, SUBJ","needs, PRED","to, O","raise, PRED","significant, O","additional, O","funds, O","to, O","support, PRED","its, O","operations, O","and, O","the, O","continued, O","development, O","of, O","PALI-2108, OBJ","the, O","timing, O","and, O","outcome, O","of, O","the, O","Companys, O","current, O","and, O","anticipated, O","clinical, O","studies, O","related, O"
https://www.globenewswire.com/news-release/2025/03/12/3041325/0/en/Portage-Biotech-Resumes-Enrollment-in-Final-Cohort-of-Dose-Escalation-for-Port-6-in-ADPORT-601-Trial.html,"Portage, SUBJ","Biotech, SUBJ","Resumes, PRED","Enrollment, OBJ","in, O","Final, O","Cohort, O","of, O","Dose, O","Escalation, O","for, O","Port-6, OBJ","in, O","ADPORT-601, OBJ","Trial, O","Portage, SUBJ","Biotech, SUBJ","had, PRED","previously, O","paused, PRED","this, O","trial, OBJ","Portage, SUBJ","will, PRED","evaluate, PRED","the, O","continuation, OBJ","Portage, SUBJ","is, PRED","making, PRED","final, O","preparations, O","for, O","PORT-7, OBJ","Alexander, SUBJ","Pickett, SUBJ","said, PRED","Portage, SUBJ","is, PRED","a, O","clinical-stage, O","immuno-oncology, O","company, O","Portage, SUBJ","is, PRED","advancing, PRED","a, O","pipeline, O","The, O","planned, O","co-administration, SUBJ","of, O","PORT-6, OBJ","and, O","PORT-7, OBJ","will, PRED","mark, PRED","the, O","first, O","time, O","This, SUBJ","aims, PRED","This, SUBJ","is, PRED","designed, PRED","For, O","more, O","information, O","All, O","statements, O","the, O","Company, SUBJ","believes, PRED","the, O","Company, SUBJ","undertakes, PRED","no, O","obligation, OBJ","For, O","More, O","Information, O","Portage, SUBJ","Biotech, SUBJ","Alexander, SUBJ","Pickett, SUBJ","Portage, SUBJ","Biotech, SUBJ","Reports, PRED","Portage, SUBJ","Biotech, SUBJ","Receives, PRED","Extension, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041279/0/zh-hant/%E6%B5%A9%E9%BC%8E-%E6%A6%AE%E7%8D%B2-%E5%8F%B0%E7%81%A3%E6%9C%80%E5%85%B7%E6%BD%9B%E5%8A%9B-ADC-%E8%87%A8%E5%BA%8A%E5%80%99%E9%81%B8%E8%97%A5%E7%89%A9%E7%8D%8E.html,"浩鼎, SUBJ","榮獲, PRED","台灣, OBJ","最具潛力, O","ADC, O","臨床候選藥物獎, O","王慧君, SUBJ","領獎, PRED","獎, OBJ","王慧君, SUBJ","發表, PRED","演講, OBJ","OBI, SUBJ","Pharma, SUBJ","Inc., SUBJ","舉行, PRED","大會, OBJ","浩鼎, SUBJ","榮獲, PRED","獎, OBJ","浩鼎, SUBJ","獲得, PRED","肯定, OBJ","獎項, SUBJ","主辦, PRED","ABEA, OBJ","頒獎典禮, SUBJ","舉行, PRED","Sands, OBJ","Expo, OBJ","Convention, OBJ","Centre, OBJ","大會, SUBJ","舉辦, PRED","期間, O","台灣, SUBJ","浩鼎, SUBJ","執行長, SUBJ","王慧君, SUBJ","博士, SUBJ","主持, PRED","座談會, OBJ","王慧君, SUBJ","發表, PRED","演講, OBJ","王慧君, SUBJ","指出, PRED","矚目, OBJ","陳祈宏, SUBJ","Derek, SUBJ","Chen, SUBJ","處, PRED","Public, OBJ","Affairs, OBJ","浩鼎, SUBJ","舉行, PRED","大會, OBJ","OBI, SUBJ","Pharma, SUBJ","annonce, PRED","congrès, OBJ","OBI, SUBJ","Pharma, SUBJ","Announces, PRED","Meeting, OBJ","OBI, SUBJ","Pharma, SUBJ","Inc., SUBJ","communiqué, PRED","données, OBJ","OBI, SUBJ","Pharma, SUBJ","Inc., SUBJ","announced, PRED","data, OBJ"
https://www.globenewswire.com/news-release/2025/03/11/3040990/0/en/MaxCyte-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Full-Year-2025-Guidance.html,"MaxCyte,SUBJ","reports,PRED","Fourth Quarter,OBJ","MaxCyte,SUBJ","reports,PRED","Full Year,OBJ","MaxCyte,SUBJ","reports,PRED","2024 Financial Results,OBJ","MaxCyte,SUBJ","provides,PRED","Full Year,OBJ","MaxCyte,SUBJ","provides,PRED","2025 Guidance,OBJ","Maher Masoud,SUBJ","said,PRED","team,OBJ","Maher Masoud,SUBJ","said,PRED","SPLs,OBJ","Maher Masoud,SUBJ","said,PRED","TG Therapeutics,OBJ","Maher Masoud,SUBJ","said,PRED","MaxCyte,OBJ","Maher Masoud,SUBJ","said,PRED","SeQure Dx,OBJ"
https://www.globenewswire.com/news-release/2025/03/11/3040687/32142/en/HealthEquity-Community-Foundation-Announces-First-Grant-Recipients-and-Opens-Next-Funding-Cycle.html,"HealthEquity, SUBJ","announced, PRED","recipients, OBJ","Dale, SUBJ","said, PRED","O, O","Soldiers, SUBJ","receive, PRED","assistance, OBJ","Amy, SUBJ","said, PRED","O, O","HealthEquity, SUBJ","has, PRED","been, PRED","recognized, PRED","O, O","HealthEquity, SUBJ","Reports, PRED","Revenue, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041251/11635/en/Harvard-Bioscience-Announces-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html,"Harvard, SUBJ","Bioscience, SUBJ","Announces, PRED","results, OBJ","Jim, SUBJ","Green, SUBJ","said, PRED","revenues, SUBJ","were, PRED","down, PRED","Green, SUBJ","continued, PRED","We, SUBJ","are, PRED","encouraged, PRED","reception, SUBJ","of, O","our, O","new, O","products, OBJ","by, O","prominent, O","academic, O","institutions, OBJ","we, SUBJ","are, PRED","seeing, PRED","interest, OBJ","we, SUBJ","remain, PRED","focused, PRED","For, O","the, O","fourth, O","quarter, O","of, O","fiscal, O","2024, O","the, O","Company, SUBJ","reported, PRED","revenues, OBJ","Gross, SUBJ","margin, OBJ","was, PRED","Net, SUBJ","income, OBJ","was, PRED","Adjusted, SUBJ","EBITDA, OBJ","was, PRED","Cash, SUBJ","was, PRED","provided, PRED","For, O","the, O","year, O","ended, O","revenues, SUBJ","were, PRED","Gross, SUBJ","margin, OBJ","was, PRED","Net, SUBJ","loss, OBJ","was, PRED","The, O","Companys, O","net, O","loss, OBJ","includes, PRED","a, O","loss, OBJ","Adjusted, SUBJ","EBITDA, OBJ","was, PRED","Cash, SUBJ","was, PRED","provided, PRED","Q1, SUBJ","expects, PRED","revenues, OBJ","Harvard, SUBJ","Bioscience, SUBJ","will, PRED","be, PRED","hosting, PRED","Analysts, SUBJ","must, PRED","register, PRED","Participants, SUBJ","should, PRED","go, PRED","Harvard, SUBJ","Bioscience, SUBJ","is, PRED","a, O","developer, O","Our, O","customers, SUBJ","range, PRED","With, O","operations, OBJ","in, O","the, O","United, O","States, OBJ","we, SUBJ","sell, PRED","Jennifer, SUBJ","Cote, SUBJ","is, PRED","the, O","Companys, O","Chief, O","Financial, O","Officer, OBJ","Harvard, SUBJ","Bioscience, SUBJ","announced, PRED","the, O","resignation, OBJ","Harvard, SUBJ","Bioscience, SUBJ","announced, PRED","Jim, SUBJ","Green, SUBJ","Jennifer, SUBJ","Cote, SUBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041242/18362/en/Amarin-Announces-Plan-to-Initiate-a-Ratio-Change-Under-Its-American-Depository-Receipt-ADR-Program.html,"Amarin, SUBJ","Announces, PRED","Plan, OBJ","Amarin, SUBJ","Announces, PRED","Plan, OBJ","Amarin, SUBJ","Initiate, PRED","Ratio, OBJ","Amarin, SUBJ","Initiate, PRED","Ratio, OBJ","Amarin, SUBJ","Announced, PRED","intent, OBJ","Amarin, SUBJ","effect, PRED","Ratio, OBJ","Amarin, SUBJ","affected, PRED","shares, OBJ","Amarin, SUBJ","trade, PRED","Nasdaq, OBJ","Amarin, SUBJ","increase, PRED","price, OBJ","Amarin, SUBJ","comply, PRED","Nasdaqs, OBJ","Amarin, SUBJ","maintain, PRED","listing, OBJ","Amarin, SUBJ","occur, PRED","exchange, OBJ","Amarin, SUBJ","surrender, PRED","ADSs, OBJ","Amarin, SUBJ","receive, PRED","ADS, OBJ","Amarin, SUBJ","issued, PRED","ADSs, OBJ","Amarin, SUBJ","sold, PRED","ADSs, OBJ","Amarin, SUBJ","distributed, PRED","proceeds, OBJ","Amarin, SUBJ","increase, PRED","price, OBJ","Amarin, SUBJ","give, PRED","assurance, OBJ","Amarin, SUBJ","found, PRED","questions, OBJ","Amarin, SUBJ","found, PRED","answers, OBJ","Amarin, SUBJ","is, PRED","company, OBJ","Amarin, SUBJ","has, PRED","offices, OBJ","Amarin, SUBJ","has, PRED","partners, OBJ","Amarin, SUBJ","has, PRED","suppliers, OBJ","Amarin, SUBJ","contains, PRED","statements, OBJ","Amarin, SUBJ","made, PRED","statements, OBJ","Amarin, SUBJ","are, PRED","statements, OBJ","Amarin, SUBJ","are, PRED","statements, OBJ","Amarin, SUBJ","involve, PRED","risks, OBJ","Amarin, SUBJ","can, PRED","risks, OBJ","Amarin, SUBJ","cautioned, PRED","investors, OBJ","Amarin, SUBJ","undertakes, PRED","obligation, OBJ","Amarin, SUBJ","updates, PRED","information, OBJ","Amarin, SUBJ","communicates, PRED","investors, OBJ","Amarin, SUBJ","communicates, PRED","public, OBJ","Amarin, SUBJ","uses, PRED","website, OBJ","Amarin, SUBJ","uses, PRED","website, OBJ","Amarin, SUBJ","encourages, PRED","investors, OBJ","Amarin, SUBJ","encourages, PRED","media, OBJ","Amarin, SUBJ","encourages, PRED","others, OBJ","Amarin, SUBJ","review, PRED","information, OBJ","Amarin, SUBJ","may, PRED","updated, OBJ","Amarin, SUBJ","may, PRED","include, OBJ","Amarin, SUBJ","shall, PRED","deemed, OBJ","Amarin, SUBJ","shall, PRED","deemed, OBJ","Amarin, SUBJ","Contact, PRED","Information, OBJ","Amarin, SUBJ","confirmed, PRED","date, OBJ","Amarin, SUBJ","confirmed, PRED","date, OBJ","Amarin, SUBJ","announced, PRED","appointment, OBJ","Amarin, SUBJ","announced, PRED","appointment, OBJ"
https://www.globenewswire.com/news-release/2025/03/11/3040660/0/en/NeuroOne-Accelerates-Timeline-of-510-k-Submission-to-FDA-for-the-OneRF-Trigeminal-Nerve-Ablation-System-to-Treat-Facial-Pain.html,"NeuroOne, SUBJ","Accelerates, PRED","Timeline, OBJ","NeuroOne, SUBJ","leverages, PRED","Companys, O","Patented, O","OneRF, O","Technology, O","Platform, OBJ","Dave, SUBJ","said, PRED","Company, SUBJ","accelerated, PRED","submission, O","timeline, OBJ","NeuroOne, SUBJ","is developing, PRED","and, O","commercializing, PRED","solutions, OBJ","Company, SUBJ","may, O","pursue, PRED","applications, OBJ","NeuroOne, SUBJ","believes, PRED","Our, O","technology, SUBJ","may, O","not, O","perform, PRED","NeuroOne, SUBJ","undertakes, PRED","no, O","obligation, OBJ","Caution, O","Federal, O","law, O","restricts, PRED","this, O","device, SUBJ","to, O","sale, PRED","by, O","or, O","on, O","the, O","order, O","of, O","a, O","physician, OBJ","Dave, SUBJ","Rosa, SUBJ","is, PRED","President, OBJ","and, O","Chief, O","Executive, O","Officer, OBJ","of, O","NeuroOne, OBJ","NeuroOne, SUBJ","Issues, PRED","Letter, OBJ","Company, SUBJ","Confirms, PRED","No, O","Material, O","Impact, OBJ","NeuroOne, SUBJ","Completes, PRED","FDA, OBJ","Submission, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041337/0/en/Biotricity-Expands-IP-Portfolio-Strategy-with-14-New-Patents-Reinforcing-Innovation-Leadership-in-Remote-Monitoring-Diagnostics-Chronic-Disease-Management.html,"Biotricity, SUBJ","Expands, PRED","portfolio, OBJ","Biotricity, SUBJ","Reinforcing, PRED","leadership, OBJ","Biotricity, SUBJ","focus, PRED","platform, OBJ","platform, SUBJ","functions, PRED","device, OBJ","Biotricity, SUBJ","advancing, PRED","solutions, OBJ","REDWOOD, SUBJ","is, PRED","Calif, OBJ","Biotricity, SUBJ","is, PRED","Company, OBJ","Biotricity, SUBJ","specializing, PRED","solutions, OBJ","Biotricity, SUBJ","announce, PRED","expansion, OBJ","expansion, SUBJ","underscores, PRED","commitment, OBJ","Biotricity, SUBJ","helps, PRED","providers, OBJ","Biotricity, SUBJ","represents, PRED","breakthrough, OBJ","group, SUBJ","will drive, PRED","device, OBJ","Biotricity, SUBJ","could enable, PRED","studies, OBJ","patients, SUBJ","would have, PRED","pathways, OBJ","Biotricity, SUBJ","said, PRED","Dr, OBJ","Dr, SUBJ","is, PRED","CEO, OBJ","Biotricity, SUBJ","develop, PRED","portfolio, OBJ","Biotricity, SUBJ","is, PRED","technology, OBJ","Biotricity, SUBJ","is, PRED","company, OBJ","Biotricity, SUBJ","bridging, PRED","gap, OBJ","Doctors, SUBJ","trust, PRED","solutions, OBJ","Biotricity, SUBJ","develops, PRED","solutions, OBJ","statements, SUBJ","may constitute, PRED","statements, OBJ","statements, SUBJ","may include, PRED","statements, OBJ","statements, SUBJ","may include, PRED","projection, OBJ","statements, SUBJ","may include, PRED","performance, OBJ","statements, SUBJ","may include, PRED","regime, OBJ","statements, SUBJ","are, PRED","assumptions, OBJ","results, SUBJ","may differ, PRED","results, OBJ","Factors, SUBJ","may influence, PRED","inaccuracy, OBJ","Company, SUBJ","assumes, PRED","obligation, OBJ","Biotricity, SUBJ","Recognized, PRED","Companies, OBJ","Biotricity, SUBJ","Growing, PRED","Period, OBJ","Biotricity, SUBJ","Delivers, PRED","Margins, OBJ","Biotricity, SUBJ","Delivers, PRED","Revenues, OBJ","Biotricity, SUBJ","Delivers, PRED","Cashflows, OBJ","Biotricity, SUBJ","reports, PRED","revenue, OBJ","Company, SUBJ","reports, PRED","revenue, OBJ","Management, SUBJ","continues, PRED","revenues, OBJ","Company, SUBJ","achieved, PRED","basis, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041511/0/en/Orion-Corporation-Disclosure-Under-Chapter-9-Section-10-of-the-Securities-Market-Act-BlackRock-Inc.html,"Orion, SUBJ","Corporation, SUBJ","received, PRED","a, O","disclosure, O","under, O","Chapter, O","9, O",", O","Section, O","5, O","of, O","the, O","Securities, O","Market, O","Act, O",", O","according, O","to, O","which, O","the, O","total, O","number, O","of, O","Orion, SUBJ","shares, O","owned, PRED","directly, O",", O","indirectly, O","or, O","through, O","financial, O","instruments, O","by, O","BlackRock, OBJ",", O","Inc, OBJ","., O","and, O","its, O","funds, O","increased, PRED","on, O","11, O","March, O","2025, O","above, O","five, O","5, O","per, O","cent, O","of, O","Orion, SUBJ","Corporations, SUBJ","total, O","shares, O","., O","BlackRock, SUBJ",", O","Inc, SUBJ","owns, PRED","141,134,278, O","shares, O","Liisa, SUBJ","Hurme, SUBJ","is, PRED","President, O","and, O","CEO, O","Olli, SUBJ","Huotari, SUBJ","is, PRED","EVP, O","Tuukka, SUBJ","Hirvonen, SUBJ","is, PRED","Contact, O","person, O","Orion, SUBJ","Corporation, SUBJ","is, PRED","a, O","publisher, O","Orion, SUBJ","is, PRED","a, O","pharmaceutical, O","company, O","Orion, SUBJ","develops, PRED","human, O","and, O","veterinary, O","pharmaceuticals, O","Orion, SUBJ","had, PRED","3,700, O","employees, O"
https://www.globenewswire.com/news-release/2025/03/12/3041262/0/en/Theratechnologies-CROI-Presentation-Highlights-Limitations-of-Using-BMI-to-Assess-Cardiovascular-CV-Risk-in-People-with-HIV.html,"Theratechnologies, SUBJ","presented, PRED","data, O","data, O","highlighting, PRED","limitations, O","limitations, O","of, O","Using, O","BMI, O","to, O","Assess, O","Cardiovascular, O","CV, O","Risk, O","in, O","People, O","with, O","HIV, O","study, O","Demonstrates, PRED","Excess, O","Visceral, O","Abdominal, O","Fat, O","Drives, O","CV, O","Risk, O","March, O","12,, O","2025, O","Source, O","Theratechnologies, SUBJ","Theratechnologies, SUBJ","MONTREAL, O","March, O","12,, O","2025, O","GLOBE, O","NEWSWIRE, O","Theratechnologies, SUBJ","Inc., O","Theratechnologies, O","or, O","the, O","Company, O","TSX, O","TH, O","NASDAQ, O","THTX,, O","a, O","commercial-stage, O","biopharmaceutical, O","company,, O","today, O","presented, PRED","data, O","highlighting, PRED","limitations, O","of, O","using, O","body, O","mass, O","index, O","BMI, O","alone, O","in, O","assessing, O","cardiovascular, O","CV, O","risk, O","in, O","people, O","with, O","HIV, O","PWH., O","The, O","study, O","underscores, PRED","need, O","to, O","incorporate, O","screening, O","for, O","excess, O","visceral, O","abdominal, O","fat, O","EVAF, OBJ","to, O","better, O","identify, O","PWH, O","at, O","risk, O","of, O","CV, O","disease., O","In, O","a, O","poster, O","presentation, O","at, O","the, O","2025, O","Conference, O","on, O","Retroviruses, O","and, O","Opportunistic, O","Infections, O","CROI, OBJ","in, O","San, O","Francisco,, O","Calif., O","investigators, SUBJ","from, O","the, O","Visceral, O","Adiposity, O","Measurement, O","and, O","Observation, O","Study, O","VAMOS, OBJ","characterized, PRED","BMI, O","as, O","a, O","poor, O","independent, O","surrogate, O","for, O","excess, O","visceral, O","adiposity, O","and, O","CV, O","risk, O","in, O","PWH, O","particularly, O","given, O","the, O","high, O","CV, O","risk, O","observed, O","in, O","study, O","participants, O","with, O","a, O","normal, O","or, O","overweight, O","BMI, O","low, O","BMI, O","but, O","high, O","levels, O","of, O","EVAF, OBJ","The, O","investigators, SUBJ","previously, O","reported, PRED","that, O","EVAF, OBJ","is, PRED","one, O","of, O","several, O","risk, O","factors, O","that, O","contribute, O","to, O","heightened, O","CV, O","risk, O","in, O","PWH, O","who, O","are, O","on, O","modern, O","antiretroviral, O","therapy, O","ART, OBJ","regimens., O","There, O","is, O","abundant, O","evidence, O","of, O","substantial, O","weight, O","gain, O","and, O","a, O","high, O","prevalence, O","of, O","obesity, O","among, O","people, O","with, O","HIV, O","in, O","the, O","modern, O","antiretroviral, O","era,, O","commented, O","lead, O","VAMOS, OBJ","investigator, O","Karam, O","C., O","Mounzer,, O","MD, O","Chief, O","Scientific, O","Officer, O","at, O","Philadelphia, OBJ","FIGHT, OBJ","Community, O","Health, O","Centers, O","in, O","Philadelphia,, O","Pa., O","Clinicians, SUBJ","routinely, O","use, PRED","BMI, OBJ","as, O","a, O","marker, O","to, O","assess, O","the, O","risk, O","of, O","cardiovascular, O","disease, O","and, O","other, O","comorbidities, O","in, O","this, O","population,, O","but, O","often, O","overlook, O","the, O","importance, O","of, O","identifying, O","excess, O","visceral, O","abdominal, O","fat,, O","or, O","EVAF, OBJ","Our, O","findings, SUBJ","not, O","only, O","suggest, O","that, O","relying, O","solely, O","on, O","BMI, OBJ","underestimates, PRED","cardiovascular, O","risk, O","but, O","show, O","a, O","high, O","prevalence, O","of, O","EVAF, OBJ","among, O","patients, O","with, O","normal, O","BMI, OBJ","which, O","is, O","an, O","actual, O","driver, O","of, O","such, O","risk, O","in, O","people, O","with, O","HIV, OBJ","that, O","many, O","clinicians, SUBJ","fail, PRED","to, O","capture, O","in, O","their, O","clinics., O","VAMOS, SUBJ","is, PRED","a, O","cross-sectional,, O","multicenter,, O","observational, O","study, O","investigating, O","the, O","relationships, O","between, O","BMI, OBJ","EVAF, OBJ","defined, O","as, O","a, O","visceral, O","adipose, O","tissue, O","VAT, OBJ","surface, O","area, O","130, O","cm2,, O","and, O","CV, OBJ","risk, O","factors, O","in, O","170, O","PWH, OBJ","who, O","had, O","attained, O","virological, O","suppression, O","on, O","ART, OBJ","for, O","at, O","least, O","one, O","year., O","The, O","investigators, SUBJ","compared, PRED","10-year, O","atherosclerotic, O","cardiovascular, O","disease, O","ASCVD, OBJ","risk, O","scores, O","across, O","four, O","distinct, O","groups, O","Low, O","BMI, OBJ","20-29, O","kgm2, O","without, O","EVAF, OBJ","VAT, OBJ","130, O","cm2,, O","n62Low, O","BMI, OBJ","with, O","EVAF, OBJ","VAT, OBJ","130, O","cm2,, O","n, O","52High, O","BMI, OBJ","30-40, O","kgm2, O","without, O","EVAF, OBJ","n, O","10High, O","BMI, OBJ","with, O","EVAF, OBJ","n, O","46, O","Unsurprisingly,, O","obese, O","individuals, O","BMI, OBJ","30-34.9, O","kgm2, O","had, O","the, O","highest, O","prevalence, O","of, O","EVAF, OBJ","88, O","in, O","the, O","study,, O","followed, O","by, O","class, O","II, O","obese, O","PWH, OBJ","BMI, OBJ","35-40, O","kgm2, O","69., O","However,, O","EVAF, OBJ","was, O","still, O","present, O","in, O","a, O","substantial, O","portion, O","of, O","PWH, OBJ","with, O","normal, O","BMI, OBJ","20-25, O","kgm2, O","43, O","and, O","those, O","classified, O","as, O","overweight, O","BMI, OBJ","25-29.9, O","kgm2, O","47., O","Notably,, O","PWH, SUBJ","with, O","EVAF, OBJ","had, O","higher, O","10-year, O","ASCVD, OBJ","risk, O","scores, O","than, O","those, O","without, O","EVAF, OBJ","irrespective, O","of, O","BMI, OBJ","p0.0019., O","Additionally,, O","high, O","levels, O","of, O","pericardial, O","fat, O","volume, O","PFV, OBJ","fat, O","within, O","the, O","heart, O","muscle, O","were, O","found, O","predominantly, O","in, O","participants, O","with, O","high, O","EVAF, OBJ","compared, O","to, O","those, O","with, O","low, O","EVAF, OBJ","levels, O","p, O","0.0001., O","In, O","a, O","related, O","finding,, O","VAT, SUBJ","area, O","was, O","more, O","strongly, O","correlated, PRED","with, O","PFV, OBJ","Spearman, O","r, O","value, O","0.73, O","p, O","0.0001., O","than, O","with, O","subcutaneous, O","fat, O","area, O","Spearman, O","r, O","0.2, O","p, O","0.0109., O","In, O","addition, O","to, O","providing, O","a, O","predictive, O","estimate, O","of, O","cardiovascular, O","risk,, O","the, O","VAMOS, SUBJ","findings, OBJ","show, O","a, O","substantial,, O","real-time, O","impact, O","of, O","fat, O","in, O","the, O","body,, O","as, O","evidenced, O"
https://www.globenewswire.com/news-release/2025/03/12/3041244/0/en/Clearside-Biomedical-to-Report-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provide-Corporate-Update-on-Thursday-March-27-2025.html,"Clearside, SUBJ","Biomedical, SUBJ","to, O","Report, PRED","Fourth, OBJ","Quarter, OBJ","and, O","Full, OBJ","Year, OBJ","2024, OBJ","Financial, OBJ","Results, OBJ","and, O","Provide, PRED","Corporate, OBJ","Update, OBJ","on, O","Thursday,, O","March, OBJ","27,, OBJ","2025, OBJ","Clearside, SUBJ","Biomedical,, SUBJ","Inc,, SUBJ","announced, PRED","its, O","fourth, OBJ","quarter, OBJ","and, O","full, OBJ","year, OBJ","2024, OBJ","financial, OBJ","results, OBJ","Clearside, SUBJ","is, PRED","a, O","biopharmaceutical, O","company, O","Clearside, SUBJ","developed, PRED","and, O","gained, PRED","approval, PRED","for, O","its, O","first, O","product,, O","XIPERE, OBJ","Clearside, SUBJ","is, PRED","developing, PRED","its, O","own, O","pipeline, O","Clearside, SUBJ","partners, PRED","its, O","SCS, OBJ","injection, OBJ","platform, OBJ","Clearside, SUBJ","to, O","Participate, PRED","in, O","a, O","Fireside, OBJ","Chat, OBJ","at, O","the, O","24th, OBJ","Annual, OBJ","Needham, OBJ","Virtual, OBJ","Healthcare, OBJ","Conference, OBJ","Clearside, SUBJ","Announces, PRED","Fourth, OBJ","Quarter, OBJ","and, O","Full, OBJ","Year, OBJ","2024, OBJ","Financial, OBJ","Results, OBJ","Clearside, SUBJ","Biomedical, SUBJ","Inc,, SUBJ","had, PRED","a, O","meeting, O","FDA, OBJ","Asia-Pacific, SUBJ","Partners, SUBJ","New, OBJ","Drug, OBJ","Application, OBJ","for, O","ARCATUS, OBJ","XIPERE, OBJ"
https://www.globenewswire.com/news-release/2025/03/11/3040796/0/en/Smith-Nephew-to-showcase-advanced-Orthopaedic-Reconstruction-technologies-for-Robotics-Knees-Hips-and-Shoulders-at-AAOS-2025.html,"SmithNephew, SUBJ","will, PRED","feature, PRED","the, O","latest, O","advancements, O","in, O","Orthopaedic, O","Reconstruction, O","at, O","the, O","American, O","Academy, O","of, O","Orthopaedic, O","Surgeons, O","Annual, O","Meeting, O","in, O","San, O","Diego, OBJ","SmithNephew, SUBJ","offers, PRED","a, O","highly, O","personalized, O","approach, O","for, O","both, O","surgeons, O","and, O","their, O","patients, O","CORIOGRAPHs, SUBJ","expands, PRED","the, O","platforms, O","reach, O","the, O","CORI, SUBJ","enhances, PRED","the, O","level, O","of, O","personalization, O","in, O","knee, O","procedures, O","SmithNephews, SUBJ","designed, PRED","a, O","triple-taper, O","stem, O","design, O","SmithNephews, SUBJ","was, PRED","recognized, O","in, O","the, O","latest, O","annual, O","report, O","from, O","the, O","Australian, O","Orthopaedic, O","Association, O","National, O","Joint, O","Replacement, O","Registry, O","SmithNephew, SUBJ","launched, PRED","proprietary, O","OXINIUM, O","implant, O","technology, O","SmithNephew, SUBJ","received, PRED","510k, O","clearance, O","from, O","the, O","FDA, OBJ","To, O","learn, O","more, O","about, O","SmithNephews, O","advanced, O","solutions, O","for, O","Orthopaedic, O","Reconstruction, O","please, O","visit, O","our, O","booth, O","3729, O","at, O","the, O","American, O","Academy, O","of, O","Orthopaedic, O","Surgeons, O","AAOS, O","Annual, O","Meeting, O","in, O","San, O","Diego, OBJ","Dave, SUBJ","Snyder, SUBJ","Media, O","Enquiries, O","SmithNephew, SUBJ","is, PRED","a, O","portfolio, O","medical, O","technology, O","business, O","SmithNephew, SUBJ","now, O","operate, PRED","in, O","around, O","100, O","countries, O","SmithNephew, SUBJ","generated, PRED","annual, O","sales, O","of, O","5.8, O","billion, O","in, O","2024, O","SmithNephew, SUBJ","is, PRED","a, O","constituent, O","of, O","the, O","FTSE100, OBJ","SmithNephew, SUBJ","may, PRED","contain, O","forward-looking, O","statements, O","SmithNephew, SUBJ","does, PRED","not, O","undertake, O","any, O","obligation, O","to, O","update, O","or, O","revise, O","any, O","forward-looking, O","statement, O"
https://www.globenewswire.com/news-release/2025/03/12/3041358/0/en/Next-Gen-Cancer-Treatment-Rakovina-s-AI-Driven-ATR-Inhibitors-Enter-Preclinical-Testing.html,"Rakovina, SUBJ","received, PRED","compounds, OBJ","Rakovina, SUBJ","announced, PRED","partnership, OBJ","Rakovina, SUBJ","shortlisted, PRED","candidates, OBJ","compounds, SUBJ","move, PRED","testing, OBJ","Jeffrey Bacha, SUBJ","said, PRED","O, O","ATR, SUBJ","play, PRED","role, OBJ","Rakovina, SUBJ","aims, PRED","gap, OBJ","Rakovina, SUBJ","is, PRED","company, OBJ","The, O","company, SUBJ","has, PRED","pipeline, OBJ","The, O","company, SUBJ","undertakes, PRED","O, O","Rakovina, SUBJ","Congratulates, PRED","Dr., OBJ","Rakovina, SUBJ","Unveils, PRED","Data, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041199/0/en/CENTOGENE-Closes-Strategic-Transaction-with-Private-Equity-Group-Charme-Capital-Partners.html,"CENTOGENE, SUBJ","Closes, PRED","Transaction, O","with, O","Charme, OBJ","Charme, SUBJ","is, PRED","Partners, OBJ","Centogene, SUBJ","announced, PRED","Transaction, OBJ","Centogene, SUBJ","had, PRED","agreements, OBJ","Centogene, SUBJ","held, PRED","Meeting, OBJ","shareholders, SUBJ","voted, PRED","proposals, OBJ","Centogene, SUBJ","intends, PRED","Centogene Switzerland AG, OBJ","Centogene, SUBJ","will, PRED","liquidation, OBJ","Centogene, SUBJ","expects, PRED","securities, OBJ","INVESTORS, SUBJ","are, PRED","shareholders, OBJ","Centogene, SUBJ","does, PRED","offer, OBJ","Centogene, SUBJ","is, PRED","distribution, OBJ","Centogene, SUBJ","contains, PRED","statements, OBJ","Centogene, SUBJ","involve, PRED","risks, OBJ","Centogene, SUBJ","may, PRED","results, OBJ","Centogene, SUBJ","include, PRED","statements, OBJ","Centogene, SUBJ","outcome, PRED","proceedings, OBJ","Centogene, SUBJ","ability, PRED","cash, OBJ","Centogene, SUBJ","ability, PRED","compliance, OBJ","Centogene, SUBJ","see, PRED","factors, OBJ","Centogene, SUBJ","disclaims, PRED","obligation, OBJ","Centogene, SUBJ","update, PRED","statement, OBJ","CONTACT, SUBJ","is, PRED","Communications, OBJ","Investor, SUBJ","is, PRED","Relations, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041253/0/en/Atsena-Therapeutics-Granted-U-S-FDA-Fast-Track-Designation-for-ATSN-201-Gene-Therapy-to-Treat-X-linked-Retinoschisis.html,"Atsena, SUBJ","Therapeutics, SUBJ","Granted, PRED","U.S. FDA Fast Track Designation, OBJ","Atsena, SUBJ","Therapeutics, SUBJ","Granted, PRED","Designation, OBJ","FDA, SUBJ","granted, PRED","Designation, OBJ","ATSN-201, SUBJ","received, PRED","Rare Pediatric Disease Designation, OBJ","ATSN-201, SUBJ","received, PRED","Orphan Drug Designation, OBJ","Patrick Ritschel, SUBJ","said, PRED","O, OBJ","Atsena, SUBJ","remains, PRED","dedicated, O","Atsena, SUBJ","developing, PRED","therapies, O","Fast Track designation, SUBJ","is, PRED","granted, O","Fast Track designation, SUBJ","may, PRED","benefit, O","XLRS, SUBJ","is, PRED","diagnosed, O","XLRS, SUBJ","affects, PRED","males, O","The, O","safety, O","and, O","tolerability, O","of, O","ATSN-201, SUBJ","is, PRED","evaluated, O","Enrollment, SUBJ","is, PRED","ongoing, O","XLRS, SUBJ","is, PRED","disease, O","XLRS, SUBJ","caused, PRED","by, O","mutations, O","in, O","the, O","RS1, OBJ","gene, OBJ","RS1, SUBJ","is, PRED","localized, O","XLRS, SUBJ","is, PRED","characterized, O","XLRS, SUBJ","causes, PRED","impaired, O","visual, O","acuity, O","XLRS, SUBJ","leads, PRED","to, O","XLRS, SUBJ","affects, PRED","males, O","AAV.SPR, SUBJ","spreads, PRED","laterally, O","AAV.SPR, SUBJ","enables, PRED","transduction, O","AAV.SPR, SUBJ","has, PRED","a, O","favorable, O","safety, O","profile, O","Atsena, SUBJ","is, PRED","developing, O","Atsena, SUBJ","lead, PRED","program, O","Atsena, SUBJ","is, PRED","evaluating, O","ATSN-201, SUBJ","has, PRED","completed, O","Atsena, SUBJ","is, PRED","advancing, O","Atsena, SUBJ","is, PRED","led, O","Gina, SUBJ","Mangiaracina, SUBJ","Contact, PRED","O, OBJ","infoatsenatx.com, SUBJ","Contact, PRED","O, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041217/0/en/Bavarian-Nordic-A-S-Notice-Convening-Annual-General-Meeting.html,"Bavarian, SUBJ","Nordic, SUBJ","AS, SUBJ","convened, PRED","shareholders, OBJ","Board, SUBJ","of, O","Directors, SUBJ","report, PRED","on, O","Companys, SUBJ","activities, OBJ","Board, SUBJ","of, O","Directors, SUBJ","proposed, PRED","transfer, OBJ","Board, SUBJ","of, O","Directors, SUBJ","proposes, PRED","adopted, OBJ","Board, SUBJ","of, O","Directors, SUBJ","proposes, PRED","discharge, OBJ","election, PRED","of, O","members, OBJ","election, PRED","of, O","Auditors, OBJ","Board, SUBJ","of, O","Directors, SUBJ","proposed, PRED","authorize, OBJ","Board, SUBJ","of, O","Directors, SUBJ","proposed, PRED","authorize, OBJ","Board, SUBJ","of, O","Directors, SUBJ","proposed, PRED","authorize, OBJ","Board, SUBJ","of, O","Directors, SUBJ","proposed, PRED","authorize, OBJ","Board, SUBJ","of, O","Directors, SUBJ","proposed, PRED","approve, OBJ","Board, SUBJ","of, O","Directors, SUBJ","proposed, PRED","approve, OBJ","Board, SUBJ","of, O","Directors, SUBJ","proposed, PRED","authorize, OBJ","Luc, SUBJ","Debruyne, SUBJ","Frank, SUBJ","Verwiel, SUBJ","Anne, SUBJ","Louise, SUBJ","Eberhard, SUBJ","Heidi, SUBJ","Hunter, SUBJ","Johan, SUBJ","van, SUBJ","Hoof, SUBJ","Montse, SUBJ","Montaner, SUBJ","are, PRED","re-elected, OBJ","Anders, SUBJ","Gersel, SUBJ","Pedersen, SUBJ","is, PRED","not, O","seeking, PRED","re-election, OBJ","KPMG, SUBJ","is, PRED","re-elected, OBJ","Board, SUBJ","of, O","Directors, SUBJ","proposes, PRED","increase, OBJ","Board, SUBJ","of, O","Directors, SUBJ","proposes, PRED","increase, OBJ","Board, SUBJ","of, O","Directors, SUBJ","proposes, PRED","authorize, OBJ","Board, SUBJ","of, O","Directors, SUBJ","proposes, PRED","approve, OBJ","Board, SUBJ","of, O","Directors, SUBJ","proposes, PRED","approve, OBJ","Board, SUBJ","of, O","Directors, SUBJ","proposes, PRED","authorize, OBJ"
https://www.globenewswire.com/news-release/2025/03/11/3040902/0/en/EssilorLuxottica-Disclosure-of-Share-Capital-and-Voting-Rights-Outstanding-as-of-February-28-2025.html,"EssilorLuxottica, SUBJ","Disclosure, PRED","transactions, OBJ","Paris, SUBJ","is, PRED","France, OBJ","The, O","Annual, O","Shareholders, O","Meeting, O","on, O","April, O","30, O","2024, O"
https://www.globenewswire.com/news-release/2025/03/11/3040669/0/en/Progyny-Expands-Family-Building-Solutions-with-New-Parent-and-Child-Well-being-Offering.html,"Progyny, SUBJ","Expands, PRED","solutions, O","with, O","offering, O","Progyny, SUBJ","launch, PRED","offering, O","offering, SUBJ","extends, PRED","support, O","Progyny, SUBJ","addresses, PRED","need, O","Progynys, SUBJ","includes, PRED","Support, O","Progynys, SUBJ","includes, PRED","Navigation, O","Progynys, SUBJ","includes, PRED","Tools, O","Progynys, SUBJ","includes, PRED","Assistance, O","Michael, SUBJ","said, PRED","theme, O","Progyny, SUBJ","is, PRED","expertise, O","Progynys, SUBJ","is, PRED","program, O","Progynys, SUBJ","is, PRED","solution, O","Progyny, SUBJ","empowers, PRED","patients, O","Progyny, SUBJ","provides, PRED","access, O","Progyny, SUBJ","drives, PRED","outcomes, O","Progyny, SUBJ","reduces, PRED","costs, O","Progyny, SUBJ","has, PRED","been, O","Progyny, SUBJ","has, PRED","recognized, O","For, O","more, O","information, O","visit, O","For, O","Further, O","Information, O","Please, O","Contact, O","Investors, O","James, SUBJ","Hart, SUBJ","Media, O","Alexis, SUBJ","Ford, SUBJ","Progyny, SUBJ","Names, PRED","Melissa, OBJ","Cummings, OBJ","as, O","Chief, O","Operating, O","Officer, O","geoffrey, OBJ","Clapp, OBJ","as, O","Chief, O","Product, O","Officer, O","Progyny, SUBJ","to, O","Host, O","Events, O","Honoring, O","Individuals, O","Families, O","and, O","Infertility, O","Throughout, O","National, O","Infertility, O","Awareness, O","Week, O","and, O","Canadian, O","Fertility, O","Awareness, O","Week, O"
https://www.globenewswire.com/news-release/2025/03/11/3040991/9738/en/SIGA-Reports-Financial-Results-for-Three-and-Twelve-Months-Ended-December-31-2024.html,"SIGA, SUBJ","Technologies, SUBJ","Inc., SUBJ","reported, PRED","financial, OBJ","results, OBJ","SIGA, SUBJ","delivered, PRED","133, OBJ","million, OBJ","Diem, SUBJ","stated, PRED","SIGA, SUBJ","received, PRED","orders, OBJ","The, O","Company, SUBJ","announced, PRED","sale, OBJ","TPOXX, SUBJ","received, PRED","approval, OBJ","SIGA, SUBJ","will, PRED","host, OBJ","Participants, O","may, O","access, O","the, O","call, O","by, O","dialing, O","1-800-717-1738, O","for, O","domestic, O","callers, O","SIGA, SUBJ","is, PRED","a, O","commercial-stage, O","pharmaceutical, O","company, O","We, O","are, O","dedicated, O","to, O","protecting, O","humanity, O","against, O","the, O","worlds, O","most, O","severe, O","infectious, O","diseases, O","TPOXX, SUBJ","is, PRED","an, O","antiviral, O","medicine, O","SIGA, SUBJ","cautions, PRED","you, OBJ","SIGA, SUBJ","does, PRED","not, O","undertake, O","any, O","obligation, O","to, O","update, O","publicly, O","any, O","forward-looking, O","statement, O","ContactsSuzanne, O","Harnettsharnettsiga.com, O","and, O","InvestorsMediaJennifer, O","Drew-Bear,, O","Edison, O","GroupJdrew-bearedisongroup.com, O","Holly, O","Stevens,, O","CG, O","Lifehstevenscglife.com, O"
https://www.globenewswire.com/news-release/2025/03/12/3041113/0/en/Zealand-Pharma-and-Roche-enter-collaboration-and-license-agreement-to-co-develop-and-co-commercialize-petrelintide-as-a-future-foundational-therapy-for-people-with-overweight-and-o.html,"Zealand, SUBJ","Pharma, SUBJ","enter, PRED","collaboration, OBJ","Roche, OBJ","Zealand, SUBJ","Pharma, SUBJ","enter, PRED","agreement, OBJ","companies, SUBJ","will, PRED","co-develop, OBJ","companies, SUBJ","will, PRED","co-commercialize, OBJ","Zealand, SUBJ","Pharma, SUBJ","will, PRED","receive, OBJ","Zealand, SUBJ","Pharma, SUBJ","is, PRED","eligible, OBJ","Zealand, SUBJ","Pharma, SUBJ","will, PRED","pay, OBJ","Roche, OBJ","collaboration, SUBJ","aims, PRED","franchise, OBJ","Zealand, SUBJ","Pharma, SUBJ","will, PRED","host, OBJ","Copenhagen, SUBJ","is, PRED","headquarters, OBJ","Zealand, SUBJ","Pharma, SUBJ","announces, PRED","agreement, OBJ","Roche, OBJ","two, O","companies, SUBJ","will, PRED","co-develop, OBJ","two, O","companies, SUBJ","will, PRED","co-commercialize, OBJ","Adam, SUBJ","Steensberg, SUBJ","is, PRED","CEO, OBJ","Zealand, SUBJ","Pharma, SUBJ","consider, PRED","Roche, OBJ","Zealand, SUBJ","Pharma, SUBJ","believe, PRED","therapy, OBJ","Teresa, SUBJ","Graham, SUBJ","is, PRED","CEO, OBJ","Roche, SUBJ","Pharmaceuticals, SUBJ","is, PRED","excited, OBJ","Roche, SUBJ","Pharmaceuticals, SUBJ","will, PRED","develop, OBJ","Zealand, SUBJ","Pharma, SUBJ","will, PRED","receive, OBJ","Zealand, SUBJ","Pharma, SUBJ","is, PRED","eligible, OBJ","Zealand, SUBJ","Pharma, SUBJ","will, PRED","pay, OBJ","Roche, OBJ","closing, SUBJ","is, PRED","subject, OBJ","Centerview, SUBJ","Partners, SUBJ","UK, SUBJ","LLP, SUBJ","served, PRED","advisors, OBJ","Goldman, SUBJ","Sachs, SUBJ","International, SUBJ","served, PRED","advisors, OBJ","Goodwin, SUBJ","Procter, SUBJ","LLP, SUBJ","served, PRED","advisors, OBJ","Plesner, SUBJ","Advokatpartnerselskab, SUBJ","served, PRED","advisors, OBJ","Zealand, SUBJ","Pharmas, SUBJ","is, PRED","confirmed, OBJ","petrelintide, SUBJ","is, PRED","analog, OBJ","petrelintide, SUBJ","was, PRED","designed, OBJ","Amylin, SUBJ","is, PRED","produced, OBJ","Amylin, SUBJ","activation, SUBJ","has, PRED","shown, OBJ","petrelintide, SUBJ","demonstrated, PRED","reductions, OBJ","petrelintide, SUBJ","was, PRED","tolerated, OBJ","petrelintide, SUBJ","is, PRED","evaluated, OBJ","ZUPREME-1, SUBJ","is, PRED","obesityoverweight, OBJ","ZUPREME-1, SUBJ","was, PRED","initiated, OBJ","ZUPREME-2, SUBJ","is, PRED","obesityoverweight, OBJ","ZUPREME-2, SUBJ","is, PRED","expected, OBJ","CT-388, SUBJ","is, PRED","agonist, OBJ","CT-388, SUBJ","was, PRED","designed, OBJ","CT-388, SUBJ","is, PRED","studied, OBJ","Obesity, SUBJ","represents, PRED","challenges, OBJ","Obesity, SUBJ","is, PRED","disease, OBJ","Zealand, SUBJ","Pharma, SUBJ","will, PRED","host, OBJ","Adam, SUBJ","Steensberg, SUBJ","is, PRED","CEO, OBJ","Henriette, SUBJ","Wennicke, SUBJ","is, PRED","CFO, OBJ","David, SUBJ","Kendall, SUBJ","is, PRED","CMO, OBJ","Eric, SUBJ","Cox, SUBJ","is, PRED","CCO, OBJ","Zealand, SUBJ","is, PRED","company, OBJ","Zealand, SUBJ","has, PRED","team, OBJ","Centerview, SUBJ","Partners, SUBJ","UK, SUBJ","LLP, SUBJ","is, PRED","acting, OBJ","Goldman, SUBJ","Sachs, SUBJ","International, SUBJ","is, PRED","acting, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041289/0/en/ZyVersa-Therapeutics-Highlights-Data-Demonstrating-Inflammasome-Inhibition-Reduces-Neuroinflammation-and-Pathological-Brain-Deposition-of-Amyloid-Beta-in-Alzheimer-s-Disease-Mouse-.html,"ZyVersa, SUBJ","demonstrates, PRED","data, OBJ","data, SUBJ","demonstrate, PRED","potential, OBJ","ZyVersas, SUBJ","developing, PRED","drugs, OBJ","ZyVersa, SUBJ","a, O","clinical, O","stage, O","specialty, O","biopharmaceutical, O","company, O","highlights, PRED","data, OBJ","data, SUBJ","demonstrating, PRED","Inflammasome, OBJ","Inhibition, OBJ","Reduces, O","Neuroinflammation, O","Stephen, SUBJ","said, PRED","data, OBJ","data, SUBJ","demonstrate, PRED","IC, OBJ","100, OBJ","decreased, O","inflammasome, O","activation, O","IC, SUBJ","associated, PRED","ASC, OBJ","ZyVersa, SUBJ","is, PRED","biopharmaceutical, OBJ","company, OBJ","ZyVersa, SUBJ","leveraging, PRED","technologies, OBJ","ZyVersa, SUBJ","positioned, PRED","space, OBJ","IC, SUBJ","is, PRED","antibody, OBJ","ZyVersa, SUBJ","is, PRED","company, OBJ","ZyVersa, SUBJ","uses, PRED","words, OBJ","ZyVersa, SUBJ","disclaims, PRED","obligation, OBJ","ZyVersa, SUBJ","does, PRED","not, O","constitute, O","an, O","offer, O","ZyVersa, SUBJ","CEO, OBJ","Issues, PRED","Letter, OBJ","Inflammasome, SUBJ","have, PRED","moved, OBJ","ZyVersa, SUBJ","CEO, OBJ","Issues, PRED","Letter, OBJ","Parasol, SUBJ","recommended, PRED","reduction, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041224/0/en/Upstream-Bio-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Business-Highlights.html,"Upstream, SUBJ","Bio, SUBJ","completed, PRED","enrollment, OBJ","of, O","Phase, OBJ","2, OBJ","clinical, OBJ","trial, OBJ","of, O","verekitug, OBJ","in, O","patients, O","with, O","chronic, O","rhinosinusitis, O","with, O","nasal, O","polyps, O","top-line, OBJ","data, OBJ","expected, PRED","in, O","the, O","second, O","half, O","of, O","2025, O","Upstream, SUBJ","Bio, SUBJ","completed, PRED","upsized, OBJ","IPO, OBJ","with, O","gross, O","proceeds, O","of, O","approximately, O","293, O","million, O","extending, PRED","runway, OBJ","through, O","2027, O","Rand, SUBJ","Sutherland, SUBJ","said, PRED","Upstream, SUBJ","has, PRED","made, PRED","significant, O","progress, O","developing, PRED","verekitug, OBJ","in, O","severe, O","asthma, O","and, O","COPD, O","Upstream, SUBJ","completed, PRED","enrollment, OBJ","in, O","CRSwNP, OBJ","Phase, OBJ","2, OBJ","clinical, OBJ","trial, OBJ","Upstream, SUBJ","appointed, PRED","Daniella, OBJ","Beckman, OBJ","to, O","its, O","Board, OBJ","of, O","Directors, OBJ","Upstream, SUBJ","appointed, PRED","Allison, OBJ","Ambrose, OBJ","as, O","General, OBJ","Counsel, OBJ","Upstream, SUBJ","completed, PRED","upsized, OBJ","initial, OBJ","public, OBJ","offering, OBJ","Upstream, SUBJ","had, PRED","cash, OBJ","cash, OBJ","equivalents, OBJ","and, O","short-term, OBJ","investments, OBJ","of, O","470.5, O","million, O","Research, SUBJ","and, O","development, SUBJ","expenses, SUBJ","were, PRED","21.8, O","million, O","General, SUBJ","and, O","administrative, SUBJ","expenses, SUBJ","were, PRED","5.2, O","million, O","Net, SUBJ","loss, SUBJ","was, PRED","21.2, O","million, O","Upstream, SUBJ","expects, PRED","to, O","participate, PRED","in, O","the, O","following, O","investor, O","conferences, O"
https://www.globenewswire.com/news-release/2025/03/11/3040977/36461/en/Voyager-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-and-Operating-Results.html,"Voyager, SUBJ","Therapeutics, SUBJ","Inc., SUBJ","reported, PRED","fourth, OBJ","quarter, OBJ","2024, OBJ","financial, OBJ","operating, OBJ","results, OBJ","Voyager, SUBJ","advanced, PRED","programs, OBJ","Voyager, SUBJ","has, PRED","partnered, OBJ","portfolio, OBJ","Voyager, SUBJ","generated, PRED","80, OBJ","million, OBJ","Voyager, SUBJ","expects, PRED","cash, OBJ","position, OBJ","provide, PRED","runway, OBJ","Voyager, SUBJ","expects, PRED","present, PRED","data, OBJ","Voyager, SUBJ","initiated, PRED","study, OBJ","Voyager, SUBJ","demonstrated, PRED","profile, OBJ","Voyager, SUBJ","expects, PRED","data, OBJ","Voyager, SUBJ","previously, O","announced, PRED","assessing, OBJ","Voyager, SUBJ","resulted, PRED","extension, OBJ","Voyager, SUBJ","anticipated, PRED","data, OBJ","Voyager, SUBJ","anticipated, PRED","filings, OBJ","Voyager, SUBJ","expects, PRED","read-outs, OBJ","Voyager, SUBJ","anticipated, PRED","filings, OBJ","Voyager, SUBJ","expects, PRED","data, OBJ","Voyager, SUBJ","had, PRED","revenue, OBJ","Voyager, SUBJ","was, PRED","loss, OBJ","Voyager, SUBJ","were, PRED","expenses, OBJ","Voyager, SUBJ","were, PRED","expenses, OBJ","Voyager, SUBJ","is, PRED","committed, OBJ","Voyager, SUBJ","expects, PRED","cash, OBJ","Voyager, SUBJ","will, PRED","host, OBJ","Voyager, SUBJ","is, PRED","company, OBJ","Voyager, SUBJ","includes, PRED","programs, OBJ","Voyager, SUBJ","has, PRED","used, OBJ","Voyager, SUBJ","retains, PRED","interest, OBJ","Voyager, SUBJ","undertakes, PRED","obligation, OBJ","Voyager, SUBJ","reported, PRED","fourth, OBJ","quarter, OBJ","2024, OBJ","financial, OBJ","operating, OBJ","results, OBJ"
https://www.globenewswire.com/news-release/2025/03/11/3040741/0/en/Biofrontera-Inc-to-Report-Fourth-Quarter-and-Full-Year-2024-Financial-Results-on-March-21-2025.html,"Biofrontera, SUBJ","will report, PRED","results, O","for the three and 12 months ended December 31, 2024on Friday, O","March, OBJ","21, OBJ","2025, OBJ","The, O","company, SUBJ","will host, PRED","a conference, O","call, O","on, O","Friday, O","March, OBJ","21, OBJ","at, O","1000am, O","Eastern, O","Time, O","Biofrontera, SUBJ","is, PRED","a U.S.-based, O","biopharmaceutical, O","company, O","specializing, O","in, O","the, O","development, O","and, O","treatment, O","of, O","dermatological, O","conditions, O","with, O","a, O","focus, O","on, O","PDT, O","The, O","Company, SUBJ","commercializes, PRED","Ameluz, OBJ","The, O","Company, SUBJ","performs, PRED","trials, O","Biofrontera, SUBJ","Announces, PRED","Completion, O","of, O","Patient, O","Enrollment, O","in, O","Phase, O","3, O","Study, O","of, O","Ameluz, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041161/0/en/Philips-highest-ranked-medical-technology-company-among-Clarivate-Top-100-Global-Innovators.html,"Philips, SUBJ","has been recognized, PRED","Clarivate, OBJ","Clarivate, SUBJ","recognized, PRED","Philips, OBJ","Philips, SUBJ","has been included, PRED","assessment, O","Philips, SUBJ","invested, PRED","EUR 1.7 billion, O","Philips, SUBJ","is focusing, PRED","innovation, O","Philips, SUBJ","dedicates, PRED","workforce, O","Philips, SUBJ","leverages, PRED","technology, O","Philips, SUBJ","is, PRED","company, O","Philips, SUBJ","generated, PRED","sales, O","Philips, SUBJ","employs, PRED","employees, O","Ben Zwirs, SUBJ","contact, PRED","information, O","Royal Philips, SUBJ","is, PRED","company, O","Philips, SUBJ","leverages, PRED","technology, O","Philips, SUBJ","deliver, PRED","solutions, O","Philips, SUBJ","is, PRED","leader, O","Philips, SUBJ","generated, PRED","sales, O","Philips, SUBJ","demonstrates, PRED","power, O","Philips, SUBJ","was, PRED","applicant, O","Philips, SUBJ","expand, PRED","partnership, O","Philips, SUBJ","supports, PRED","diagnosis, O"
https://www.globenewswire.com/news-release/2025/03/11/3041042/0/en/Digicann-Ventures-Announces-Agreement-to-Extend-Maturity-Date-for-Convertible-Debentures.html,"Digicann, SUBJ","Ventures, SUBJ","Inc., SUBJ","announces, PRED","agreement, OBJ","to, O","extend, PRED","maturity, OBJ","date, OBJ","for, O","Convertible, O","Debentures, OBJ","Digicann, SUBJ","entered, PRED","agreement, OBJ","Company, SUBJ","satisfied, PRED","interest, OBJ","Company, SUBJ","issued, PRED","shares, OBJ","Company, SUBJ","announced, PRED","agreement, OBJ","Nick, SUBJ","is, PRED","CEO, OBJ","Digicann, SUBJ","is, PRED","company, O","Digicann, SUBJ","provides, PRED","update, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041565/0/en/Inaugural-Global-Longevity-Summit-Architects-New-Horizons-In-Human-Health-Potential.html,"Informa, SUBJ","Connect, SUBJ","Medical, SUBJ","Division, SUBJ","announces, PRED","landmark, O","Geneva-based, O","conference, OBJ","Global, SUBJ","Longevity, SUBJ","Summit, SUBJ","convening, PRED","the, O","worlds, O","foremost, O","industry, O","leaders, OBJ","leaders, SUBJ","to, O","forge, PRED","strategic, O","partnerships, OBJ","Summit, SUBJ","aims, PRED","to, O","accelerate, O","global, O","advancements, OBJ","James, SUBJ","Ho, SUBJ","guide, PRED","this, O","event, OBJ","Switzerlands, SUBJ","leverages, PRED","participants, OBJ","Qualified, O","leaders, SUBJ","are, O","invited, PRED","to, O","apply, O","for, O","a, O","limited, O","number, O","of, O","delegate, O","positions, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041221/0/en/ROSE-LifeScience-Expands-Pure-Laine-and-Tam-Tams-Lineups-with-New-Pre-Rolls-Vapes-and-Fan-Favourite-Cultivars-for-Winter-2025.html,"ROSE, SUBJ","LifeScience, OBJ","Expands, PRED","Pure, OBJ","Laine, OBJ","and, O","Tam, OBJ","Tams, OBJ","Lineups, O","with, O","New, O","Pre-Rolls,, O","Vapes,, O","and, O","Fan-Favourite, O","Cultivars, O","for, O","Winter, O","2025, O","ROSE, SUBJ","LifeScience, OBJ","is, PRED","committed, PRED","to, O","ensuring, O","that, O","consumers, O","benefit, O","from, O","the, O","responsible, O","production,, O","sale,, O","and, O","consumption, O","of, O","cannabis, O","in, O","Québec, OBJ","and, O","across, O","Canada, OBJ","Village, SUBJ","Farms, OBJ","leverages, PRED","decades, O","of, O","experience, O","as, O","a, O","large-scale,, O","Controlled, O","Environment, O","Agriculture-based,, O","vertically, O","integrated, O","supplier, O","for, O","high-value,, O","high-growth, O","plant-based, O","Consumer, O","Packaged, O","Goods, O","opportunities,, O","with, O","a, O","strong, O","foundation, O","as, O","a, O","leading, O","fresh, O","produce, O","supplier, O","to, O","grocery, O","and, O","large-format, O","retailers, O","throughout, O","the, O","U.S., OBJ","and, O","Canada,, O","and, O","new, O","high-growth, O","opportunities, O","in, O","the, O","cannabis, O","and, O","CBD, O","categories, O","in, O","North, O","America,, O","the, O","Netherlands, OBJ","and, O","selected, O","markets, O","internationally., O"
https://www.globenewswire.com/news-release/2025/03/11/3041025/0/en/Vera-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,"Vera, SUBJ","Therapeutics, SUBJ","Reports, PRED","Inducement, OBJ","Grants, OBJ","Under, O","Nasdaq, OBJ","Listing, OBJ","Rule, OBJ","5635c4, O","Vera, SUBJ","Therapeutics, SUBJ","announced, PRED","awards, OBJ","Compensation, SUBJ","Committee, SUBJ","granted, PRED","awards, OBJ","Vera, SUBJ","focused, PRED","treatments, OBJ","Vera, SUBJ","is, PRED","developing, OBJ","Vera, SUBJ","retains, PRED","rights, OBJ","Vera, SUBJ","holds, PRED","agreement, OBJ","Stanford, SUBJ","University, SUBJ","has, PRED","agreement, OBJ","Investor, O","Contact, O","Joyce, SUBJ","Allaire, SUBJ","Media, O","Contact, O","Madelin, SUBJ","Hawtin, SUBJ","Vera, SUBJ","Reports, PRED","Grants, OBJ","Vera, SUBJ","announced, PRED","awards, OBJ","Compensation, SUBJ","Committee, SUBJ","granted, PRED","awards, OBJ","Vera, SUBJ","Completes, PRED","Enrollment, OBJ","Vera, SUBJ","planned, PRED","submission, OBJ","FDA, SUBJ","planned, PRED","submission, OBJ"
https://www.globenewswire.com/news-release/2025/03/11/3040976/0/en/Mural-Oncology-Announces-Fourth-Quarter-and-Year-End-2024-Financial-Results-and-Highlights-Upcoming-Clinical-Milestones.html,"Mural, SUBJ","Oncology, SUBJ","Announces, PRED","Fourth, OBJ","Quarter, OBJ","Year, OBJ","End, OBJ","2024, OBJ","Mural, SUBJ","Oncology, SUBJ","Announces, PRED","Financial, OBJ","Results, OBJ","Mural, SUBJ","Oncology, SUBJ","highlights, PRED","Upcoming, OBJ","Clinical, OBJ","Milestones, OBJ","Caroline, SUBJ","Loew, SUBJ","said, PRED","Mural, SUBJ","announced, PRED","ARTISTRY-7, OBJ","trial, OBJ","reached, PRED","events, OBJ","Mural, SUBJ","announced, PRED","enrollment, OBJ","ARTISTRY-6, OBJ","trial, OBJ","is, PRED","complete, OBJ","Mural, SUBJ","expanded, PRED","pipeline, OBJ","Mural, SUBJ","expects, PRED","readout, OBJ","ARTISTRY-7, OBJ","Mural, SUBJ","expects, PRED","readout, OBJ","ARTISTRY-6, OBJ","Mural, SUBJ","plans, PRED","submission, OBJ","BLA, OBJ","Mural, SUBJ","expects, PRED","readout, OBJ","final, OBJ","OS, OBJ","Mural, SUBJ","expects, PRED","readout, OBJ","ARTISTRY-6, OBJ","Mural, SUBJ","expects, PRED","readout, OBJ","ARTISTRY-6, OBJ","Mural, SUBJ","expects, PRED","submission, OBJ","IND, OBJ","Mural, SUBJ","Oncology, SUBJ","Announces, PRED","Plans, OBJ","Mural, SUBJ","Oncology, SUBJ","Provides, PRED","Update, OBJ","ARTISTRY-7, OBJ","Trial, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041210/0/en/PatchMD-Introduces-New-GLP-1-Support-Patches-for-Individuals-on-Weight-Loss-Medications.html,"PatchMD, SUBJ","Introduces, PRED","GLP-1, OBJ","Support, OBJ","Patches, OBJ","PatchMD, SUBJ","is, PRED","innovator, O","in, O","transdermal, O","nutrient, O","delivery, O","PatchMD, SUBJ","announce, PRED","launch, O","PatchMD, SUBJ","provide, PRED","way, O","PatchMD, SUBJ","remains, PRED","forefront, O","PatchMD, SUBJ","published, PRED","insights, O","PatchMD, SUBJ","is, PRED","leader, O","PatchMD, SUBJ","offering, PRED","variety, O","PatchMD, SUBJ","empowers, PRED","individuals, O","PatchMD, SUBJ","Launches, PRED","Mito, OBJ","Cocktail, OBJ","Patch, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041090/0/en/Mineralys-Therapeutics-Announces-Pricing-of-175-0-Million-Underwritten-Public-Offering-of-Common-Stock.html,"Mineralys, SUBJ","Therapeutics, SUBJ","Announces, PRED","pricing, PRED","offering, OBJ","Mineralys, SUBJ","Therapeutics, SUBJ","is, PRED","company, O","focused, PRED","on, O","developing, PRED","medicines, O","Mineralys, SUBJ","Therapeutics, SUBJ","announced, PRED","offering, OBJ","Mineralys, SUBJ","has, PRED","option, O","Mineralys, SUBJ","intends, PRED","to, O","use, PRED","proceeds, OBJ","Mineralys, SUBJ","is, PRED","offering, PRED","securities, OBJ","BofA, SUBJ","Securities, SUBJ","Evercore, SUBJ","ISI, SUBJ","Goldman, SUBJ","Sachs, SUBJ","Stifel, SUBJ","Wells, SUBJ","Fargo, SUBJ","Securities, SUBJ","are, PRED","acting, PRED","LifeSci, SUBJ","Capital, SUBJ","is, PRED","acting, PRED","H.C., SUBJ","Wainwright, SUBJ","is, PRED","acting, PRED","Mineralys, SUBJ","is, PRED","company, O","Mineralys, SUBJ","is, PRED","developing, PRED","lorundrostat, OBJ","Mineralys, SUBJ","is, PRED","based, PRED","in, O","Radnor, OBJ","Mineralys, SUBJ","was, PRED","founded, PRED","by, O","Catalys, OBJ","Pacific, OBJ","Mineralys, SUBJ","Therapeutics, SUBJ","Announces, PRED","Publication, OBJ","Mineralys, SUBJ","Therapeutics, SUBJ","Announces, PRED","Data, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041107/0/en/Prime-Biome-Redefines-Beauty-Health-The-Gut-Skin-Solution-Backed-by-Science.html,"Prime, SUBJ","Biome, SUBJ","Redefines, PRED","Beauty, OBJ","Health, OBJ","Prime, SUBJ","Biome, SUBJ","presents, PRED","Maintaining, O","optimal, O","health, O","can, O","feel, O","daunting, O","in, O","todays, O","fast-paced, O","world, O","Prime, SUBJ","Biome, SUBJ","combines, PRED","probiotics, OBJ","prebiotics, OBJ","botanicals, OBJ","Prime, SUBJ","Biome, SUBJ","addresses, PRED","skin, OBJ","issues, OBJ","Prime, SUBJ","Biome, SUBJ","promotes, PRED","harmony, OBJ","Scientific, O","research, O","has, O","established, O","the, O","intricate, O","relationship, O","between, O","gut, O","health, O","and, O","skin, O","vitality, O","Prime, SUBJ","Biome, SUBJ","leverages, PRED","connection, OBJ","The, O","ingredients, O","in, O","Prime, O","Biome, O","such, O","as, O","inulin, O","dandelion, O","and, O","lemon, O","balm, O","are, O","specifically, O","chosen, O","for, O","their, O","ability, O","to, O","promote, O","a, O","balanced, O","microbiome, O","and, O","improve, O","skin, O","appearance, O","Inulin, SUBJ","acts, PRED","bacteria, OBJ","Dandelion, SUBJ","is, PRED","celebrated, OBJ","properties, OBJ","Lemon, SUBJ","balm, SUBJ","known, PRED","effects, OBJ","Prime, SUBJ","Biome, SUBJ","targets, PRED","dysbiosis, OBJ","Research, O","has, O","shown, O","that, O","probiotics, O","like, O","Bacillus, O","coagulans, O","support, O","gut, O","health, O","and, O","contribute, O","to, O","clearer, O","skin, O","Prime, SUBJ","Biome, SUBJ","plays, PRED","role, OBJ","Maintaining, O","a, O","balanced, O","microbiome, O","is, O","essential, O","for, O","overall, O","health, O","Prime, SUBJ","Biome, SUBJ","is, PRED","formulated, OBJ","environment, OBJ","Prime, SUBJ","Biome, SUBJ","focuses, PRED","balance, OBJ","Prime, SUBJ","Biome, SUBJ","adapts, PRED","needs, OBJ","Prime, SUBJ","Biome, SUBJ","provides, PRED","support, OBJ","Prime, SUBJ","Biome, SUBJ","benefits, PRED","hygiene, OBJ","Prime, SUBJ","Biome, SUBJ","promotes, PRED","hygiene, OBJ","Prime, SUBJ","Biome, SUBJ","helps, PRED","growth, OBJ","Prime, SUBJ","Biome, SUBJ","promotes, PRED","hygiene, OBJ","Prime, SUBJ","Biome, SUBJ","helps, PRED","breath, OBJ","Prime, SUBJ","Biome, SUBJ","promotes, PRED","wellness, OBJ","Prime, SUBJ","Biome, SUBJ","incorporates, PRED","complex, OBJ","Prime, SUBJ","Biome, SUBJ","enhances, PRED","production, OBJ","Prime, SUBJ","Biome, SUBJ","provides, PRED","support, OBJ","Prime, SUBJ","Biome, SUBJ","offers, PRED","support, OBJ","Prime, SUBJ","Biome, SUBJ","is, PRED","designed, OBJ","supplement, OBJ","Prime, SUBJ","Biome, SUBJ","is, PRED","exclusively, O","available, O","online, O","Prime, SUBJ","Biome, SUBJ","comes, PRED","guarantee, OBJ","Prime, SUBJ","Biome, SUBJ","offers, PRED","options, OBJ","Prime, SUBJ","Biome, SUBJ","comes, PRED","guarantee, OBJ","Prime, SUBJ","Biome, SUBJ","represents, PRED","solution, OBJ","Prime, SUBJ","Biome, SUBJ","offers, PRED","solution, OBJ","Prime, SUBJ","Biome, SUBJ","empowers, PRED","health, OBJ","beauty, OBJ","Prime, SUBJ","Biome, SUBJ","leads, PRED","changes, OBJ","Prime, SUBJ","Biome, SUBJ","is, PRED","a, O","valuable, O","addition, O","to, O","any, O","wellness, O","routine, O"
https://www.globenewswire.com/news-release/2025/03/11/3041028/0/is/Oculis-birtir-uppgj%C3%B6r-fyrir-fj%C3%B3r%C3%B0a-%C3%A1rsfj%C3%B3r%C3%B0ung-og-%C3%A1ri%C3%B0-2024-og-kynnir-%C3%A1fanga-%C3%AD-rekstri-f%C3%A9lagsins.html,"Oculis, SUBJ","birtir, PRED","uppgjör, OBJ","Oculis, SUBJ","kynnir, PRED","áfanga, OBJ","Riad, SUBJ","Sherif, SUBJ","náðum, PRED","gríðarlegum, OBJ","árangri, OBJ","Oculis, SUBJ","ljúka, PRED","skráningu, OBJ","Oculis, SUBJ","er, PRED","staðföst, OBJ","Oculis, SUBJ","er, PRED","leiðandi, OBJ","Oculis, SUBJ","kynna, PRED","tækifæri, OBJ","Oculis, SUBJ","hlökkum, PRED","kynna, OBJ","Oculis, SUBJ","á, PRED","áætlun, OBJ","Oculis, SUBJ","búist, PRED","fyrstu, OBJ","niðurstöðum, OBJ","Oculis, SUBJ","er, PRED","búið, OBJ","Oculis, SUBJ","sækja, PRED","markaðsleyfi, OBJ","Privosegtor, SUBJ","OCS-05, SUBJ","var, PRED","öruggt, OBJ","Privosegtor, SUBJ","OCS-05, SUBJ","þoldist, PRED","vel, OBJ","Privosegtor, SUBJ","OCS-05, SUBJ","sýndi, PRED","framfarir, OBJ","FDA, SUBJ","eru, PRED","fyrirhuguð, OBJ","Licaminlimab, SUBJ","OCS-02, SUBJ","staðfestu, PRED","næstu, OBJ","skref, OBJ","Oculis, SUBJ","verða, PRED","veittar, OBJ","Oculis, SUBJ","fer, PRED","fram, OBJ","Oculis, SUBJ","átti, PRED","handbært, OBJ","fé, OBJ","Oculis, SUBJ","námu, PRED","handbæru, OBJ","fé, OBJ","Oculis, SUBJ","tryggir, PRED","fjármögnun, OBJ","Oculis, SUBJ","nam, PRED","rannsóknar-, OBJ","þróunarkostnaður, OBJ","Oculis, SUBJ","nam, PRED","almennur, OBJ","rekstrarkostnaður, OBJ","Oculis, SUBJ","nam, PRED","nettótap, OBJ","Oculis, SUBJ","nam, PRED","nettótap, OBJ","Oculis, SUBJ","er, PRED","alþjóðlegt, OBJ","líftæknifyrirtæki, OBJ","Oculis, SUBJ","hefur, PRED","markmiði, OBJ","Oculis, SUBJ","eru, PRED","höfuðstöðvar, OBJ","Oculis, SUBJ","er, PRED","með, OBJ","starfsstöðvar, OBJ","Sylvia, SUBJ","Cheung, SUBJ","er, PRED","fjármálastjóri, OBJ","LifeSci, SUBJ","AdvisorsCorey, SUBJ","Davis, SUBJ","Ph.D., SUBJ","er, PRED","fjárfesta-, OBJ","fjölmiðlatengsl, OBJ","Oculis, SUBJ","er, PRED","þýðing, OBJ","Oculis, SUBJ","er, PRED","staðfesting, OBJ","Oculis, SUBJ","kynna, PRED","tækifæri, OBJ","Oculis, SUBJ","verður, PRED","fram, OBJ","Oculis, SUBJ","undirbýr, PRED","sjónvarpsþátt, OBJ","Oculis, SUBJ","kynnir, PRED","árangur, OBJ","Oculis, SUBJ","kynnir, PRED","áfanga, OBJ","Oculis, SUBJ","kynnir, PRED","áætlun, OBJ","Oculis, SUBJ","kynnir, PRED","stefnu, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED","niðurstöður, OBJ","Oculis, SUBJ","kynnir, PRED"
https://www.globenewswire.com/news-release/2025/03/11/3040677/0/en/Medera-Completes-Patient-Dosing-in-Phase-1-2a-MUSIC-HFrEF-Trial-of-SRD-001-Gene-Therapy-for-Heart-Failure-with-Reduced-Ejection-Fraction.html,"Medera, SUBJ","completes, PRED","dosing, PRED","patients, OBJ","in, O","Phase, O","12a, O","MUSIC-HFrEF, OBJ","Medera, SUBJ","announced, PRED","completion, OBJ","of, O","dosing, O","in, O","MUSIC-HFrEF, OBJ","Phase, O","12a, O","trial, O","of, O","SRD-001, OBJ","gene, O","therapy, O","for, O","heart, O","failure, O","with, O","reduced, O","ejection, O","fraction, O","Brian, SUBJ","said, PRED","milestone, OBJ","Ronald, SUBJ","said, PRED","results, OBJ","Medera, SUBJ","and, O","Keen, SUBJ","entered, PRED","agreement, OBJ","SRD-001, SUBJ","is, PRED","candidate, OBJ","HFrEF, SUBJ","is, PRED","syndrome, OBJ","Medera, SUBJ","is, PRED","company, OBJ","Medera, SUBJ","operates, PRED","units, OBJ","Novoheart, SUBJ","capitalizes, PRED","Technology, OBJ","Sardocor, SUBJ","is, PRED","dedicated, O","to, O","development, O","of, O","therapies, OBJ","Sardocor, SUBJ","has, PRED","clearances, OBJ","Sardocor, SUBJ","has, PRED","designations, OBJ","Sardocor, SUBJ","includes, PRED","candidates, OBJ","Keen, SUBJ","is, PRED","company, OBJ","Keen, SUBJ","is, PRED","focused, O","on, O","opportunities, OBJ","Medera, SUBJ","Presented, PRED","Results, OBJ","Medera, SUBJ","Receives, PRED","Clearance, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041132/0/en/Purespring-Therapeutics-appoints-Haseeb-Ahmad-as-Chief-Executive-Officer.html,"Purespring, SUBJ","appoints, PRED","Haseeb, SUBJ","Ahmad, SUBJ","as, O","Chief, O","Executive, O","Officer, O","Haseeb, SUBJ","Ahmad, SUBJ","brings, PRED","over, O","25, O","years, O","of, O","leadership, O","experience, O","in, O","life, O","sciences, O","serving, PRED","as, O","President, O","of, O","Novartis, OBJ","Europe, OBJ","will, O","lead, PRED","the, O","Company, SUBJ","follows, PRED","successful, O","completion, O","of, O","Series, O","B, O","financing, O","Purespring, SUBJ","is, PRED","the, O","first, O","company, O","to, O","successfully, O","treat, PRED","kidney, O","disease, O","models, O","The, O","Company, SUBJ","has, PRED","a, O","pipeline, O","of, O","programmes, O","targeting, PRED","IgA, OBJ","Nephropathy, OBJ","IgAN, OBJ","London, SUBJ","Purespring, SUBJ"," Therapeutics,, O","announces, PRED","the, O","appointment, O","of, O","Haseeb, SUBJ","Ahmad, SUBJ","as, O","its, O","Chief, O","Executive, O","Officer, O","Haseeb, SUBJ","has, PRED","been, O","appointed, PRED","to, O","steer, PRED","Purespring, OBJ","He, O","brings, PRED","significant, O","senior, O","industry, O","leadership, O","joining, PRED","Purespring, OBJ","Haseeb, SUBJ","served, PRED","as, O","President, O","of, O","Novartis, OBJ","Europe, OBJ","Haseeb, SUBJ","succeeds, PRED","Julian, OBJ","Hanak, OBJ","John, SUBJ","Tsai, SUBJ","said, PRED","On, O","behalf, O","of, O","the, O","Board, O","I, O","want, O","to, O","express, O","our, O","sincere, O","gratitude, O","to, O","Julian, SUBJ","Hanak, SUBJ","Haseeb, SUBJ","Ahmad, SUBJ","said, PRED","Purespring, SUBJ","is, PRED","the, O","first, O","company, O","to, O","successfully, O","treat, PRED","kidney, O","disease, O","models, O","Julian, SUBJ","Hanak, SUBJ","will, O","continue, PRED","with, O","the, O","company, O","In, O","October, O","Purespring, SUBJ","announced, PRED","the, O","completion, O","of, O","its, O","Series, O","B, O","financing, O","For, O","further, O","information, O","contact, O","Purespring, OBJ","About, O","Purespring, SUBJ","Founded, PRED","on, O","the, O","work, O","of, O","Professor, O","Moin, SUBJ","Saleem, SUBJ","Purespring, SUBJ","is, PRED","the, O","first, O","company, O","to, O","successfully, O","treat, PRED","kidney, O","disease, O","The, O","Company, SUBJ","has, PRED","a, O","pipeline, O","of, O","programmes, O","Based, PRED","in, O","London, OBJ"
https://www.globenewswire.com/news-release/2025/03/11/3041024/0/en/Polyrizon-Ltd-Files-Annual-Report-on-Form-20-F-for-the-Fiscal-Year-Ended-December-31-2024.html,"Polyrizon, SUBJ","Ltd., SUBJ","Files, PRED","Annual, OBJ","Report, OBJ","on, OBJ","Form, OBJ","20-F, OBJ","for, O","the, O","Fiscal, O","Year, O","Ended, O","December, O","31, O","2024, O","March, O","11, O","2025, O","1627, O","ET, O","Source, O","Polyrizon, SUBJ","Ltd., SUBJ","Raanana, OBJ","Israel, OBJ","March, O","11, O","2025, O","GLOBE, O","NEWSWIRE, O","Polyrizon, SUBJ","Ltd., SUBJ","Nasdaq, OBJ","PLRZ, OBJ","the, O","Company, SUBJ","or, O","Polyrizon, SUBJ","a, O","development, O","stage, O","biotech, O","company, O","specializing, O","in, O","the, O","development, O","of, O","innovative, O","intranasal, O","hydrogels, O","today, O","announced, PRED","that, O","it, O","has, O","filed, PRED","its, O","Annual, OBJ","Report, OBJ","on, O","Form, OBJ","20-F, OBJ","for, O","the, O","fiscal, O","year, O","ended, O","December, O","31, O","2024, O","with, O","the, O","U.S., O","Securities, O","and, O","Exchange, O","Commission, OBJ","the, O","SEC, OBJ","The, O","report, O","is, O","available, O","on, O","the, O","SECs, O","website, O","at, O","www.sec.gov, O","and, O","Polyrizons, O","Investor, O","Relations, O","website, O","at, O","httpsinvestor.polyrizon-biotech.com, O","Shareholders, O","can, O","obtain, O","copies, O","of, O","Polyrizons, O","Annual, OBJ","Report, OBJ","on, O","Form, OBJ","20-F, OBJ","free, O","of, O","charge, O","by, O","making, O","a, O","request, O","within, O","a, O","reasonable, O","period, O","of, O","time, O","to, O","Polyrizons, O","Investor, O","Relations, O","Department, O","at, O","IRpolyrizon-biotech.com, O","About, O","Polyrizon, SUBJ","Polyrizon, SUBJ","is, O","a, O","development, O","stage, O","biotech, O","company, O","specializing, O","in, O","the, O","development, O","of, O","innovative, O","medical, O","device, O","hydrogels, O","delivered, O","in, O","the, O","form, O","of, O","nasal, O","sprays, O","which, O","form, O","a, O","thin, O","hydrogel-based, O","shield, O","containment, O","barrier, O","in, O","the, O","nasal, O","cavity, O","that, O","can, O","provide, O","a, O","barrier, O","against, O","viruses, O","and, O","allergens, O","from, O","contacting, O","the, O","nasal, O","epithelial, O","tissue, O","Polyrizons, O","proprietary, O","Capture, O","and, O","Contain, O","TM, O","or, O","CC, O","hydrogel, O","technology, O","comprised, O","of, O","a, O","mixture, O","of, O","naturally, O","occurring, O","building, O","blocks, O","is, O","delivered, O","in, O","the, O","form, O","of, O","nasal, O","sprays, O","and, O","potentially, O","functions, O","as, O","a, O","biological, O","mask, O","with, O","a, O","thin, O","shield, O","containment, O","barrier, O","in, O","the, O","nasal, O","cavity, O","Polyrizon, SUBJ","are, O","further, O","developing, O","certain, O","aspects, O","of, O","our, O","CC, O","hydrogel, O","technology, O","such, O","as, O","the, O","bioadhesion, O","and, O","prolonged, O","retention, O","at, O","the, O","nasal, O","deposition, O","site, O","for, O","intranasal, O","delivery, O","of, O","drugs, O","Polyrizon, SUBJ","refers, PRED","to, O","its, O","additional, O","technology, O","which, O","is, O","in, O","an, O","earlier, O","stage, O","of, O","pre-clinical, O","development, O","that, O","is, O","focused, O","on, O","nasal, O","delivery, O","of, O","active, O","pharmaceutical, O","ingredients, O","or, O","APIs, O","as, O","Trap, O","and, O","Target, O","or, O","TT, O","For, O","more, O","information, O","please, O","visit, O","httpspolyrizon-biotech.com, O","For, O","contact, O","Michal, SUBJ","Efraty, SUBJ","Investor, O","Relations, O","IRpolyrizon-biotech.com, O","Polyrizon, SUBJ","Receives, PRED","Nasdaq, OBJ","Notification, OBJ","Regarding, O","Minimum, O","Bid, O","Requirements, O","Polyrizon, SUBJ","Engages, PRED","Leading, OBJ","Branding, OBJ","Firm, OBJ"
https://www.globenewswire.com/news-release/2025/03/11/3041028/0/en/Oculis-Reports-Q4-and-Full-Year-2024-Financial-Results-and-Provides-Company-Update.html,"Oculis, SUBJ","Reports, PRED","Q4, OBJ","financial, O","results, O","Oculis, SUBJ","Reports, PRED","Full, OBJ","Year, OBJ","2024, OBJ","financial, O","results, O","Oculis, SUBJ","Provides, PRED","Company, OBJ","Update, OBJ","Riad, SUBJ","had, PRED","year, OBJ","Oculis, SUBJ","delivered, PRED","readouts, OBJ","Oculis, SUBJ","is, PRED","track, OBJ","Oculis, SUBJ","completed, PRED","financing, OBJ","Oculis, SUBJ","planned, PRED","Day, OBJ","Oculis, SUBJ","had, PRED","cash, OBJ","Oculis, SUBJ","announced, PRED","results, OBJ","Riad, SUBJ","had, PRED","year, OBJ","Oculis, SUBJ","delivered, PRED","readouts, OBJ","Oculis, SUBJ","is, PRED","track, OBJ","Oculis, SUBJ","completed, PRED","financing, OBJ","Oculis, SUBJ","planned, PRED","Day, OBJ","Oculis, SUBJ","had, PRED","cash, OBJ","Oculis, SUBJ","announced, PRED","results, OBJ","Oculis, SUBJ","provided, PRED","overview, OBJ","Oculis, SUBJ","had, PRED","loss, OBJ","Oculis, SUBJ","had, PRED","loss, OBJ","Oculis, SUBJ","had, PRED","loss, OBJ","Oculis, SUBJ","had, PRED","loss, OBJ","Oculis, SUBJ","is, PRED","Company, OBJ","Oculis, SUBJ","is, PRED","purposefully, O","driven, O","save, O","sight, O","improve, O","eye, O","care, O","Oculis, SUBJ","has, PRED","pipeline, OBJ","Oculis, SUBJ","is, PRED","Headquartered, O","Oculis, SUBJ","is, PRED","led, O","Oculis, SUBJ","is, PRED","supported, O","Oculis, SUBJ","Contacts, PRED","Ms., OBJ","Oculis, SUBJ","Contacts, PRED","Investor, OBJ","Oculis, SUBJ","Contacts, PRED","Media, OBJ","Oculis, SUBJ","Contacts, PRED","LifeSci, OBJ","Oculis, SUBJ","Contacts, PRED","Corey, OBJ","Oculis, SUBJ","contains, PRED","statements, OBJ","Oculis, SUBJ","contains, PRED","information, OBJ","Oculis, SUBJ","undertakes, PRED","obligation, OBJ","Oculis, SUBJ","doesn't, PRED","contain, OBJ","Oculis, SUBJ","doesn't, PRED","contain, OBJ","Oculis, SUBJ","Contact, PRED","Data, OBJ","Oculis, SUBJ","Contact, PRED","This, OBJ","Oculis, SUBJ","doesn't, PRED","contain, OBJ","Oculis, SUBJ","and, PRED","EURETINA, OBJ","Oculis, SUBJ","Announce, PRED","Award, OBJ","Oculis, SUBJ","Hosts, PRED","Event, OBJ","Oculis, SUBJ","Hosts, PRED","Event, OBJ","Oculis, SUBJ","is, PRED","Company, OBJ"
https://www.globenewswire.com/news-release/2025/03/12/3041585/0/en/ACTG-Presents-Data-from-Mpox-Study-STOMP-at-CROI.html,"ACTG, SUBJ","Presents, PRED","Data, OBJ","Data, SUBJ","demonstrating, PRED","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O","O, O"
https://www.globenewswire.com/news-release/2025/03/11/3041010/0/en/Optinose-Announces-Reporting-Date-for-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html,"Optinose, SUBJ","Announces, PRED","date, O","for, O","Fourth, O","Quarter, O","and, O","Full, O","Year, O","2024, O","Financial, O","Results, O","Conference, O","Call, O","and, O","Webcast, O","to, O","be, O","held, O","March, O","20, O","2025, O","at, O","800, O","a.m., O","Eastern, O","Time, O","March, O","11, O","2025, O","1615, O","ET, O","Source, O","Optinose, OBJ","Inc, OBJ","Optinose, SUBJ","is, O","a, O","pharmaceutical, O","company, O","focused, O","on, O","patients, O","treated, O","by, O","ear, O","nose, O","and, O","throat, O","ENT, O","and, O","allergy, O","specialists, O","Company, SUBJ","will, O","report, PRED","financial, O","results, O","for, O","the, O","fourth, O","quarter, O","and, O","full, O","year, O","of, O","2024, O","and, O","corporate, O","updates, O","Members, O","of, O","the, O","Companys, O","leadership, O","team, O","will, O","host, O","a, O","conference, O","call, O","to, O","discuss, O","financial, O","results, O","and, O","corporate, O","updates, O","Optinose, SUBJ","is, O","a, O","specialty, O","pharmaceutical, O","company, O","focused, O","on, O","serving, O","the, O","needs, O","of, O","patients, O","cared, O","for, O","by, O","ear, O","nose, O","and, O","throat, O","ENT, O","and, O","allergy, O","specialists, O","Optinose, SUBJ","reports, PRED","Fourth, O","Quarter, O","and, O","Full, O","Year, O","2024, O","Financial, O","Results, O","and, O","Recent, O","Operational, O","Highlights, O","Company, SUBJ","reports, PRED","2024, O","XHANCE, OBJ","net, O","revenue, O","of, O","22.4, O","million, O","and, O","78.2, O","million, O","Optinose, SUBJ","Cancels, PRED","Fourth, O","Quarter, O","and, O","Full, O","Year, O","2024, O","Earnings, O","Call, O"
https://www.globenewswire.com/news-release/2025/03/11/3041038/0/en/Globus-Medical-extends-versatility-of-Advanced-Materials-Science-anterior-interbody-portfolio-with-launch-of-COHERE-ALIF-Spacer-and-Modulus-ALIF-Blades.html,"Globus, SUBJ","Medical, SUBJ","extends, PRED","versatility, OBJ","Globus, SUBJ","Medical, SUBJ","announced, PRED","launches, OBJ","Frank, SUBJ","Phillips, SUBJ","said, PRED","Anthony, SUBJ","Kwon, SUBJ","said, PRED","David, SUBJ","Hole, SUBJ","said, PRED","Globus, SUBJ","Medical, SUBJ","is, PRED","Globus, SUBJ","Medical, SUBJ","will announce, PRED","Globus, SUBJ","Medical, SUBJ","announced, PRED","completion, OBJ","Brian, SUBJ","Kearns, SUBJ","Moran, SUBJ","Chavez, SUBJ"
